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Chapter 1 
General Introduction 
 
 
 
 
 
 
 
1.1 Primary malignant brain tumors 
 
Primary malignant brain tumors originate in the brain itself. They often spread into other sites 
in the central nervous system, such as the spinal cord, but rarely metastasize to other parts of 
the body. These tumors show a high biological diversity, and can be named and classified 
according to the normal brain tissue from which they have derived. A major part of all 
primary brain tumors are collectively known as gliomas. They are malignant forms of glial 
cells, which primarily constitute the connective and supportive tissue in the central nervous 
system. Several glial cell types are known from which gliomas can derive: 
 
- Astrocytomas are primary brain tumors derived from astrocytes, which serve 
supportive functions for nerve cells, and their foot processes encapsulate the brain 
capillaries. 
- Oligodendrogliomas originate from oligodendrocytes, which surround nerve cells and 
thereby provide a protective coating. Pure oligodendrogliomas however are rare, and 
in most cases malignant oligodendroglioma cells occur in mixed gliomas. 
- Ependymomas are derived from ependymal cells. These cells line the brain ventricles 
and the central canal of the spinal cord. 
- Mixed gliomas consist of a mixture of different malignant glioma cells, mostly 
malignant oligodendrocytes and astrocytes. 
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In adults astrocytomas amount to about 75 % of all primary malignant brain tumors. The most 
commonly used World Health Organization (WHO) classification system for astrocytomas 
distinguishes four different grades, whereas three of them are considered as malignant tumors. 
The grade I tumors break ranks, due to their low incidence of brain infiltration and distant 
spreading. The other grades comprise the low-grade astrocytomas (WHO grade II), anaplastic 
astrocytomas (WHO grade III), and glioblastomas (WHO grade IV). By now, the survival of 
patients with WHO grade II–IV gliomas is poor, despite various multimodal clinical treatment 
approaches. According to the Central Brain Tumor Registry of the United States, the 5-year 
survival rate for anaplastic astrocytoma is 29.7 %, and 3.4 % for glioblastoma (Central Brain 
Tumor Registry of the United States 2004). 
 
1.2 Biological peculiarities of astrocytomas 
 
Astrocytomas can infiltrate normal brain tissue, and thus even extensive resections are 
unlikely to eradicate the entire malignant tissue. Burger et al. disclosed a great variability in 
the geometry, extent, and character of the peripheral infiltrating margin of glioblastomas 
(Burger et al. 1988). The regional histological heterogeneity within each tumor poses a 
diagnostic problem. In many cases the first diagnosis from the biopsy has to be changed when 
the tumors have been removed by resection (Jackson et al. 2001). Furthermore, when a low-
grade glioma is diagnosed, transformation to another, higher malignant grade is very 
probable. Nigro et al. ascribed this to a progressive genetic instability, linked to the loss of 
chromosome 10 in the tumor cells (Nigro et al. 2005). 
The further detailed genetic profiling of tumors, using gene expression arrays, is currently 
evaluated in order to establish a molecular classification system as shown for an epidermal 
growth factor receptor-associated molecular signature in glioblastoma multiforme (Mischel et 
al. 2003). This approach may also provide the basis for a more accurate and histology-
independent classification system in the future. Freije et al. reported on a list of 44 genes, 
which reliably classify gliomas into previously unrecognized biological and prognostic 
groups, and revealed heterogeneity of tumors and prognosis-related gene expression (Freije et 
al. 2004). Fig. 1-1 gives an overview of the most frequent genetic abnormalities in 
astocytomas, reviewed by Gonzalez and Gilbert (Gonzalez and Gilbert 2005). The genetic 
profiling and molecular analysis of tumors is suggested to allow optimized individual 
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treatment. Generally, tumor treatment can include tumor resection, radiation treatment, and 
chemotherapy. 
 
Astrocytoma
Anaplastic astrocytoma
WHO III
Precursor cell
Glioblastoma 
WHO Grade IV
LOH 17p/TP53 mutations
PDGFRα overexpression
TP53 mutations
MDM2 and p14 arf mutations
LOH 10q
EGFR amplification
p16/BK4A mutation
PTEN mutation
TP53 mutation
TP53 mutations
LOH 10q
EGFR amplification
p16/NK4a deletion
PTEN mutation  
Figure 1-1: Pathways from normal precursor cells to gliomas. Several genetic 
abnormalities have been associated with the development of glioblastoma via different WHO 
grades, or by direct transformation into WHO grade IV (from Gonzalez et al. 2005, modified). 
 
 
1.3 Tumor resection 
 
Surgical resection can achieve rapid symptom control, which is of primary relevancy for 
patients with large tumors, causing life-threatening situations. Moreover, resection provides 
tissue for histological diagnosis. Even though a complete eradication of the tumor is rather 
unlikely, extensive tumor resection has an impact on survival. As reported by Lacroix et al., a 
significant advantage in patients’ survival was associated with the resection of 98 % or more 
of the tumor volume (median survival of 13 months) compared to resections of less than 98 % 
(median survival of 8.8 months) (Lacroix et al. 2001). However, in many cases surgical 
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removal to the abovementioned extent is not possible due to the highly invasive growth of the 
tumor. 
1.4 Irradiation 
 
Nearly all treatment regimens for newly diagnosed tumors include radiation treatment. It 
represents one of the most effective forms of treatment for gliomas. Also the postoperative 
radiation therapy plays an important role in patients´ survival. This has been shown in several 
studies, e.g. for anaplastic astrocytoma (Walker et al. 1978) and for glioblastoma multiforme 
patients (Deutsch et al. 1989). The optimal radiation dose is estimated as 60 Gy, whereas a 
further increase in the dose does not appear to provide any additional benefit (Nelson et al. 
1988). Hyperfractionation of the dose does not improve the outcome significantly, as shown 
in patients suffering from WHO grade III and grade IV tumors (Ludgate et al. 1988). 
Another variant in radiotherapy involves the use of radiosensitizers, chemotherapeutic 
agents, which are supposed to increase the sensitivity of the tumors against radiation. Several 
compounds have been evaluated for this therapeutic purpose, e.g. misonidazole (Huncharek 
1998; Prados et al. 1999), carmustin (BCNU), lomustin (CCNU), and vincristine, with or 
without bromdesoxyuridine (Prados et al. 1999). To date, no clear clinical benefit compared 
to the standard radiation regimen has been demonstrated. The stereotactic radiosurgery (SRS) 
also has been considered as a promising treatment approach. However, a study by Souhami et 
al. revealed that SRS, followed by conventional radiation therapy in combination with BCNU, 
showed no improved outcome in the treated glioblastoma multiforme patients (Souhami et al. 
2004). Finally, the interstitial brachytherapy of glioma has been evaluated, also with no 
decisive success. Laperriere et al. concluded from their studies with stereotactic radiation 
implants, that this approach does not provide a statistically significant improvement in 
survival in the initial management of patients with malignant astrocytoma (Laperriere et al. 
1998). 
 
1.5 Chemotherapy 
 
The treatment of malignant gliomas with pharmacologically active compounds has been 
studied for several decades, and up to now no curative chemotherapy for malignant gliomas 
exists. Due to the poor penetration from the blood to the brain after systemic administration, 
the choice of applicable chemotherapeutic agents for the therapy of malignant brain tumors is 
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limited to a few compounds. Amongst them are the alkylating nitrosoureas carmustin 
(BCNU), lomustine (CCNU), procarbazine, and temozolomide. Most of the present 
chemotherapy regimens are involved in adjuvant therapy after tumor resection or irradiation 
therapy. 
 
Cl
N N
H
O
Cl
N O N
H
H
N
N
H
O
Cl
N N
H
O
N O
N N
N
N
N
O
NH2O
Carmustine (BCNU)
Lomustine (CCNU))
Procarbazine
Temozolomide  
Figure 1-2: Structures of carmustine, lomustine, procarbazine and temozolomide. 
 
Since 1970 several randomized trials have been conducted on the combined radiotherapy and 
chemotherapy. Some studies failed to demonstrate a significant increase in survival when 
chemotherapy was added to radiation treatment (Walker et al. 1978; Walker et al. 1980; 
Medical Research Council Brain Tumor Working party 2001). However, meta-analysis of 
several randomized clinical trials demonstrated some benefit for the adjuvant chemotherapy. 
Fine et al. used the results from 16 randomized clinical trials and reported on an absolute 
increase in patients survival of 10.1 % at 1 year and 8.6 % at 2 years after treatment with 
combined radiation and chemotherapy (Fine et al. 1993). Another meta-analysis with the data 
from 12 randomized controlled trials was performed by Stewart (Stewart 2002). The results 
showed a significant increase of 6 % in the 1-year survival, and an increase of two months in 
the median survival. Despite the positive results from the meta-analysis, individual trials 
failed to provide a significant therapeutic advantage. As mentioned in a review on the 
treatment of astrocytomas by Gonzalez and Gilbert (Gonzalez and Gilbert 2005), much of the 
controversy on the administration of adjuvant chemotherapy was the concern about toxic side 
effects associated with the use of nitrosoureas in classical adjuvant chemotherapy. 
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1.5.1 Temozolomide 
 
The introduction of the alkylating agent temozolomide (Temodal®) renewed the interest in 
chemotherapy for glioma treatment, especially due to its almost 100 % oral bioavailability 
and its ability to pass the blood-brain barrier (BBB). Ostermann et al. reported on a 
cerebrospinal fluid concentration of temozolomide of 20 % of the plasma concentration in 
patients with newly diagnosed or recurrent glioma (Ostermann et al. 2004). In a phase II trial 
with patients suffering from recurrent glioblastoma at first relapse, temozolomide was 
compared to procarbazine (Yung et al. 2000). A significantly improved progression-free 
survival (PFS) rate at 6 months was observed for temozolomide (21 % versus 8 % with 
procarbazine treatment). Moreover the median PFS was increased (12.4 versus 8.3 weeks), 
and a higher 6-month survival rate was observed (60 % versus 44 %). Despite a current lack 
of a direct clinical comparison temozolomide has largely replaced the nitrosoureas in the 
treatment primary malignant brain tumors, and is considered as the mainstay of chemotherapy 
of high-grade gliomas. A recent study showed that the combined irradiation and 
temozolomide treatment in newly diagnosed glioblastoma multiforme patients improved 
median survival by 3 months, compared to radiotherapy alone, with acceptable levels of 
severe side effects (Stupp et al. 2005). The results from these trials were encouraging, since 
no single chemotherapeutic agent has demonstrated an improvement in patients survival to 
such an extent before. The use of temozolomide in the chemotherapy of brain tumors has been 
reviewed in detail by van den Bent et al. (van den Bent et al. 2006). 
 
Table 1-1: Median 1- and 2-year survival of patients with high-grade glioma after various 
postoperative adjuvant treatment (from van den Bent et al. 2006, modified). 
51
61
40
46
3
12
24
32
1-year survival (%)
10
27
12 mo
15 mo
RT
RT + temozolomide
EORTC 26981
Stupp et al. 2005
3 mo
4 mo
8 mo
8 mo
Median survival
RT
RT + CTX
Supportive care
BCNU
RT
RT + BCNU
Treatment
0
0
1
5
Walker et al. 
1987
15
20
Glioma Meta-
analysis Trialists
Group 2002
2-year survival (%)Reference
RT: radiotherapy; CT: chemotherapy; BCNU: carmustine; mo: months  
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1.5.2 Modulation of O6-methylguanine-DNA methyltransferase 
 
Since temozolomide produces cytotoxicity by methylation of DNA (O6-methylation of 
guanine), the activity of DNA repair mechanisms has been suggested to stand against 
temozolomide efficacy, and may cause poor response to temozolomide treatment. Especially 
the O6-methylguanine-DNA methyltransferase (MGMT) represents the most important and 
clinically relevant resistance mechanism. Friedman et al. found a significant negative 
correlation between the MGMT expression in newly diagnosed glioblastoma, and the 
response to temozolomide treatment (Friedman et al. 1998). Similar results were reported on 
the relationship between the intracellular MGMT concentration, estimated by 
immunohistochemistry and the response to BCNU (Esteller et al. 2000). Moreover, Esteller et 
al. showed that hypermethylation of the MGMT gene promoter inhibits the transcription and 
finally MGMT synthesis (Esteller et al. 1999). Two studies published by Hegi et al. (Hegi et 
al. 2004; Hegi et al. 2005) demonstrated a clear relationship between the methylation status of 
the MGMT promoter, MGMT expression, response to chemotherapy, and clinical outcome. 
Especially in the study from 2005, the 2-year survival rate was 46 % in patients with 
MGMTpromotor hypermethylation, compared to 2 % in patients suffering from tumors with 
unmethylated MGMT-promoter. Due to the results from these studies, the modulation of 
MGMT activity has been investigated in order to enhance response to chemotherapeutic 
treatment with alkylating agents. A specific MGMT-inhibitor, O6-benzylguanine (O6BG), 
was demonstrated to almost quantitatively suppress MGMT activity in gliomas (Friedman et 
al. 1998). After phase I dose evaluation for the combined treatment with BCNU and O6BG 
(Friedman et al. 2000) a first phase II study was performed in patients with progressive or 
recurrent malignant glioma, resistant to nitrosourea treatment. However, none of the 18 
patients showed a partial or complete response (Quinn et al. 2002). By now, another clinical 
phase II trial is recruiting patients for the evaluation of this concept in recurrent childhood 
brain stem gliomas and recurrent childhood brain tumors (US National Institutes of Health 
2006). 
 
1.5.3 Inhibitors of signal transduction  
 
Since up to now temozolomide is the only single agent with promising efficacy in the 
treatment of high-grade gliomas, there is great interest in the identification of new targets for 
pharmacotherapy, such as particular elements of signal transduction pathways. Currently, 
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several signal transduction inhibitors are subject to clinical evaluation, e.g. the epidermal 
growth factor receptor (EGFR) inhibitor gefitinib (Iressa®). As reviewed by Halatsch et al. 
preclinical data strongly supported that the inhibition of the EGFR tyrosine kinase by gefitinib 
might be an attractive approach to the chemotherapy of gliomas (Halatsch et al. 2006). 
However, the data from phase I and phase II clinical trials of gefitinib appear to conflict the 
promising preclinical experiences. Treatment with gefitinib was generally well tolerated, but 
in two phase II single agent therapy trials patients with newly diagnosed glioblastoma 
multiforme (Uhm 2004) and patients with recurrant glioblastoma (Rich et al. 2004) failed to 
objective response. In contrast, in another phase I/II trial application of gefitinib led to 
response in patients with recurrent glioma which had progressed after radiotherapy. However, 
the observed response was not accompanied by an increase in the progression-free survival 
compared with historical controls (Lieberman 2004). Despite these rather disappointing 
results, another phase I/II trial of gefitinib, in combination with radiotherapy in patients with 
newly diagnosed glioblastoma multiforme is ongoing (US National Institutes of Health 2006). 
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Figure 1-3: Structure of the EGFR tyrosine kinase inhibitor gefitinib. 
 
1.6 Summary 
 
Taken together, after more than three decades of intensive research efforts the median 
survival of 12 to 15 months in glioma patients has not changed markedly since the 
introduction of radiation therapy, and an effective chemotherapy regimen for glioblastoma 
multiforme does not exist. Despite advances in surgery, irradiation treatment, and some 
advances in chemotherapy, only modest therapy improvements were achieved, and no 
improved long-term survival for most patients with malignant glioma was accomplished. 
Among the recent clinical therapy approaches, only the combined therapy of temozolomide 
and radiation treatment produced encouraging clinical results in long term survival of patients 
suffering from malignant glioma. Furthermore, the identification of biological peculiarities of 
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gliomas and advances in the techniques to discover and to study genetic alterations may 
provide new opportunities in the development of more effective treatment in the future, and 
eventually may allow individualized treatment of patients. 
There is still a great need to develop new therapy approaches, including the evaluation of 
new potential pharmacological targets, and new classes of pharmacologically active 
compounds, capable of penetrating into the brain after standard drug administration. 
Furthermore, since the expression of drug resistance-mediating proteins at the BBB (such as 
the p-glycoprotein 170) causes poor penetration of many registered anticancer drugs from the 
blood to the brain, new approaches to the overcome of the BBB and of the drug-resistance 
mechanisms are of particular interest in order to enlarge the variety of applicable anticancer 
drugs in the treatment of malignant brain tumors. 
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The poor accessibility of the brain for many clinically well evaluated anticancer drugs 
constitutes a major problem in the treatment of malignant brain tumors. Especially the p-
glycoprotein 170 (pgp)-mediated classical multi-drug resistance plays an important role, not 
only in the poor penetration of compounds from the blood into the brain, but it also can cause 
resistance of the tumors themselves. One approach to overcome the pgp-mediated resistance 
against the DNA intercalating agent and pgp substrate doxorubicin is the use of 
polybutylcyanoacrylate (PBCA) nanoparticles, which have been evaluated as targeted drug 
delivery systems by different workgroups (see Introduction of Chapter 3). However, little is 
known about the mechanism of the enhanced drug penetration into the brain across the blood-
brain barrier (BBB) and about how the pgp-efflux mechanism is circumvented, respectively. 
Thus, the objective of the first part of this work was to investigate whether PBCA 
nanoparticles are suitable carriers for doxorubicin in order to overcome pgp-mediated multi-
drug resistance in vitro, and if so, to elucidate the mechanism of the enhanced 
antiproliferative activity of nanoparticle-bound doxorubicin compared to the efficacy of the 
dissolved drug (Chapter 3). The experiments comprised the determination of the 
chemosensitivity of pgp-overexpressing KBv1 cells to different doxorubicin nanoparticle 
formulations as an in vitro model for the classical multi-drug resistance. Furthermore, flow 
cytometric and confocal laser-scanning microscopic (CLSM) studies were performed to 
determine uptake and distribution of doxorubicin into pgp-negative human glioblastoma cells 
and pgp-overexpressing KBv1 cells, and to investigate whether PBCA nanoparticles permeate 
into the cells in vitro. 
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The second part of this thesis was concerned with the concept of selective inhibition of the 
platelet-derived growth factor (PDGF) receptor as a new approach to the treatment of 
glioblastoma (Chapter 4). The autocrine activation of PDGF receptors by PDGF has been 
commonly suggested to be of major importance for the maintenance and malignancy of 
glioblastoma, and has been considered as an extremely promising pharmacological target (see 
Introduction of Chapter 4). The inhibition of tumor growth by selective PDGF receptor 
tyrosine kinase inhibitors would provide a selective and non-cytotoxic chemotherapeutic 
approach to the treatment of human glioblastoma. Therefore, the expression of PDGF 
receptors in human glioblastoma cells was determined as well as the chemosensitivity of 
human glioblastoma cell variants to various PDGF receptor tyrosine kinase inhibitors. Further 
experiments included the determination of the activity of PDGF receptors in human 
glioblastoma cells, and the effect of PDGF on glioblastoma cell proliferation. 
Besides the classical cytotoxic anticancer drugs (alkylating agents, DNA intercalators, 
microtubule-interfering agents) and the non-cytotoxic signal transduction inhibitors, new 
compounds targeting the action of a mitotic motor protein, the Eg5 kinesin, are currently 
preclinically evaluated (see Introduction of Chapter 5). Eg5 inhibition causes mitotic arrest 
and is supposed to leave quiescent cells unaffected. Since cytotoxicity and especially 
neurotoxicity of the classical microtubule-interfering agents such as paclitaxel or vinblastine 
are mainly ascribed to their effect on microtubule-dependent processes, the development of 
potent and selective Eg5 inhibitors is suggested to lead to a new class of well tolerated 
anticancer drugs. In the last part of this work the effects of new analogs of the first identified 
selective Eg5 inhibitor monastrol on the spindle formation and the cytoskeleton of human 
glioblastoma cells were investigated by confocal laser-scanning microscopy. 
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Chapter 3 
Investigations on doxorubicin-loaded poly-
butylcyanoacrylate nanoparticle formulations 
as an approach to overcome p-glycoprotein-
mediated drug efflux 
 
 
3.1 Introduction 
 
3.1.1 Nanoparticle carrier systems 
 
The use of biodegradable polymeric nanoparticles as drug delivery systems has been 
evaluated over the last few decades. Compared to other drug application modes they offer 
some particular advantages. They can increase stability of drugs or proteins and can provide 
controlled drug release. Up to now, various polymers have been investigated for their 
suitability for targeted drug delivery to the particular site of interest. Those studies included 
controlled drug release, targeting of particular organs and tissues, carriers for DNA in gene 
therapy, and delivery of peptides and DNA by oral administration (Langer 2000; Soppimath 
et al. 2001). Compared to standard drug formulations the nanoparticle drug formulations have 
been anticipated to provide an optimized therapeutic effect while minimizing drug side 
effects. 
Nanoparticles are colloidal polymeric particles with a size of up to 1000 nm. Depending 
on the method of preparation nanospheres or nanocapsules are obtained. Most reports on the 
development and evaluation of nanoparticle drug carriers deal with the polymers poly(D,L-
lactide), poly(lactic acid), poly(D,L-glycolide), poly(lactide-co-glycolide), poly(lactic-co-
glycolic acid) (PLGA), and poly(cyanoacrylate). Nanoparticles have also been prepared from 
poly(methylidenemalonate) (Lescure et al. 1994), gelatin (Farrugia and Groves 1999), 
chitosan (Fernandez-Urrusuno et al. 1999; Janes et al. 2001), and sodium alginate (Soppimath 
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et al. 2001). In general, compounds to be delivered by nanoparticles can be bound to the 
nanoparticle matrix by sorption, incorporation, or chemical binding (Kreuter 1994). The drug 
release depends on desorption of the surface-bound drug, the diffusion through the 
nanoparticle matrix, the erosion of the nanoparticle matrix, and on combined diffusion/erosion 
processes. Thus, except for diffusion, biodegradation makes the major contribution to the 
controlled drug release from nanoparticles (Soppimath et al. 2001). 
 
a
b
c
 
Figure 3-1: Morphology of polybutylcyanoacrylate (PBCA) nanoparticles (originally in 
water), determined by scanning electron microscopy (SEM). a: densely packed particles; b 
and c: isolated particles; bar: 200 nm (a), 100 nm (b and c) (from Bootz et al. 2004, modified). 
 
After intravenous injection, the nanoparticles adsorb blood components of which the amount 
and composition depend on the size and on the hydrophobicity of the nanoparticle surface. 
This determines their distribution into the organs, particularly of the reticulo-endothelial 
system (RES: liver, spleen, lung, and bone marrow), whereas phagocytosis plays a major role 
in the elimination of the nanoparticles from the blood circulation. Surface modifications have 
been shown to drastically change the binding of plasma proteins to the nanoparticles. For 
example, the coating of PLGA microspheres with poly(L-lysine)-poly(ethylene glycol) 
reduced protein binding to the surface by two orders of magnitude compared to uncoated 
microspheres (Müller et al. 2003). Therefore, modified protein adsorption has been suggested 
to protect nanoparticles from phagocytosis and thus from fast elimination by the RES. This 
has been shown for polystyrene microspheres and other colloidal carriers, coated with 
poloxamer 338 (Illum and Davis 1983; Illum et al. 1987). The influence of surface 
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composition on phagocytosis has been basically described and reviewed by van Oss (van Oss 
1978). Several studies reviewed by Soppimath et al. suggested surface-dependent body 
distribution of various biodegradable nanoparticle systems (Soppimath et al. 2001), whereas 
the most intensively investigated surface modifications involved coatings with hydrophilic 
polymers (surfactants) such as polyethylene glycol, polyethylene oxide, poloxamer, 
poloxamine, lauryl ethers, and polysorbate 80 (Tween 80®). 
The successful targeted drug delivery to particular tissues and organs, in many cases, 
would also imply the overcome of certain drug resistance mechanisms such as the p–
glycoprotein 170 (pgp)-mediated multi-drug resistance. Since the pgp basically contributes to 
the physiological blood-brain barrier (BBB) function, the overcome of the BBB by the use of 
nanoparticle carrier systems would provide enhanced accessibility of the brain with 
pharmacologically active compounds, and might improve the treatment of diseases of the 
central nervous system (CNS), such as primary malignant brain tumors. 
 
3.1.2 The blood-brain barrier 
 
In order to treat diseases within the CNS with pharmacologically active compounds the 
administered drugs must reach their biological target in therapeutic concentrations. Despite 
high blood perfusion the brain is one of the least accessible organs for the delivery of 
pharmacologically active molecules. For the entry into as well as for the exit from the brain 
endogenous and exogenous compounds have to pass two physiological barriers. Those are the 
BBB and the blood-cerebrospinal fluid barrier (BCSFB). Both barriers separate the brain from 
the systemic blood circulation and control the interchange of biomolecules. However the 
contribution of the BCSFB to the regulation of drug concentrations in the brain is considered 
negligibly small (Rautioa and Chikhale 2004). 
The particular cytoarchitecture of the BBB was elucidated by electron microscopic 
studies. The BBB is formed by the microvasculature of the brain, consisting of a monolayer 
of polarized brain capillary endothelial cells, which are connected with tight junctions 
(zonulae occludentes). These are formed by a number of transmembrane proteins such as 
occludin and claudin (Kniesel and Wolburg 2000), and effectively block paracellular aqueous 
diffusion, sealing the brain off from free diffusion of polar solutes from the blood. Hence, the 
brain capillary endothelium maintains a high expression of transporters in order to supply the 
brain with essential nutrients, e.g. glucose and amino acids. The brain capillaries are 
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embedded in astrocyte end feet, pericytes, and nerve endings, forming altogether a network on 
the abluminal surface of the capillaries. The differentiation of the endothelial cells to a 
polarized blood-brain barrier is thought to be a result of close association of the endothelial 
cells with astrocytes and pericytes (Kacem et al. 1998; Dore-Duffy 2003). 
 
 
Figure 3-2: Schematic drawing of the BBB cytoarchitecture (from Begley 2004, with 
modifications). The brain capillaries are lined by endothelial cells which are connected via 
tight junctions at their adjacent cell membranes. The abluminal side of the endothelium is 
covered by a network of numerous astrocytic end feet and discontinuously distributed 
pericytes maintaining the structural integrity of the BBB. The cellular environment of the 
endothelium is completed by immunocompetent cells of the brain, perivascular macrophages 
(microglial cells), which are derived from systemic circulating monocytes and macrophages. 
 
The BBB serves two major physiological functions. First, the composition of the interstitial 
fluid and the cerebrospinal fluid have to be controlled within very close limits to maintain the 
integrative neuronal function. For example, the availability of the potent CNS 
neurotransmitters glycine and glutamic acid, which are present at high concentrations in the 
blood, has to be controlled precisely in the brain extracellular fluid. The second basic function 
is the protection of the brain against the exposure to toxic endogenous metabolites. Since 
neuronal replacement in the mammalian CNS after cell damage or cell death is considered to 
be minimal or absent the BBB is of major importance. 
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3.1.3 Regulation of drug uptake into the brain across the blood-brain barrier 
 
The uptake of a drug into the brain across the BBB depends on the sum of uptake and efflux 
processes regulated by the BBB. Thus the net uptake is influenced by various factors. One of 
them is the drug plasma concentration characterized by the area under the curve (AUC) and 
the maximal systemic blood concentration (Cmax). These parameters represent the amount of 
drug available for crossing the BBB, and determine the concentration gradient between the 
blood and the brain. Since a paracellular drug transport normally does not occur due to the 
tight junctions, the permeability of the BBB is primarily controlled by the properties of the 
endothelium cells, whereas the permeability and metabolic capacity basically contribute to the 
regulation of influx and efflux processes. The endothelial cells contain several enzymes 
implicated in first and second pass metabolism processes, e.g. NADH-cytochrom P-450 
reductase, epoxide hydrolase, and UDP glucuronosyltransferase (Ghersi-Egea et al. 1994). 
Thus, these enzymes may metabolize drugs and alter their ability to permeate the BBB and to 
penetrate into the brain, respectively.  
 
Systemic drug availability
(AUC, Cmax)
Drug permeability
at the luminal and
abluminal membrane
Drug metabolism
Drug disposition profile
(AUC, Cmax)
Drug influx clearence
Drug efflux clearence
Active drug transport
Brain extracellular fluid Blood lumenBrain capillary endothelial cell  
Figure 3-3: The sum of uptake and efflux processes determines the net uptake of 
compounds from the blood into the brain through the capillary endothelial cells (modified 
from Scherrmann 2002). 
 
According to Levin small lipophilic molecules with a molecular weight below 600 Da are 
capable of passing the plasma membrane of the endothelial cells (Levin 1980). The passive 
diffusion of the drugs depends on their concentration gradient between the blood and the 
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brain, and its octanol-water partition coefficient (Po/w) which has been determined to be 
optimal between logPo/w values of 1.5 and 2.5 (Madrid et al. 1991). Furthermore, the diffusion 
is inversely related to the ionization degree of the drug at physiological pH (7.4). Moreover, 
non-diffusible compounds such as hydrophilic drugs, peptides and proteins can cross the BBB 
via carrier-mediated transport and via endocytotic mechanisms. Due to the polarized 
expression of ion channels, bidirectional transporters, energy-dependent pumps, and 
endocytosis-mediative receptors in the luminal and abluminal membrane of the endothelium, 
these highly specialized transport pathways provide a capacity of asymmetric transport of 
certain compounds across the BBB. 
 
Cell migration
(e.g. leukocytes)
Tight junction modulation
(e.g. hypertonic opening)
Passive
diffusion
Carrier-mediated
efflux            influx
blood
brain
Endo- and trans-
cytosis
 
Figure 3-4: Transport routes across the blood brain barrier (from Begley et al. 2003, 
modified). Besides permeation of the BBB via cell migration or paracellular crossing by tight 
junction modulation, all molecules must pass the membranes and the cytosol of the capillary 
endothelial cells. Thereby, permeation of substances depends on passive diffusion, carrier-
mediated efflux and influx processes, and receptor- or adsorptive-mediated endo- and 
transcytosis. Moreover, the permeation of a compound may also depend on more than one of 
the schematically drawn mechanisms. 
 
Several transmembrane transport proteins, located in the luminal and in the abluminal 
membrane of the brain capillary endothelium, are involved in the regulation of the uptake of 
numerous drugs into the brain. Many amphipathic cationic compounds are substrates for at 
least one of these proteins, the pgp, which is expressed at the luminal pole of the brain 
capillary endothelium (Cordon-Cardo et al. 1989). Drion et al. provided solid evidence for a 
major contribution of pgp to the BBB function (Drion et al. 1996). In perfusion studies with 
rat brains the uptake of the pgp substrates colchicine and vinblastine was enhanced to the 8.5- 
and 9.0-fold, respectively, after the pretreatment with valspodar (PSC 833), a second 
generation pgp inhibitor. Thus, pgp and other transport proteins are considered to mediate the 
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efflux of many pharmacologically active molecules from the brain to the blood. As a 
consequence this leads to poor accessibility of the brain for various drugs after systemic 
administration, making several CNS diseases refractory to treatment. 
 
3.1.4 Targeted drug delivery to the brain 
 
Several approaches to circumvent the blood-brain barrier via targeted drug delivery have been 
evaluated: 
 
• the use of prodrugs and chemical delivery systems 
• carrier- and receptor-mediated transport across the BBB 
• liposomal drug carriers 
• nanoparticle drug carriers 
 
3.1.4.1 Prodrugs and chemical delivery systems 
Since the lipophilicity of a compound improves its permeability with respect to 
biomembranes, the use of lipophilic prodrugs may be considered as a rather non-selective 
enhancement of drug delivery from the blood to the brain. After crossing the BBB the 
prodrugs are usually metabolized to more hydrophilic compounds, incapable of permeating 
the BBB towards the blood. In general such compounds have to be expected to accumulate 
not only in the brain, but also in other organs and tissues, resulting in an increased systemic 
toxicity and a decreased efficiency of the intended drug delivery. 
Similar problems occur with chemical drug delivery systems. For this concept, developed 
from the prodrug approach, drugs are provided with several additional chemical moieties in 
order to improve their pharmacokinetic properties. The moieties increase lipophilicity and 
permeation of the drug through lipid membranes, they protect certain pharmacologically 
important functional groups from metabolic degradation, and target the compounds to the 
tissue of interest. Brewster et al. introduced 1-methyl-1,4-dihydronicotinic acid as a moiety 
providing various benefits for drug delivery to the brain, when covalently linked to drugs by 
esterification. Due to the enhanced lipophilicity the esterified compound passes the BBB 
followed by enzymatic oxidation of the targeting moiety to the quarternary ammonium salt in 
the brain parenchyma. Consequently, the charged metabolite is trapped inside the CNS and 
ester hydrolysis separates the pharmacologically active compound from the delivery moiety. 
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This drug delivery principle has been successfully applied to zidovudine in rabbits (Brewster 
et al. 1991). The administration of the 1-methyl-1,4-dihydronicotinic acid ester generated 
higher and more sustained levels of zidovudine in the brain tissue than unchanged zidovudine. 
The increase in the area under the brain concentration-time curve occurred with lower 
systemic zidovudine concentrations. Yet, various chemical delivery systems have been 
established, comprising chemotherapeutic agents (Bodor and Buchwald 1999) and steroids 
(Bodor and Buchwald 2002). 
 
3.1.4.2 Carrier- and receptor-mediated transport across the BBB 
A large number of endogenous solute transporters at the BBB can be utilized for targeted drug 
delivery from the blood to the brain (Begley 2003). The physiological role of many of those 
transport mechanisms is to carry polar metabolites into the brain. The directed transport 
across the BBB towards to brain side is further enhanced by the polarized expression of the 
transporters at the cerebral endothelium membrane. Thus, drugs designed as pseudosubstrates 
for these transport proteins can be carried across the BBB (Tab. 3-1). However, in several 
cases the stereochemical requirements for the carrier-mediated transport are very stringent, 
and consequently the number of applicable compounds is limited. For example, since the 
nucleoside carriers do not accept a broad variety of substrates, many antiviral and cytostatic 
drugs, according to the nucleoside analog approach, do not permeate the BBB to a sufficient 
extent. 
Another transport route across the BBB involves endocytotic pathways, which can be 
accessed by peptides and proteins, leading to a transcytotic uptake into the brain. It has to be 
distinguished between receptor-mediated and adsorption-induced transcytosis. Since many 
drugs are not substrates, neither for receptor-mediated nor adsorption-induced endocytotic 
pathways, the linkage to targeting molecules provides a useful approach to create 
pseudosubstrates, capable of accessing transcytotic mechanisms. In experiments in rats, 
Bickel et al. showed uptake into the brain of a monoclonal anti-transferrin receptor antibody 
coupled to colloidal gold particles (OX26-Au) via transcytosis (Bickel et al. 1994). 
Furthermore, the linkage to the OX26 antibody led to the uptake of vasoactive intestinal 
peptide, nerve growth factor, glial cell line-derived neurotrophic factor, and brain derived 
neurotrophic factor into the brain (Begley 2003). It has been suggested that binding of the 
anti-transferrin receptor antibody to the transferrin receptor induces endocytosis of the 
antibody-peptide construct, which is then entirely or in part translocated through the capillary 
endothelial cell and released into the brain. Further examples for vector-mediated delivery 
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across the BBB have been reviewed by Pardridge (Pardridge 1999). Moreover, vesicle 
formation and internalization at the luminal membrane of brain capillary endothelial cells can 
be induced by electrostatic interactions between the membrane surface and charged peptides 
or proteins from the blood circulation. This mechanism has been used for the delivery of 
cationized rat albumin to the rat brain  (Pardridge et al. 1990), and furthermore has been 
suggested to be applicable to other highly positively charged compounds. 
 
Table 3-1: Examples for drug delivery to the brain via endogenous transport mechanisms 
(from Begley 2003 with modifications). 
 
AbacivirNucleoside carrier
Mepyramine
Diphenhydramine
Diphenylpyraline
Lidocaine
Imipramine
Propranolol
Organic cation transporter
Oxazolamine COR3224Purine carrier
Active metabolites of simvastatin and lovastatin
(carboxylic acid form)
Monocarboxylic acid carrier
Valproic acid
Docosahexanoic acid (DHA)–paclitaxel
Medium chain fatty acid carrier
Dehydroascorbic acid
Glycosylated morphine
Hexose carrier
L-dopa
α-methyl-dopa
Melphalan
Baclophen
Gabapentin
Large neutral amino acid carrier (L-system)
Carried drugEndogenous transporter
 
 
3.1.4.3 Liposomal drug carriers 
Liposomes, which have a size of up to 500 nm, represent a drug carrier system, exhibiting 
various benefits compared to conventional dosage forms. Drugs can be encapsulated into the 
lumen of the liposomes or incorporated into the liposomal matrix. Thereby the drugs are 
protected from degradation and the liposomes can be targeted to the site of pharmacodynamic 
action by various modifications of the liposomal surface. The high lipophilicity enables the 
liposomes to cross the BBB, and drug release starts with the degradation of the liposomes. 
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Surface modifications of liposomes, e.g. the incorporation of monoclonal antibodies into the 
liposomal matrix, can enhance targeting and delivery efficiency of pgp substrates to the brain. 
Huwyler et al. demonstrated the overcome of pgp-mediated drug efflux by the use of targeted 
liposomes in vitro (Huwyler et al. 2002). After the modification of the liposomal surface with 
the monoclonal anti-transferrin receptor antibody OX26, radiolabeled liposomal digoxin 
permeated into cells, which were coexpressing pgp and transferrin receptors. Since digoxin is 
a substrate of the pgp, this study demonstrated the validity not only of antibodies as targeting 
vectors, but also of immunoliposomes for drug delivery across the BBB. 
Despite of several benefits of liposomes as drug carrier systems, the progress in the 
development of more efficient liposomal drug formulations has been limited due to several 
immanent problems, e.g. low encapsulation efficiency, rapid leakage of hydrophilic drugs in 
the presence of blood components, and low stability of liposomal drug formulations in 
storage. 
 
3.1.4.4 Tween 80®-coated polybutylcyanoacrylate nanoparticles 
The first drug transport across the BBB using Tween 80®-coated PBCA nanoparticles (NP) 
has been demonstrated for the hexapeptide dalargin, a leu-enkephalin analog with opioid 
activity, which is not capable of passing the BBB when applied in solution. The degree of 
dalargin transport into the brain was indirectly measured by its analgesic effect in mice using 
the tail flick test (Kreuter et al. 1995) and the hot plate test (Schroeder et al. 1998). An 
analgesic effect was only observed after the application of the Tween 80®-coated dalargin-
loaded nanoparticles, whereas uncoated dalargin PBCA NP or a simple mixture of PBCA NP, 
Tween 80®, and dalargin had no effect. Coating with other surfactants, such as polysorbate 
20, 40, and 60 led to lower antinociceptive effects, whereas no effect was observed with 
various poloxamers, poloxamine 908, Cremophor EL® and Cremophor® RH 40, and 
polyoxyehtylene-(23)-laurylether (Brij® 35) (Kreuter et al. 1997). Analogous experiments 
with the dipeptide kytorphin (Schroeder et al. 1998) and loperamide (Alyautdin et al. 1997) 
led to similar results. Compared to the simple mixture of drug-loaded nanoparticles and 
surfactant, a significantly higher and dose-dependent analgesic effect was only observed when 
the compounds were bound to Tween 80®-, respectively Tween 85®-coated PBCA 
nanoparticles. Furthermore, in brain perfusion studies with rats, tubocurarine-loaded Tween 
80®-coated PBCA NP led to frequent severe spikes in the EEG, as observed after 
intraventricular injection of the dissolved drug. The drug in solution or a mixture of drug, 
PBCA NP, and the surfactant did not cause any changes in the EEG (Alyautdin et al. 1998). 
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Another non-peptidic compound, delivered by Tween 80®-coated PBCA NP is the NMDA 
receptor antagonist MRZ 2/576 (Friese et al. 2000). This compound is excluded from the CNS 
by efflux pump-mediated processes. In mice with electroshock-induced convulsions the 
anticonvulsive effect of the short acting MRZ 2/576 (5-15 minutes) was prolonged (up to 210 
minutes) after the compound was applied as the Tween 80® coated PBCA NP formulation. 
 
3.1.4.5 Delivery of doxorubicin to the brain via Tween 80®-coated PBCA 
nanoparticles 
Gulyaev et al. investigated the pharmacokinetics of doxorubicin-loaded Tween 80®-coated 
PBCA NP after intravenous injection to rats, by the basis of HPLC determination of 
doxorubicin plasma concentrations (Gulyaev et al. 1999). Compared to the standard drug 
application in solution, the plasma half-life of doxorubicin, when applied as the nanoparticle-
bound formulation, was 4-fold higher, and the mean residence time was increased to the 6-
fold. Furthermore, compared to the drug in solution and to the simple combination of 
doxorubicin with Tween 80® and empty PBCA NP, the Tween 80®-coated nanoparticles led 
to the highest initial plasma concentration, whereas the differences in the body distribution 
were not large, but in some organs statistically significant. In previous studies by Couvreur et 
al. (Couvreur et al. 1982) the coated as well as the uncoated nanoparticle formulations led to a 
drastically decreased doxorubicin concentration in the heart. Since the therapeutical use of 
doxorubicin is known to be limited by its cardiotoxicity, PBCA NP-bound doxorubicin may 
provide an alternative therapeutic doxorubicin administration. The most important 
observation of Gulyaev et al. was that doxorubicin was delivered into the brain after 
administration of Tween 80®-coated doxorubicin PBCA nanoparticles (Gulyaev et al. 1999). 
While with all other drug formulations concentrations were below the detection limit (0.1 
µg/g), the coated doxorubicin PBCA nanoparticles yielded a doxorubicin concentration of 6 
µg/g within the brain. Steiniger et al. were able to show that this application mode of 
doxorubicin is suitable to affect tumor growth in vivo (Steiniger et al. 2004). Rats bearing 
intracranially implanted glioblastoma showed significantly higher survival times when they 
were treated with Tween 80®-coated doxorubicin-loaded nanoparticles, accordant to a total 
dose of 2.5 mg/kg doxorubicin. Over 20 % of this animal group showed long term remission 
(100-180 days), whereas animals in all other groups, treated with vehicle, drug in solution, or 
with combinations of doxorubicin with Tween 80® or empty PBCA NP, died within 50 days. 
Interestingly, no doxorubicin-related neurotoxicity was observed (Steiniger et al. 2004), being 
a controversially discussed issue for several years. Neuwelt et al. concluded from their 
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experiments on osmotic opening of the BBB and intracarotid drug application in rodent and 
canine models that even small amounts of doxorubicin or its metabolites cause neurotoxicity 
(Neuwelt et al. 1981). However, in clinical trials liposomal doxorubicin and daunorubicin, 
another anthracycline, exhibited no significant neurotoxic effects, even though both drugs 
were successfully delivered to the brain after i.v. injection (Boiardi et al. 1999; Lippens 1999; 
Koukourakis et al. 2000). A more detailed study on the toxicity of doxorubicin formulations 
was performed by Gelperina et al. (Gelperina et al. 2002). When applied to healthy rats and to 
rats with intracranial glioma, nanoparticle-bound doxorubicin showed lower toxicity 
compared to the drug in solution. These findings were confirmed by the results of Steiniger et 
al., who further demonstrated that, compared to the uncoated doxorubicin PBCA NP, the 
coating with Tween 80® did not lead to increased, but to alleviated systemic drug-related 
toxicity (Steiniger et al. 2004). 
In summary, Tween 80®-coated PBCA NP are considered as a very promising therapeutic 
system for the delivery of doxorubicin and possibly also other antitumor drugs across the 
BBB to the brain, and consequently a promising approach to overcome the pgp-mediated 
multi-drug resistance. In view of the reported minimized systemic toxicity and the lack of 
short-term neurotoxicity, the surfactant-coated doxorubicin-loaded PBCA nanoparticles may 
provide an efficient non-invasive, and probably well tolerated chemotherapeutic approach to 
the treatment of CNS malignancies, such as glioblastoma multiforme. 
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3.2 Objective 
 
The chemotherapy of malignant brain tumors by the systemic application of anticancer drugs 
is strongly restricted by physiological barriers between the systemic blood circulation and the 
near tumor environment. Amongst those barriers the BBB bears several physiological 
resistance mechanisms against toxins and toxic metabolites. Those mechanisms are 
responsible for the strictly limited penetration of many registered drugs and experimental 
compounds into the brain as the primary step for drug delivery after systemic administration. 
The pgp efflux transporter consists one of the main representatives of these resistance 
mechanisms, responsible for absence of a successful pharmacological treatment. Doxorubicin, 
a registered anticancer drug, is a good substrate for pgp, and thus hardly enters the brain. 
Biodegradable PBCA NP, coated with the surfactant polysorbate 80 (Tween 80®) have been 
evaluated as a carrier system for this compound in studies with glioma in rats, showing a 
significant transport of doxorubicin into the brain (Gulyaev et al. 1999). 
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Figure 3-5: Chemical structure of the anthracycline derivative doxorubicin (adriamycin). 
Due to its planar anthracycline partial structure the compound intercalates into double 
stranded DNA, causing inhibition of the topoisomerase II enzyme. The DNA transcription is 
perturbed, and as a consequence also the DNA/RNA synthesis. Doxorubicin is registered for 
the treatment of various malignancies (Adriblastin®, Caelyx®, DOXO-Cell®, and others). 
Since it does not penetrate into the CNS after systemic administration, it is not registered for 
the chemotherapy of any type of CNS tumor. Targeted doxorubicin delivery to certain body 
compartments is not only anticipated to provide an increased therapeutic efficacy against 
tumors, but also to minimize the common side effects, like bone marrow suppression, 
cardiotoxicity, and the development of secondary neoplasia. 
 
However, up to now, the mechanism of the enhanced drug delivery to the brain, by the use of 
the Tween 80®-coated PBCA NP carrier system, has not been sufficiently elucidated. The 
transport across the BBB has been suggested to occur due to various single or combined 
mechanisms (Kreuter 2001): 
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• passive diffusion of the drug after binding of nanoparticles to the inner endothelial 
lining of the brain capillaries, and thereby creating a concentration gradient of 
nanoparticle-released drug at the BBB. 
• drug uptake by endocytosis of nanoparticles by the brain endothelial cells, 
followed by the intracellular drug release and delivery to the brain. 
• transcytosis of drug-loaded nanoparticles through the endothelial cells. 
• the tight junctions could be opened by the nanoparticles, allowing paracellular 
transport of released drug or of whole drug-loaded nanoparticles. 
• a general effect of the surfactant Tween 80® on the endothelial cell membrane 
fluidity, e.g. by membrane solubilization. 
• Tween 80® could modulate the function of membranous efflux transporters such as 
pgp. 
 
The objective of this work was to evaluate the efficacy of the polybutylcyanoacrylate 
nanoparticles as a carrier for the registered anticancer drug doxorubicin against pgp-
overexpressing cells. Since the pgp largely contributes to drug resistance of most of the 
primary malignant brain tumors in adults, such as glioblastoma multiforme, the aim of the 
performed experiments was to investigate the possibility of breaking through the pgp efflux 
mechanism with the doxorubicin-loaded nanoparticles in vitro. Therefore, cells with pgp-
overexpression were included in a major part of the described investigations. The  presented 
work includes the determination of pgp expression in KB wild type and KBv1 cells, and in 
the human glioblastoma cell variants U-87 MG, U-118 MG, and U-373 MG. Moreover, the 
determination of the chemosensitivity of KB wild type and KBv1 cells to doxorubicin and 
doxorubicin nanoparticle formulations was subject to this work. The effect of different drug 
formulations on the doxorubicin uptake was investigated flow cytometrically, using the 
abovementioned cell types. A major emphasis was put on microscopic investigations on the 
uptake and the intracellular distribution of doxorubicin and of doxorubicin nanoparticle 
formulations. Therefore, new glioblastoma cell lines were established and used in confocal 
laser-scanning microscopic studies of cellular drug distribution and localization. 
Chapter 3 Doxorubicin-loaded nanoparticle formulations 29
 
 
3.3 Materials and methods 
 
3.3.1 Drugs and chemicals 
 
If not especially stated, chemicals were of analytical grade and purchased from Merck 
(Darmstadt, Germany). Doxorubicin was purchased from Sigma (Deisenhofen, Germany); a 1 
mM stock solution was made in 70 % ethanol. Vinblastine (Sigma) was kept as a 1 mM stock 
solution in 70 % ethanol. SDZ PSC 833 (Valspodar®) was a gift from Novartis (Nürnberg, 
Germany); a 1 mM stock solution was prepared in 70% ethanol. All stock solutions were 
stored at -20 °C. The following selection antibiotics were used: ampicillin (Amp, 100 µg/µl, 
Sigma), kanamycin (Kan, 50 µg/µl, Sigma), geneticin (G418, 400 µg/µl, PAA Laboratories, 
Cölbe, Germany) and puromycin (Pur, 10 µg/µl, Sigma). All antibiotics were kept as 
aliquoted stock solutions in millipore water at -20 °C.  
 
3.3.2 Preparation of polybutylcyanoacrylate nanoparticle formulations 
 
All nanoparticles were prepared in the workgroup of Prof. Kreuter (Institute for 
Pharmaceutical Technology, Johann Wolfgang Goethe Universität, Frankfurt, Germany). To a 
solution of 2 % dextran 70,000 in 0.01 N hydrochloric acid adjusted to pH 2.0, monomeric 
butylcyanoacrylate was added, yielding a final monomer concentration of 1 % (weight per 
volume). After stirring on a magnetic stirrer at 500 rpm for 4 hours, the mixture was 
neutralized with 0.1 N sodium hydroxide solution, filtered through a G2 glass filter, and 
afterwards aliquoted into 2 ml vials for lyophilization (3 % mannitol served as cryoprotector). 
For the preparation of doxorubicin-loaded nanoparticles (DoxoNP) the total stirring time was 
2.5 hours instead of 4 hours, and after the first 30 minutes a solution of doxorubicin (10 
mg/ml in 0.9 % NaCl saline) was added in order to yield a final concentration of 0.25 %. Prior 
to the experiments the nanoparticles of one lyophilized aliquot were freshly resuspended in 
0.9 % saline or in the appropriate culture medium, respectively. Surfactant-coated 
nanoparticles were prepared by resuspending lyophilized PBCA nanoparticles in 0.9 % saline 
containing 1 % Tween 80®, followed by stirring at room temperature for 15 minutes. With 
respect to the performed experiment, the nanoparticle stock suspensions were further diluted 
using 0.9 % NaCl solution or serum free culture medium, respectively. 
30 Doxorubicin-loaded nanoparticle formulations Chapter 3
 
3.3.3 Cell lines and culture conditions 
 
The human U-87 MG (HTB 14, passage 126), the U-118 MG (HTB 15, passage 448) and the 
U-373 MG (HTB-17, passage 182) glioblastoma/astrocytoma cell lines (Beckman et al. 1971) 
were obtained from the American Type Culture Collection (ATCC). Cell banking and quality 
control were performed according to the "seed stock concept" (Hay 1988). U-87 MG and U-
373 MG cells were grown in Eagle´s minimum essential medium (EMEM, Sigma,) containing 
L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium pyruvate, and 5 % fetal calf serum (FCS, 
Biochrom, Berlin, Germany), whereas the U-118 MG cells were maintained in Dulbecco´s 
minimum essential medium (DMEM, Sigma) which was also supplemented with 5 % FCS. 
The human KB wild type (KBwt) cells (ATCC CCL-17) were cultured in DMEM with 10 % 
FCS supplement, and the pgp-overexpressing KBv1 variant was maintained in DMEM 10 % 
FCS, containing 300 ng/ml vinblastine. All cells were cultured in a water-saturated 
atmosphere of 95 % air and 5 % carbon dioxide at 37 °C in 75-cm² culture flasks (Nunc, 
Wiesbaden, Germany) and were serially passaged following trypsinization using trypsin (0.05 
%)/EDTA(0.02 %) (Roche Diagnostics, Mannheim, Germany). 
 
3.3.4 Chemosensitivity assay 
 
The assays were performed according to Bernhardt et al. (Bernhardt et al. 1992). In brief: 
tumor cell suspensions (100 µl/well) were seeded into 96-well flat bottomed microtitration 
plates (Greiner, Frickenhausen, Germany) at a density of ca. 15 cells/microscopic field 
(magnification 320x). After 2-3 days the culture medium was removed by suction and 
replaced by fresh medium (200 µl/well) containing varying drug concentrations, different 
nanoparticle formulations, or vehicle, respectively. Drugs and nanoparticle formulations were 
added as 1000-fold concentrated feed solutions. On every plate 16 wells served as controls 
and 16 wells were used per drug concentration. After various times of incubation the cells 
were fixed with glutardialdehyde (Merck, Darmstadt, Germany) and stored in a refrigerator. 
At the end of the experiment all plates were stained with crystal violet (Serva, Heidelberg, 
Germany) simultaneously. Absorbance was measured at 578 nm using a Biotek 309 
Autoreader (Tecnomara, Fernwald, Germany). Growth curves were created using SigmaPlot 
analysis software (Systat Software GmbH, Erkrath, Germany). When necessary for data 
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illustration, the absorbance values were further transformed into corrected T/C values, 
expressing the net growth of the treated cells, relative to the growth of the vehicle control.  
 
3.3.5 Immunostaining 
 
The expression of pgp in KBwt, KBv1, and the human glioblastoma cell variants was 
investigated by immunostaining and confocal fluorescence microscopy. The cells were seeded 
into chamberslides (Nunc, Wiesbaden, Germany). At an appropriate density, the cells were 
fixed with 4 % paraformaldehyde (PFA) solution in phosphate buffered saline (PBS) for 20 
minutes at room temperature. After discarding the fixative the cells were washed three times 
with 300 µl of PBS containing 0.5 % bovine serum albumin (BSA, Serva, Heidelberg, 
Germany). Cells were permeabilized by incubation with 0.1 % Triton X-100 solution in PBS 
containing 0.5 % BSA (PBS/BSA) for 10 minutes at room temperature (150 µl per well). The 
cells were washed three times with 300 µl of PBS/BSA and incubated with 125 µl of a 1:200 
dilution of the monoclonal mouse anti-human pgp Ab2 primary antibody Clone F4 (Dianova, 
Hamburg, Germany) for 1 hour at room temperature. After removing the excess primary 
antibody and washing three times with PBS/BSA, the cells were incubated with 125 µl of 
1:200 diluted fluorescein isothiocyanate (FITC)-conjugated polyclonal rabbit anti-mouse IgG 
secondary antibody (F0261, DAKO, Hamburg, Germany) for 1 hour at room temperature. For 
pgp staining after incubation of cells with doxorubicin, an Alexa (Panchuk-Voloshina et al. 
1999) Fluor® 546-conjugated anti-mouse secondary antibody (A11030, Molecular Probes, 
Eugene, USA) was used at a dilution of 1:200. The cells were washed three times with 
PBS/BSA and with millipore water. After air drying and mounting with Fluoromount 
mounting medium (Serva, Heidelberg, Germany) the cells were inspected with a Carl Zeiss 
Axiovert 200M confocal laser-scanning microscope, equipped with a LSM510 scanning unit. 
 
3.3.6 UV-vis and fluorescence spectroscopy 
 
For the determination of the doxorubicin stock concentrations, UV absorption spectra of 
doxorubicin were acquired in 96 % ethanol. UV-vis absorption difference spectra of 
doxorubicin/DNA were recorded using a set of matched tandem cuvettes (Hellma, No. 230-
QS, Müllheim, Germany), containing two compartments of equal pathlength (4.375 mm). 
DNA concentrations of 10 µg/ml, 20 µg/ml and 60 µg/ml were added to a 20 µM doxorubicin 
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solution in CS buffer (10 mM tri-sodium citrate, 150 mM NaCl). All absorption spectra were 
measured using a Cary 100 conc. spectrophotometer (Varian, Darmstadt, Germany) at room 
temperature. Different concentrations of DNA (from calf thymus, Sigma, final concentrations: 
0.5, 1.0, 3.0, 5.0, 10.0, 30.0, and 50.0 µg/ml) were added to a 1 µM doxorubicin solution in 
CS buffer and fluorescence excitation (λex = 488 nm) and emission spectra (λem = 589 nm) 
were acquired five times and averaged using an AMINCO-Bowman AB2 spectrofluorometer 
(workgroup of Prof. Wolfbeis, University of Regensburg). All spectra were corrected for the 
wavelength dependent photomultiplier sensitivity by using an internal calibration feature of 
the instrument. After that, excitation and emission spectra were normalized to 100 arbitrary 
units of relative fluorescence excitation respectively emission. 
 
3.3.7 Flow cytometry 
 
Confluent cells were trypsinized and harvested from 75-cm² culture flasks (Nunc, Wiesbaden, 
Germany). The cell suspension was washed one time with PBS and adjusted to a cell number 
of 5·105 cells/ml PBS. 1 ml aliquots were dispensed into 1.5 ml reaction vessels (Eppendorf, 
Wesseling-Berzdorf, Germany), the cells were centrifuged at 300 g for 5 minutes, and the 
supernatant was discarded. The cell pellets were resuspended in 200 µl of PBS containing the 
respective drug formulation: dissolved doxorubicin 500 nM, PBCA NP suspension (blank), 
PBCA NP suspension containing the equivalent concentration of doxorubicin, Tween 80®-
coated PBCA NP suspension, Tween 80®-coated PBCA NP suspension containing the 
equivalent concentration of doxorubicin. The cells were incubated for 2 hours or 4 hours, 
respectively, at 37 °C in the dark. For flow cytometric analysis with a FACSCalibur™ 
(Becton Dickinson, Heidelberg, Germany) the samples were filled up with PBS to a final 
volume of 500 µl. Cell-associated doxorubicin fluorescence was detected in the FL2 detection 
channel. For each measurement data were acquired for 30,000 events gated from a FSC/SSC 
dotplot. Instrument settings: E-1 for FSC, 260 for SSC and 474 for FL2. Data were analyzed 
by the WinMDI 2.8 FACS analysis software. 
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3.3.8 Amplification and purification of localization vectors  
3.3.8.1 Localization vectors 
The following localization vectors were used: pECFP-ER (Takara Bio Europe/Clontech, 
Saint-Germain-en-Laye, France), pECFP-Golgi (Clontech), pECFP-Mem (Clontech) and 
pECFP-Mito (Clontech), whereas the latter two vectors were modified by subcloning into the 
retroviral expression vector pQCXIP (Clontech). For restriction maps of all used localization 
vectors see Fig. 3-6. For amplification of all vectors, competent E. coli (strain TOP10, 
Invitrogen GmbH Karlsruhe, Germany) were transformed with 1 ng of plasmid DNA. 
 
 
Figure 3-6: Restriction maps of localization vectors. The sequences encoding the 
fluorescent fusion proteins for plasma membrane and mitochondria localization were 
subcloned into the multiple cloning site (MCS) of the retroviral expression vector pQCXIP. 
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3.3.8.2 Culture media and selection agar 
E. coli cells were cultured in Luria Bertani (LB) medium, which was prepared by dissolving 
10 g of NaCl (Merck, Darmstadt, Germany), 10 g of tryptone (Difco, Detroit, USA), and 5 g 
of yeast extract (Roth, Karlsruhe, Germany) in 1 l of millipore water, adjusted to pH 7.0. 
After autoclaving, the selective media were prepared by adding Amp (Kan) to a final 
concentration of 100 mg/l (50 mg/l). For the preparation of selective agar plates 20 g of agar 
agar (Roth, Karlsruhe, Germany) were dissolved in 1 l of LB medium, followed by 
autoclaving. The sterilized medium was cooled down to 55–60 °C, and Amp (Kan) was added 
to a final concentration of 100 mg/l (50 mg/l). The agar plates were poured immediately (20 
ml solution per plate) and stored at 4 °C. The salt optimized + carbon (SOC) medium was 
prepared by dissolving KCl (2.5 mM MgCl2 [10 mM] andMgSO4 [10 mM] in LB medium. 
After autoclaving, glucose was added to yield a concentration of 20 mM. 
 
3.3.8.3 Preparation of competent bacteria 
For the preparation of competent E. coli cells, 5 ml of LB medium were inoculated with E. 
coli TOP10 (glycerol stock) and incubated overnight at 37 °C on a shaker (200 rpm). 200 ml 
of LB medium were inoculated with 2 ml from an overnight culture and grown for 2-2.5 hours 
until the bacteria had reached an optical density (OD600 nm) of 0.2. The bacterial suspension 
was cooled on ice for 10 minutes, centrifuged for 7 minutes at 3000 rpm (4 °C), and the 
supernatant was discarded. The pellet was resuspended in 32 ml of ice-cold CaCl2 solution 
(60 mM CaCl2·2 H2O, 10 mM PIPES, 15 % glycerol, pH 7.0, sterilized by autoclaving) and 
incubated on ice for 30 minutes. Again the bacteria were centrifuged (7 minutes, 2500 rpm, 4 
°C) and the pellet was resuspended in 6.4 ml of ice-cold CaCl2 solution. The suspension was 
portioned into 200 µl aliquots (1.5 ml reaction vessels, Eppendorf), and after incubation on 
ice for 2 hours the aliquots were frozen in liquid nitrogen and stored in a -80 °C freezer. 
 
3.3.8.4 Transformation of E. coli cells 
For each transformation one aliquot (200 µl) of competent bacteria (E. coli TOP10) was 
thawn on ice, and then the plasmid DNA (dissolved in 10 mM HEPES, pH 8.5) was added. 
After incubation on ice for 30 min, the bacteria were put onto a 42 °C water bath for 90 
seconds and immediately put back on ice for 5 minutes. 1 ml of SOC medium was added, and 
the bacteria were incubated for 45 minutes at 37 °C (shaker, 200 rpm) to obtain a starting 
culture. Then, 20-100 μl of the bacterial suspension were plated on selective agar and the 
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plates were incubated at 37 °C until single colonies appeared. When no colonies had appeared 
after 48 hours transformation was repeated. The resistant colonies were used for the 
inoculation of LB medium for plasmid DNA preparations from overnight cultures. 
 
3.3.8.5 Plasmid DNA maxipreparation and determination of plasmid DNA 
For each plasmid DNA maxipreparation 200 ml of LB medium, supplemented with the 
appropriate selection antibiotic (Amp 100 µg/ml, Kan 50 µg/ml), were inoculated with a 
single colony from a selection agar plate. The culture was grown overnight at 37 °C (shaker, 
200 rpm). Next day, the DNA was isolated using the Qiagen Plasmid Purification Kit 
(Qiagen, Hilden, Germany) after taking a sample from the bacterial culture for the preparation 
of a glycerol stock culture (800 µl of bacterial suspension, 200 µl 85 % glycerol), which was 
stored at -80 °C. The isolation of the DNA was performed according to the manufacturer´s 
instructions (Qiagen-tip 500 column). 
 
3.3.8.6 Restriction digest 
The following enzymes were used for restriction analysis of plasmid DNA: BamHI (20 U/µl, 
New England Biolabs GmbH [NEB], Frankfurt am Main, Germany), EcoRI (10 U/μl, MBI 
Fermentas GmbH, St. Leon-Rot, Germany), NotI (10 U/µl, Fermentas), NheI (10 U/µl, NEB); 
StuI (10 U/µl, Amersham Pharmacia Biotech, Piscataway, NJ, USA). Normally, 1 μl of the 
enzyme stock solution was mixed with 2 μl of the appropriate 10x reaction buffer from the 
respective manufacturer. After addition of 1 µg of DNA the samples were diluted to a final 
volume of 20 μl with millipore water, and incubated for 60 minutes at 37 °C. The samples 
were cooled to room temperature and either processed immediately for agarose gel 
electrophoresis or stored at -20 °C. 
 
3.3.8.7 Agarose gelelectrophoresis 
5x TBE buffer contained 445 mM tris-base (USB, Cleveland, USA), 445 mM boric acid and 
10 mM EDTA (Titriplex III). The 5x TBE buffer stock was diluted by 1:5 with millipore 
water to obtain 1x TBE for preparation of agarose gels. 0.375 g of agarose (peqGOLD 
Universal-Agarose; Peqlab, Erlangen, Germany) were dissolved in 50 ml of 1x TBE buffer 
under heating on a magnetic stirrer, then 2 μl of ethidium bromide solution (10 mg/ml H2O, 
Janssen Chimica, Beerse, Belgium) were added. The mixture was cooled at room temperature 
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for an appropriate period of time and poured into the gel chamber. The solidified gel was 
covered with 1x TBE buffer up to the denoted fill line. The DNA samples were prepared from 
the restriction digest products, whereas 10 µl of digested DNA solution were mixed with 2 µl 
of 6x gel loading buffer. The gel pockets were filled with 5 µl of the DNA/loading buffer 
mixture immediately before the electrophoresis was started. On each gel one or two pockets 
were filled with 5 µl of the MassRulerTM DNA Ladder High Range (1.5-10 kb, Fermentas) 
ready-to-use DNA standard (grading: 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, and 10.0 bp). 
Electrophoresis was run at a voltage of 90 V, resulting in a total duration of  80–120 minutes. 
After electrophoresis, the gels were inspected in a gel analysis and documentation system 
(Gel-Doc, Bio-Rad Laboratories, Munich, Germany) with UV excitation of 254 nm. The 
acquired data were analyzed with the Quantity One software (Bio-Rad). 
 
3.3.9 Transient and stable transfection of human glioblastoma cells 
 
For transient transfection, cells were seeded into LabTek® chambered coverglasses (8 well, 
Nunc, Wiesbadenm, Germany) in the appropriate culture medium, 350 µl of cell suspension 
per well. At 50 % confluency, at least 48 hours after seeding, the cells were transfected with 
the respective localization vector DNA, using the FuGene® 6 transfection reagent (Roche, 
Mannheim, Germany). The DNA/FuGene®-complex was prepared prior to the transfection, 
according to the manufacturers instructions. For each well 0.25 µg of plasmid DNA were 
used. Controls were run without FuGene® and without the DNA/FuGene®-complex, 
respectively. After 36-48 hours the transiently transfected cells were prepared for microscopic 
examination. In order to obtain stably transfected cell lines, wild-type cells were seeded in 6-
well plates (Greiner, Frickenhausen, Germany) and transfected as described for the transient 
transfection, whereas 1 µg of DNA was used for each well. 48 hours after transfection the 
culture medium was exchanged by medium containing the respective selection antibiotic. 
G418 (Geneticin, PAA Laboratories) was used at concentrations ranging from 400 to 800 
µg/ml and puromycin (Sigma) at concentrations from 1 to 3 µg/ml. After the first passage 
cells were maintained in 25-cm² culture flasks (Nunc, Wiesbaden, Germany). 
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3.3.10   Image acquisition of living cells by confocal laser-scanning microscopy 
 
Living cells were seeded into 8-well LabTek® chambered cover slides (Nunc, Wiesbaden, 
Germany). After 48 hours respectively at the appropriate cell density, the culture medium was 
exchanged with Leibovitz L15 medium (Sigma), supplemented with 5 % FCS. DRAQ5TM 
(Biostatus Limited, Leicestershire, UK) was used as nuclear counterstain for 
multifluorescence CLSM imaging at a final concentration of 5 µM. All cell variants were 
imaged with a Carl Zeiss Axiovert 200M LSM510 confocal laser-scanning microscope 
(CLSM), surrounded by a tempered incubation chamber (37 °C). The proper instrument 
settings were evaluated for all used fluorophor combinations, with respect to excitation and 
emission crosstalk between the fluorophors. The particular instrument settings (laser 
excitation wavelengths, beam paths, filter combinations) for the acquisition of each image of 
fluorophore combination are described in the legends of the respective figures. When 
required, images were processed with the Carl Zeiss LSM Image Examiner or LSM Image 
Browser software. 
 
3.3.11   Preparation of fixed samples for confocal laser-scanning microscopy 
 
Cells were fixed with 400 µl of paraformaldehyde solution (PFA, 4 % in PBS, 20 min, room 
temperature) for each well of a chambered coverglass and chamberslide, respectively. When 
the cells had been grown on chambered coverglasses the fixative was removed, the cells were 
washed with PBS, supplemented with 0.5 % BSA, and 400 µl of PBS was added, followed by 
immediate image acquisition. After fixation of cells grown on chamberslides the cells were 
washed with PBS 0.5 % BSA and air dried for 5 min. The microscopic slides were mounted 
with either Confocal-Matrix® (Micro-Tech-Lab, Graz, Austria) or Fluoromount mounting 
medium (Serva, Heidelberg, Germany). 
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3.4 Results 
3.4.1 Expression of pgp by human glioblastoma cells and by KBwt and KBv1 
cells 
 
Figure 3-7 shows the results of the immunostaining with the anti-pgp antibody. While KBv1 
cells showed the expected high membranous expression, pgp was not detected in the 
glioblastoma variants. These results are in agreement with the RT-PCR results (Chapter 4). 
 
KBv1 U-87 MG
U-118 MG U-373 MG
cm
nuc
 
Figure 3-7: Immumostaining of fixed human glioblastoma cell variants U-87 MG, U-118 
MG, and U-373 MG. KBv1 cells served as positive control for pgp-overexpression. Besides 
the non-specific binding of the secondary antibody, no FITC fluorescence emission was 
detected in the glioma cells; cm: cytoplasmic membrane; nuc: nucleus; Plan-Apochromat 
63x/1.4 oil, Ar 488, HFT 488, LP505.  
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Compared to the vinblastine-treated KBv1 control cells, the KB wild type cells showed a 
markedly lower extent of pgp expression (Fig. 3-8). However, KBwt cells were not 
completely negative for pgp. Since the images represent a single optical section within the z-
expansion of the cells, it had to be ensured, that the surrounding cells were imaged too and not 
excluded from data acquisition due to the confocal image acquisition mode. As becomes 
obvious from the false color display (Fig. 3-8), the selected z-plane is representative of the 
surrounding KBwt cells too. 
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Figure 3-8: Immunofluorescent staining of pgp in KBv1 and KBwt cells. 90 % of the 
KBv1 cells show high membranous pgp expression compared to ca. 16 % of the wild type 
cells (upper row). The rainbow false color mode (lower row) displays the fluorescence 
intensity in each image pixel, whereas warmer colors represent higher intensities. cm: 
cytoplasmic membrane; nuc: nucleus. Plan-Apochromat 63x/1.4 oil, Ar 488, HFT 488, 
LP505. 
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3.4.2 Effect of the mode of doxorubicin application on the proliferation of pgp-
overexpressing KBv1 cells 
 
The concentration of the doxorubicin stock solution was determined photometrically (Fig. 3-
9). The spectra of two dilutions of the stock solution were acquired (1:100 and 1:200), and the 
doxorubicin concentration was calculated from the primary absorption maximum value A234 
and ε234 = 37120 M-1 cm-1 (European Pharmacopoeia 1997) according to Lambert-Beer’s law 
(c(doxorubicin) = 2.16 mM). 
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Figure 3-9: Overlay of baseline-corrected UV spectra of doxorubicin stock solutions in 96 
% ethanol. The denoted absorption maxima are in accordance with the values of reference 
spectra in the literature (Ph. Eur. 1997). 
 
According to the results of the UV-measurements, the feed solutions (1000-fold) for the 
chemosensitivity assays were prepared. The chemosensitivity of pgp-overexpressing KBv1 
cells (continuously treated with 300 ng/ml vinblastine in culture) to doxorubicin was 
determined at concentrations ranging from 100 nM to 2 µM doxorubicin (Fig. 3-10). The 
highest doxorubicin concentration (2 µM) yielded a moderate cytotoxic effect from which the 
cells recovered completely. The high resistance of the KBv1 cells is clearly connected to the 
pgp-overexpression. This becomes obvious from the results of the incubation of KBv1 cells 
with a combination of doxorubicin to the selective pgp inhibitor valspodar (PSC 833), 
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demonstrating the dependency of the KBv1 doxorubicin-resistance on pgp functionality (Fig. 
3-10). Compared to the sole incubation of the KBv1 with 2 µM doxorubicin, the 
doxorubicin/valspodar combination resulted in a cytostatic or even cytocidal effect, 
respectively. 
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Figure 3-10:  Incubation of KBv1 cells with various concentrations of doxorubicin. PBS was 
used as negative control. ? vehicle; doxorubicin concentration: ? 100 nM, ? 500 nM, ? 1 
µM, ? 2 µM. ? doxorubicin 1 µM + valspodar (PSC 833) 1 µM. 
 
To investigate the effects of different modes of doxorubicin application against pgp-
overexpressing cells, KBv1 cells were incubated with DoxoNP and polysorbate 80-caoted 
DoxoNP up to a concentration corresponding to 3 µM of dissolved doxorubicin (Fig. 3-11). 
At a doxorubicin concentration of 1 µM all drug formulations exhibited a cytotoxic effect on 
the KBv1 cells. No significant differences in the antiproliferative activities of doxorubicin in 
solution, DoxoNP, and doxorubicin combined to polysorbate 80 were observed, even though 
the latter two modes of  application showed a slightly higher cytotoxic effect. Interestingly, 
incubation of the cells with the polysorbate 80-coated DoxoNP resulted in a stronger 
inhibition of cell proliferation.. However, the cells recovered from this temporary 
antiproliferative effect on the same time scale as the cells incubated with the other drug 
formulations. The same pattern of inhibition of cell growth was found under conditions 
equivalent to 2 µM doxorubicin, although the incubation of the cells at this concentration led 
to a generally higher extent of cytotoxicity. The DoxoNP and the mixture of dissolved 
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doxorubicin with polysorbate 80 exceeded the cytotoxic effect of dissolved doxorubicin 
alone. Moreover, the coated DoxoNP formulation exceeded the effects of the other 
formulations, and led to a delay in cell recovery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11: Chemosensitivity of pgp-
overexpressing KBv1 cells (98th 
passage) against differently formulated 
doxorubicin, up to a concentration 
equivalent to 3 µM dissolved 
doxorubicin; PBS was used as negative 
growth control. ? vehicle (PBS), ? 
doxorubicin, ? doxorubicin + 
polysorbate 80, ? doxorubicin 
nanoparticles, ? polysorbate 80-coated 
doxorubicin nanoparticles, ? paclitaxel 
20 nM. 
 
 
 
 
Finally, under conditions corresponding to 3 µM doxorubicin, differential antiproliferative 
activities were observed for the different modes of drug application. The incubation with 
doxorubicin in solution yielded a cytotoxic effect of about 35 % of growth inhibition, 
compared to the vehicle control. The cells recovered until the end of the incubation period (ca. 
200 hours). Doxorubicin + polysorbate 80 produced approximately 80 % inhibition of cell 
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growth, but the cells started to recover after this nadir. Beginning of cell recovery was also 
observed after a 90 % growth inhibition by DoxoNP. With the polysorbate 80-coated 
doxorubicin-loaded PBCA nanoparticles a cytostatic effect occurred. Cell proliferation was 
inhibited by ca. 95 % of vehicle control, and the cells failed to recover. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12: Incubation of KBv1 cells 
(75th passage) with various 
concentrations and combinations of 
polymeric PBCA nanoparticles and 
polysorbate 80. PBS was used as 
negative control. ? vehicle (PBS), ? 
PBCA nanoparticles accordant to the 
respective amount of DoxoNP, ? 
polysorbate 80 accordant to 
doxorubicin combined to polysorbate 
80, ? PBCA nanoparticles combined 
to polysorbate 80 accordant to 
DoxoNPT80. 
 
 
 
To ensure that the observed antiproliferative effects did not occur due to non-specific 
cytotoxicity of the surfactant, the nanoparticle polymer, or a combination of both, KBv1 cells 
were incubated with the respective amounts of the combination of empty PBCA nanoparticles 
and polysorbate 80. The results are shown in Fig. 3-12. As becomes obvious from the T/Ccorr 
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graphs, the proliferation of the KBv1 cells was not inhibited at any concentration of the 
applied controls. A slight cytotoxic effect seems to occur with polysorbate 80 (according to 1 
µM and 2 µM doxorubicin combined to polysorbate 80). However, since the T/Ccorr values of 
the vehicle control are found within the experimental errors of the treated cells, this effect is 
insignificant. 
The KBwt cells showed surprisingly low chemosensitivity to doxorubicin, even though 
expressing low levels of pgp. Concentrations up to 1 µM doxorubicin led to a strong cytotoxic 
effect. However, the cells recovered, and 2 µM doxorubicin were required to provide a 
cytocidal effect (Fig. 3-13). These findings may be explained by a fast upregulation of the pgp 
expression in KB wildtype cells, when incubated with the pgp substrate doxorubicin. 
 
 
 
 
 
 
 
 
 
 
Figure 3-13: Chemosensitivity of 
KBwt cells to doxorubicin. ? vehicle 
(PBS); doxorubicin concentration: ? 
100 nM, ? 200 nM, ? 500 nM, ? 1 
µM, ? 2 µM. 
 
In order to investigate, if the portion of pgp-overexpressing cells may be raised within a few 
days of incubation with a pgp substrate, KBwt cells were incubated for 72 hours with 1 µM 
doxorubicin. Then, after a fixation step, the pgp expression was determined by 
immunostaining followed by CLSM image acquisition. As shown in Fig. 3-14, the percentage 
of pgp-overexpressing cells increased from ca. 10 % at 0 hours to almost 100 % at 72 hours of 
doxorubicin exposure. Fig. 3-14 also depicts a nuclear localization of doxorubicin, which is 
fluorescent due to its anthracycline partial structure (Fig. 3-5), and thus serves as a nuclear 
stain in these experiments. 
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Figure 3-14: Determination of pgp-expression in KBwt cells after 0 hours and 72 hours of 
incubation with 1 µM doxorubicin. Left: fluorescence emission of Alexa-Fluor® 546-
conjugated secondary antibody bound to anti-pgp primary antibody (green false color); 
middle: fluorescence emission of doxorubicin, localized in the nuclei; right: merged images. 
Plan-Apochromat 63x/1.4 oil, Ar 488, HFT 488, LP505, HeNe 543, HFT 458/543, BP560-
615.  
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Figure 3-15: Normalized fluorescence excitation and emission spectra of doxorubicin 
(black, 1 µM in citrate buffered saline, excitation slit: 5, emission slit 10) and Alexa Fluor® 
546 (orange, in aqueous buffer, pH 7.2, from http://probes.invitrogen.com). Emission spectra 
λex = 488 nm, excitation spectra λem = 589 nm. The displayed spectra represent five scans, 
averaged by the spectrofluorometer. The colored lines parallel to the ordinates represent the 
laser lines available for doxorubicin excitation. 
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3.4.3 Flow cytometric quantification of doxorubicin fluorescence associated 
with glioblastoma cells after incubation with different doxorubicin 
formulations 
 
The fluorescence properties of doxorubicin allow the flow cytometric quantitation of the cell-
associated doxorubicin fluorescence, after cellular uptake or adsorption to the surface of cells. 
Therefore, the three glioma cell variants were incubated with equivalent doxorubicin 
concentrations of dissolved drug, DoxoNP, and polysorbate 80-coated DoxoNP, whereas  
empty PBCA NP and PBCA NP + polysorbate 80 served as controls. The cell-associated 
doxorubicin fluorescence was determined after incubation periods of 2 hours and 4 hours. Out 
of the total number of acquired events of each measurement, the intact cell population was 
gated (Fig. 3-16). From these gated events, the corresponding histogram plot overlays were 
created, whereas the abscissa scales the relative doxorubicin fluorescence emission and the 
ordinate depicts the number of events at the respective emission intensity (Fig. 3-17). The 
geometric means of the histograms were extracted and compared in Fig. 3-18. 
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Figure 3-16: Scattergrams of (a) U-87 MG, (b) U-118 MG and (c) U-373 MG cells. The 
gated (red) events (gate R1) were used for histogram analysis. 
 
Since all of the controls (vehicle, empty nanoparticles with and without polysorbate 80) 
showed similar results, the histogram and geometric mean data are only shown for the drug 
containing formulations (Fig. 3-17, 3-18). After an incubation period of 2 hours, cell-
associated doxorubicin fluorescence was detected in all of the three glioma cell variants 
between a 2-fold (U-118 MG) and 4-fold emission intensity (U-87 MG, U-373 MG) 
compared to the autofluorescence of the cells. Similar fluorescence emission was detected 
after another two hours of incubation under the same conditions. With U-87 MG cells, after 
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an incubation period of 2 hours the DoxoNP showed an approximately 2-fold higher increase 
in fluorescence compared to dissolved doxorubicin. With the latter a further increase in 
fluorescence was observed after another 2 hours of incubation (2.5-fold of the values of the 
drug in solution). A similar pattern of cell-associated fluorescence was observed after the 
incubation of U-118 MG and U-373 MG cells. In the case of U-118 MG cells a 2 hours 
incubation period with DoxoNP led to a 3-fold higher increase in fluorescence compared to 
dissolved doxorubicin (4-fold increase after 4 h), whereas a 3-fold and 5-fold raise was 
measured with U-373 MG after 2 hours and 4 hours, respectively. 
 
 
 
 
 
 
 
 
 
Figure 3-17: FL2 fluorescence histo-
gram overlays of the gated glioblastoma 
cells. The figure shows the cell-associated 
doxorubicin fluorescence after 4 hours of 
incubation with doxorubicin formulations. 
Red: blank (no doxorubicin); black: 
doxorubicin in solution; green: DoxoNP; 
blue: polysorbate 80-coated DoxoNP. 
 
  
For the first 2 hours of incubation with the Tween80®-coated nanoparticles all three cell 
variants showed an increase in cell-associated fluorescence slightly higher than observed for 
the incubation of the glioblastoma cells with the uncoated DoxoNP. After 4 hours, the 
DoxoNPT80 exceeded the fluorescence of the uncoated DoxoNP formulation. The 
fluorescence rose to 3.5–7.5-fold, compared to the dissolved drug.  
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Figure 3-18: Effect of the mode of 
drug application on the cell-associated 
doxorubicin fluorescence of human 
glioblastoma cells. The geometric 
means were normalized to the cell-
associated doxorubicin fluorescence 
after incubation of the cells with 
doxorubicin (500 nM) in solution (100 
AU). 
 
 
 
3.4.4 Flow cytometric determination of cell-associated doxorubicin 
fluorescence in KB cells 
 
Human KBwt and KBv1 cells were incubated with doxorubicin formulations corresponding 
to 500 nM of dissolved doxorubicin by analogy to the experiments with the glioblastoma 
cells. The analysis of the histogram overlay data is shown in Fig. 3-19. Again the geometric 
means from the histograms were normalized to 100 arbitrary units amounting to the emission 
intensity of dissolved doxorubicin. After incubation periods of 2 and 4 hours with equivalent 
doxorubicin concentrations up to 500 nM doxorubicin, the KBwt cells showed a differential 
increase in the cell-associated doxorubicin fluorescence. The exposure to dissolved 
doxorubicin yielded an about 1.6-fold increase in the FL2 fluorescence after 4 hours, in the 
presence of the doxorubicin-loaded PBCA nanoparticles the fluorescence increased 2.5-fold.. 
The highest increase was observed with the Tween80®-coated nanoparticles. This mode of 
drug application led to an about 6.6-fold elevation of the cell-associated fluorescence and 
clearly exceeded the effects of the other drug formulations. Compared to an incubation period 
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of 2 hours, a further fluorescence increase was observed after 4 hours of incubation, 
especially for the Tween80®-coated nanoparticles.  
The different modes of doxorubicin application show clear differential effects on the 
increase in the cell-associated fluorescence of the KBwt cells with weak pgp-expression, but 
not in the cells with pgp-overexpression (KBv1). After 2 hours of incubation a 2-2.5-fold 
increase in the cell-associated doxorubicin fluorescence was measured. This was followed 
only by a marginal rise after the 4 hours incubation period. The effect of dissolved 
doxorubicin on cell-associated fluorescence was not drastically exceeded by the nanoparticle 
formulations. 
As becomes obvious from the results of the chemosensitivity experiments (Fig. 3-10, 3-
11), 500 nM doxorubicin is a concentration which does not inhibit the growth of KBv1 cells, 
presumably due to the overexpression of pgp. A first significant difference in the extent of the 
cytotoxic effect of different doxorubicin formulations against KBv1 cells was observed with a 
concentration of 2 µM doxorubicin (Fig. 3-11). Compared to the dissolved drug, an enhanced 
cytotoxic activity was observed with the DoxoNP and polysorbate 80-coated DoxoNP. This 
indicates an overcome of the pgp-mediated doxorubicin efflux and an increased cellular 
accumulation of the compound, respectively, when applied as nanoparticle formulations. 
Therefore, KBv1 cells were incubated with doxorubicin formulations, equivalent to 2 µM 
doxorubicin, for 2 and 4 hours. Flow cytometric measurement and data analysis were 
performed as described for the previously used concentration (500 nM). The results are shown 
in Fig. 3-20. Both cell types, KBwt and KBv1, show a pattern of doxorubicin-related 
fluorescence similar to U-87 MG, U-118 MG, and U-373 MG, after incubation with 500 nM 
doxorubicin. The concentration of 2 µM doxorubicin appears to break through the pgp-
mediated multi-drug resistance, leading to high cell-associated doxorubicin fluorescence in 
pgp-overexpressing KBv1 cells. 
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Figure 3-19: Effect of the mode of doxorubicin application on the cell-associated 
fluorescence of human KB cells. Upper row: dotplots of KBwt and KBv1 cells. Middle row: 
histogram overlays of gated KB cells after 4 hours of incubation. Red: blank (no 
doxorubicin); black: doxorubicin in solution; green: DoxoNP; blue: polysorbate 80-coated 
DoxoNP.  Lower row: comparison of normalized doxorubicin-related fluorescence emission 
associated with pgp low expressing KBwt (right) and pgp high expressing KBv1 cells (left).  
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Figure 3-20: Comparison of cell-associated doxorubicin fluorescence in KBwt and KBv1 
cells after incubation of the cells with different doxorubicin formulations, amounting to 2 µM 
doxorubicin. Upper row: forward-sideward scattergrams (dotplots) of KBv1 (a) and KBwt (b) 
cells. Middle row: FL2 fluorescence histogram overlays of the different samples; red: blank 
(autofluorescence), black: doxorubicin in solution, green: doxorubicin loaded nanoparticles, 
blue: polysorbate 80-coated DoxoNP. Lower row: comparison of normalized doxorubicin 
fluorescence values. 
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3.4.5 Distribution of doxorubicin fluorescence in human glioblastoma cells 
 
The findings from the flow cytometric experiments indicate a differential cellular doxorubicin 
accumulation after incubation with various drug formulations. Thus, the cellular distribution 
of doxorubicin-related fluorescence in living glioblastoma cells was investigated by confocal 
laser-scanning microscopy. In a preliminary experiment U-87 MG glioblastoma cells were 
incubated with doxorubicin in solution, at a concentration of 10 µM, for 5 minutes at 37 °C 
(inside the incubation chamber of the microscope) followed by CLSM image acquisition of 
the living cells (Fig. 3-21). After this short period of incubation with the dissolved drug, 
doxorubicin-related fluorescence was detected throughout the cytoplasm with higher intensity 
in the proximity of the nuclei. Surprisingly, the nuclei remained unstained. 
 
Doxorubicin Doxorubicin
 
Figure 3-21: Distribution of doxorubicin fluorescence in living U-87 MG cells, incubated 
with doxorubicin. The rainbow false color mode (right image) displays the fluorescence 
intensity of each image pixel. Warmer colors represent higher intensities. This display mode 
illustrates the diffuse fluorescence in the cytosol with accumulation of doxorubicin in the 
vicinity of the nuclei, which appear unstained. Plan-Apochromat 63x/1.4 oil, HeNe 543, HFT 
488/543/633, LP650. 
 
Since doxorubicin exclusively stained cell nuclei in fixed KBwt cells (Fig. 3-14), this major 
difference in the cellular doxorubicin distribution was further investigated by comparison of 
living and fixed cells, incubated with doxorubicin under equal conditions. To make sure that 
lack of nuclear staining did not occur due to the short incubation time of 5 minutes, the 
incubation time was increased and the doxorubicin concentration was decreased. Doxorubicin 
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was applied to human U-87 MG glioblastoma cells at a concentration of 2 µM. After 60 
minutes of incubation, CLSM images were acquired of the living cells immediately. The cells 
were fixed with PFA (4 % solution in PBS) for 20 minutes at room temperature and imaged. 
Images of the living and the fixed cells are shown in Fig. 3-22. 
 
Living U-87 MG glioblastoma cells After 20 minutes of PFA fixation
nuc
nuc
 
Figure 3-22: Differential distribution pattern of doxorubicin in living and fixed U-87 MG 
cells after 1 hour of incubation; nuc: nuclei. Plan-Apochromat 63x/1.4 oil, HeNe 543, HFT 
488/543/633, BP560-615. 
 
Again, the living cells showed doxorubicin distribution mainly in the cytoplasm but no 
doxorubicin-related fluorescence was detected in the nuclei of the cells. After PFA fixation 
this distribution pattern was almost completely inverted, and the doxorubicin fluorescence 
was localized mainly in the nuclei, as depicted in Fig. 3-14, also representing fixed cells 
previously incubated with doxorubicin. Since the nuclear DNA is the primary site of action of 
the intercalating agent doxorubicin, the drug has to enter the nuclei of living cells. The lack of 
nuclear fluorescence may have occurred due to the interaction of doxorubicin with DNA, 
leading to altered fluorescence properties of the Doxo-DNA adducts. This hypothesis was 
investigated by acquisition of doxorubicin/DNA UV-vis difference spectra and fluorescence 
spectra of doxorubicin/DNA mixtures. For the UV-vis measurements a 20 µM doxorubicin 
solution was used together with DNA concentrations of 10 µg/ml, 20 µg/ml, and 60 µg/ml, 
whereas the samples for the acquisition of fluorescence spectra were prepared with 1 µM 
doxorubicin and DNA concentrations ranging from 0.5 to 50 µg/ml. The high doxorubicin 
concentration had to be chosen for the UV-vis measurements because of the lower sensitivity 
of the absorption compared to the sensitivity of fluorescence detection. The acquired 
54 Doxorubicin-loaded nanoparticle formulations Chapter 3
 
difference spectra and fluorescence excitation and emission spectra are shown in Fig. 3-23 
and Fig. 3-24, respectively. The addition of DNA did not reduce doxorubicin absorbance to a 
remarkable extent (Fig. 3-23). The slight deviations from zero shown in the inset of Fig. 3-23 
most probably result from experimental errors during sample preparation. On the contrary, 
with increasing concentrations of DNA, the relative fluorescence excitation and the 
fluorescence emission of doxorubicin decreased notably (Fig. 3-24). As becomes obvious 
from Fig. 3-25, the DNA quenches the doxorubicin fluorescence with decreasing 
doxorubicin/DNA molar ratio. This explains the observation that doxorubicin fluorescence is 
hardly found in nuclei of living cells, due to the high excess of DNA in the nucleus. Nuclear 
staining with doxorubicin after fixation with PFA may occur due to denaturation of the DNA-
histon complex, and this may lead to an increase in the nuclear concentration of free, not 
DNA-bound doxorubicin. As a consequence, further investigations on the subcellular 
distribution of doxorubicin were performed with living cells. 
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Figure 3-23: UV-vis difference spectra of doxorubicin/DNA. The inset shows the difference 
spectra with adjusted axes. Only minor differences in absorbance are observed between 200–
300 nm and 400–600 nm. The chosen DNA concentrations result in doxorubicin/DNA ratios 
identical to those of the samples containing the lowest DNA concentration in the 
spectrofluorometric measurements (see Fig. 3-24). 
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Figure 3-24: Normalized fluorescence spectra of doxorubicin and doxorubicin/DNA 
mixtures in citrate buffered saline (CS buffer). Excitation spectra λem = 589 nm; emission 
spectra λex = 488 nm (excitation slit: 5, emission slit: 10). 
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Figure 3-25: Effect of DNA on doxorubicin fluorescence. The abscissa depicts the molar 
ratio of doxorubicin and DNA. The ordinate scales the fluorescence amount as area under the 
excitation spectra curve (?) respectively under the emission spectra curves (?) from Fig. 3-
24. All areas under the curves were normalized to the areas of doxorubicin spectra curves 
without DNA (100 %). 
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3.4.6 Multifluorescence live-cell imaging and colocalization studies 
 
In order to study the cellular distribution of doxorubicin fluorescence in living cells, selective 
fluorescent labeling of various cellular compartments was evaluated for multifluorescence 
imaging, with respect to colocalization with doxorubicin. 
3.4.6.1 Fluorescent staining of nuclei in living cells 
Several requirements have to be fulfilled by an ideal fluorescent dye as nuclear counterstain 
for further multifluorescence experiments. Firstly, rapid permeation of the dye into the nuclei 
of the cells. Secondly, the dye should selectively stain nuclear DNA without causing 
background fluorescence, neither from the dissolved dye in the culture medium nor by 
staining of mitochondria or binding to RNA. Furthermore, the staining protocol should not 
require extensive preincubation periods followed by washing steps, which could lead to 
changes in the cellular distribution of other fluorescent compounds. All of these prerequisites 
were fulfilled by the fluorescent nuclear staining dye DRAQ5TM (Fig. 3-26). At a 
concentration of 5 µM DRAQ5TM selectively stained the nuclei after 1-2 minutes (Fig. 3-27). 
No washing steps of the cells were necessary and the mitochondria were excluded from 
staining (Fig. 3-27), even after incubation with DRAQ5TM up to 48 hours. 
 
DRAQ5TM
λmax = 622 nm
λmax = 676 nmOOH HN
NH O OH
N
CH3
CH3
N
H3C
CH3
 
Figure 3-26: Fluorescent cell-permeant anthrachinone derivative DRAQ5TM. Left: chemical 
structure; right: UV-vis absorbance spectrum (Smith et al. 2000). 
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DRAQ5TM MergeECFP-Mito  
Figure 3-27: DRAQ5TM-stained nuclei in living U-87 MG cells, bearing ECFP-labeled 
mitochondria. The nuclear dye (final concentration 5 µM) was added 1 minute prior to CLSM 
imaging. DRAQ5TM exclusively stained the nuclei, and no dye was detected in the 
mitochondria. Moreover, no crosstalk between ECFP and DRAQ5TM was observed. Plan-
Apochromat 63x/1.4 oil, Ar 458, HFT 548, LP475; HeNe 633, HFT 488/543/633, LP650. 
 
3.4.6.2 Mitochondrial staining in living cells 
Several compounds show high affinity to metabolically active mitochondria due to their high 
electrical potential at the inner membrane. Up to now a broad variety of fluorescent 
mitochondrial stains is commercially available, e.g. Rhodamine 123, Tetramethylrosamine, 
MitoFluorTM-, and the MitoTracker®-dyes. Especially the latter compounds stand out by their 
rapid staining and low cytotoxicity in live cell imaging. Moreover, compared to Rhodamine 
123 or Tetramethylrosamine, the MitoTracker® dyes are not washed off the mitochondria 
when their membrane potential breakes down during fixation. 
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Figure 3-28: Chemical structures of MitoTracker® Green (left) and MitoTracker® Red 
CMXRos (right). The structures were taken from the Molecular Probes homepage 
http://probes.invitrogen.com. 
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Fig. 3-29 shows images of a living U-87 and a U-373 MG cell, stained with MitoTracker® 
Green and MitoTracker® Red CMXRos, respectively. Due to its fluorescence properties 
MitoTracker® Green was evaluated for co-labeling of glioblastoma cells, incubated with 
doxorubicin. An overlay of the fluorescence excitation spectra is given in Fig. 3-30. After co-
staining with doxorubicin and MitoTracker® Green, fluorescence images were acquired in the 
multichannel acquisition mode, using the argon laser (488 nm). Though the excitation spectra 
of both compounds show a high overlap, the fluorescence signals were separated using proper 
emission filters (Fig. 3-30). 
 
MitoTracker® Green MitoTracker® Red CMXRos
 
Figure 3-29: Selelctive fluorescent staining of mitochondria in U-373 MG (left) and U-87 
MG (right) cells. In U-373 MG the mitochondria appear as twine-like structures, spanning 
through the whole cell, whereas in U-87 MG they appear as beads. The diameter is about 1 
µM with a length of 1-2 µM. Plan-Apochromat 63x/1.4 oil; Ar 488, HFT 488, LP505 
(MitoTracker Green); HeNe 543, HFT 488/543/633, LP560 (MitoTracker® Red CMXRos). 
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Figure 3-30: Overlay of fluorescence excitation (upper chart) and emission (lower chart) 
spectra of doxorubicin (black), MitoTracker® Green (light green), and MitoTracker® Red 
CMXRos (red). Using a 505-530 nm band pass filter and a 650 nm long pass filter, the green 
MitoTracker® may be considered as a suitable couterstain to doxorubicin. The excitation 
spectra of MitoTracker® Red CMXRos and doxorubicin overlap at 543 nm (dark green line), 
which represents the only available excitation wavelength for the mitochondrial stain. Due to 
the concomitant overlap of fluorescence emission spectra the red MitoTracker® dye is 
improper for a co-staining with doxorubicin. MitoTracker® reference spectra were taken from 
the Molecular Probes homepage http://probes.invitrogen.com (with modifications). 
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After the simultaneous incubation of U-87 MG cells with doxorubicin and MitoTracker® 
Green, doxorubicin accumulation in an organelle close to the nucleus was observed, whereas 
the selectively counterstained mitochondria showed a markedly differing distribution pattern 
(Fig. 3-31). Though anticipating no crosstalk between the two compounds, processing of the 
original images with the multichannel unmixing module uncloaked a slight bleeding of 
MitoTracker® emission into the doxorubicin detection channel. 
 
Doxorubicin MergeMitoTracker®
Doxorubicin MergeMitoTracker®
nuc
after linear
unmixing
unprocessed
image
 
Figure 3-31: U-87 MG cell, labeled with 100 nM of MitoTracker® Green and 1 µM 
doxorubicin for 30 minutes. Upper row: original images of fluorescence emission channels; 
lower row: images after linear unmixing. Most of the doxorubicin fluorescence is localized in 
a compartment near the nucleus. However, the fluorescence channel unmixing revealed slight 
fluorescence crosstalk between the two stains. Plan-Apochromat 63x/1.4 oil; Ar 488, HFT 
488, BP505-530, HeNe 543, HFT 458/543, LP585. 
 
This automatic component extraction (ACE) software module extracts the characteristic 
fluorescence components of the multifluorescence image and reassigns them to different 
channels in the processed image. Within certain limitations this method can substitute spectral 
unmixing procedures, which usually necessitate fluorophor reference spectra and the 
acquisition of the spectral data of each image pixel. If the fluorescence emission spectra of the 
used fluorophores do not exceed a certain extent of overlap, the ACE can overcome excitation 
as well as emission crosstalk. However, the fluorescence of the mitochondrial stain was not 
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stable under the used imaging conditions. After a few scans, the decreased fluorescence 
emission had to be compensated by an increased excitation intensity, which led to 
cytotoxicity, probably caused by phototoxic reactions. 
Due to the drawback from the experiments with the MitoTracker® dye, another approach 
was employed to achieve selective fluorescent labeling of mitochondria in human 
glioblastoma cells, the transfection with a modified mitochondria localization vector, pECFP-
Mito. This vector is specifically designed for the fluorescent labeling of mitochondria. It 
encodes a modified mitochondrial targeting sequence from the human cytochrome C oxidase 
precursor fused to the N-terminus of the enhanced cyan fluorescent protein (Rizzuto et al. 
1989; Rizzuto et al. 1995) This EGFP variant (Heim et al. 1994; Heim and Tsien 1996; 
Miyawaki et al. 1997) shows its major fluorescence excitation maximum at 433 nm and its 
minor excitation maximum at 453 nm, making it suitable for the excitation by the Ar 458 
laser plasma line of the CLSM scanning unit. Since the major fluorescence emission 
maximum is at 475 nm (a minor peak is at 501 nm), the fluorescence emission was detected 
using either longpass (LP) or bandpass (BP) filters, starting from 475 nm. 
 
Figure 3-32: Agarose gel analysis of 
pQCXIP/ECFP-Mito. After propagation in 
E. coli, the plasmid was digested the 
restriction enzymes EcoRI and BamHI. 
Both digests led to bands at 8 kb, 
representing the linearized vector, whereas 
the non-digested plasmid showed much 
slower migration through the gel matrix.  
 
 
 
 
 
 
 
 
Furthermore, the pECFP-Mito localization vector contains a neomycin resistance (Neor) gene 
for eukaryotic selection of transfected cells, using geneticin (G418), and a kanamycin 
resistance sequence for propagation in E. coli. The sequence encoding the fluorescent fusion 
protein was subcloned into the retroviral expression vector pQCXIP, which encodes for 
puromycin and ampicillin resistance for selection in eukaryotic and procaryotic cells, 
respectively. After amplification in E. coli TOP10, the plasmid was put to a restriction digest 
as a control of the vector size (Fig. 3-32). The pQCXIP/ECFP-Mito vector was transfected 
8 kb
6 kb
EcoRI
digest
BamHI
digest
no digest DNA
standard
Linearized vector
(8 kb)
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into U-87 MG, U-118 MG, and U-373 MG cells, and stable cell lines were established with 
all three glioblastoma cell types by continuous selection with puromycin.  
 
 
Figure 3-33: U-373 ECFP-Mito cells after continuous selection with G418. Left: overview 
image. Plan-Neofluar 20x/0.5, Ar 458, HFT 458, BP475-525. Right: single U-373 ECFP-Mito 
cell. The image represents a 2-d projection of 9 CLSM optical z-sections. The z-stack was 
processed employing 3-d deconvolution, using an non-blind adaptive point spread function 
algorithm. Plan-Apochromat 63x/1.4 oil, Ar 477, NT 80/20, LP505. 
 
The expression of mitochondrial expression of ECFP-Mito is exemplarily shown for U-373 
ECFP-Mito cells (Fig. 3-33). For colocalization experiments, U-87 ECFP-Mito cells were 
incubated with 1 µM doxorubicin and 5 µM of the nuclear dye DRAQ5TM for 30 min. Fig. 3-
34 shows the successful multifluorescence imaging of doxorubicin and the nuclear 
counterstain in U-87 ECFP-Mito. As becomes obvious from the merged fluorescence 
detection channels, doxorubicin is not colocalized with mitochondria. Again, a high 
accumulation was observed in “vesicular organelles” next to the nucleus. 
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Figure 3-34: Multifluorescence CLSM image (false color display) of a living U-87 ECFP-
Mito cell, after incubation with doxorubicin and DRAQ5TM. No particular accumulation of 
doxorubicin in mitochondria was observed, but a rather diffuse distribution in the intracellular 
room and a vesicular accumulation close to the nucleus. Plan-Apochromat 63x/1.4 oil, Ar 
458, HFT 458, BP475-525; HeNe 543, HFT 488/543/633, LP560; HeNe 633, HFT 
488/543/633, LP650. 
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3.4.6.3 CLSM imaging of the plasma membrane 
Due to the successful separation of the fluorescence emission of ECFP and doxorubicin, 
combined to the nuclear counterstain DRAQ5TM, other target structures were also 
fluorescently labeled by transfection with the respective localization vectors. For the 
fluorescent labeling of the plasma membrane in living cells, U-87 MG and U-373 MG cells 
were transfected with the localization vector pECFP-Mem, subcloned into the pQCXIP 
retroviral expression vector, changing the resistance cassettes for prokaryotic and eukaryotic 
selection from Kan/Neo to Amp/Pur. The vector pECFP-Mem encodes a fusion protein 
consisting of ECFP and of the N-terminal 20 amino acids of neuromodulin (Skene and Virag 
1989). This N-terminal fragment contains a signal for posttranslational palmitoylation of 
cysteines 3 and 4 within the mature protein, which thereby directs ECFP to cellular 
membranes. 
 
Figure 3-35: Agarose gel electrophoresis of 
of NotI-digested and non-digested 
pQCXIP/ECFP-Mem. NotI digest led to 
linearization of the localization vector, 
showing a band at 8 kb. Two bands were 
detected with the non-digested control from 
the DNA maxipreparation of the E. coli 
overnight culture. The bands represent the 
open circular and the supercoiled form of the 
plasmid, mimicking DNA fragment sizes of 
far above 10 kb and ca. 7 kb, respectively. 
 
 
 
The expression of ECFP-Mem protein after the transfection with pQCXIP/ECFP-Mem is 
exemplarily shown for U-373 ECFP-Mem cells in Fig. 3-36. However, ECFP-Mem was not 
only localized in the plasma membrane, but also in intracellular membranes. Fig. 3-37 shows 
a fixed U-87 ECFP-Mem cell, counterstained with the nuclear stain SYTOXGreen® 
(Molecular Probes). Due to the fluorescence crosstalk between the two fluorophores, nuclear 
SYTOXGreen® emission was detected in the detection channel of ECFP, leading to an 
imaging artefact, which was removed by ACE image processing. ECFP-Mem fluorescence 
was detected not only in the cytoplasmic membrane but also in an entity indicative for the 
golgi complex. This may be explained by the posttranslational processing of the ECFP-Mem 
fusion protein prior to its transport towards the plasma membrane. The multifluorescence 
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imaging of U-373 ECFP-Mem cells incubated with doxorubicin and DRAQ5TM counterstain 
showed no accumulation of doxorubicin in the cytoplasmic membrane (Fig. 3-38). 
 
DRAQ5TM MergeECFP-Mem  
Figure 3-36: CLSM imaging of U-373 ECFP-Mem cells (nuclear counterstain DRAQ5TM). 
Plan-Apochromat 63x/1.4 oil, Ar 458, BP475-525; Ar 514, HFT 514/633, NFT 635/VIS, 
BP530-600; HeNe 633, HFT 488/543/633, LP650. 
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Figure 3-37: U-87 ECFP-Mem cell after PFA fixation, counterstained with SYTOXGreen® 
nuclear staining dye. Upper row: original images showing excitation crosstalk between 
SYTOXGreen® and ECFP. Lower row: images after ACE processing. The ECFP-Mem 
protein is not only found in the cytoplasmic membrane (cm) but also in a vesicular organelle 
(golgi) next to the nucleus (nuc). Plan-Apochromat 63x/1.4oil, Ar 458 nm/BP475-525 nm; Ar 
488 nm/LP505 nm. 
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Figure 3-38: False color multifluorescence CLSM image of living U-373 ECFP-Mem cells, 
after incubation with doxorubicin and DRAQ5TM. No distinct colocalization of doxorubicin 
and the cytoplasmic membrane was observed. Plan-Apochromat 63x/1.4 oil, Ar 458, HFT 
458, BP475-525; HeNe 543, HFT 488/543/633, LP560; HeNe 633, HFT 488/543/633, LP650. 
 
3.4.6.4 CLSM imaging of the endoplasmic reticulum in living human glioblastoma 
cells 
For CLSM imaging of the endoplasmatic reticulum (ER), cells were transfected with the 
pECFP-ER localization vector. This vector contains the DNA sequence for the enhanced cyan 
fluorescent protein (ECFP) and an endoplasmic reticulum (ER) targeting sequence, encoding 
for calreticulin (Fliegel et al. 1989), cloned to the 5´-end of the ECFP sequence. To 3´-end is 
fused to the ER retrieval sequence KDEL (Munro and Pelham 1987; Pelham 1996). When 
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introduced into mammalian cells, the vector leads to the expression of a soluble protein, 
localizing in the lumen of the ER (Kendall et al. 1994; Roderick et al. 1997) and bearing 
ECFP fluorescence emission. Fig. 3-40 shows ECFP-ER transfected U-87 MG cells after 
continuous selection with G418, counterstained with DRAQ5TM. Again, the multifluorescence 
imaging of U-87 ECFP-ER cells showed no exclusive colocalization of doxorubicin with the 
ECFP-labeled ER-structures (Fig. 3-41). As observed before in other cell variants, the highest 
accumulation remains in another, supra-nuclear substructure. 
 
Figure 3-39: Gel analytics of NheI-
digested pECFP-ER and non-digested 
control. The linearized plasmid is detected 
close to the 5 kb band of the DNA 
standard. As observed with the 
pQCXIP/ECFP-Mem vector, two bands are 
detected with the non-digested control, 
representing the open circular and the 
supercoiled form of the plasmid, 
mimicking false DNA fragment sizes. (ca. 
9 kb and 2.3 kb, respectively). 
 
 
 
 
DRAQ5TM MergeECFP-ER  
Figure 3-40: ECFP-ER-expressing human U-87 MG glioblastoma cells with nuclear 
counterstain DRAQ5TM. Plan-Apochromat 63x/1.4 oil, Ar 458, BP475-525; Ar 514, HFT 
514/633, NFT 635/VIS, BP530-600; HeNe 633, HFT 488/543/633, LP650. 
 
4 kb
5 kb
NheI
digest
no digest DNA
standard
Linearized
vector
(4.8 kb)
8 kb
2 kb
2.5 kb
10 kb
68 Doxorubicin-loaded nanoparticle formulations Chapter 3
 
DoxorubicinDRAQ5TM
ECFP-ER Merge
 
Figure 3-41: Multifluorescence image of a living U-87 ECFP-ER cell, after incubation with 
doxorubicin and nuclear counterstain. Doxorubicin is partially, but not exclusively 
colocalized with the ER-structure. Again, the anthracycline accumulates close to the nucleus. 
Plan-Apochromat 63x/1.4 oil, Ar 458, HFT 458, BP475-525; HeNe 543, HFT 488/543/633, 
LP560; HeNe 633, HFT 488/543/633, LP650. 
 
3.4.6.5 Fluorescently labeled golgi complex in living human glioblastoma cells 
The golgi complex (golgi) consists of smooth membrane-limited cisternae, and is usually 
localized close to the nucleus. The commercially available localization vector for this 
organelle, pECFP-Golgi, encodes for a fusion protein consisting of ECFP and the N-terminal 
81 amino acid sequence of the human golgi-specific 1,4-galactosyltransferase (Watzele and 
Berger 1990). The N-terminal sequence contains a membrane-anchoring signal peptide. Thus 
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the fusion protein is targeted to the trans-medial region of the golgi (Gleeson et al. 1994; 
Yamaguchi and Fukuda 1995; Llopis et al. 1998). The plasmid further encodes for a 
resistance cassette, allowing procaryotic and eucaryotic selection, using kanamycin and G418 
respectively. Continuously G418-selected U-87 ECFP-Golgi cells are shown in Fig. 3-43. As 
expected from the preceeding experiments, multifluorescence image acquisition with ECFP-
Golgi transfected cells showed partial colocalization of doxorubicin with the ECFP-labeled 
trans-medial golgi structure (Fig. 3-44). 
 
Figure 3-42: Agarose gel electrophoresis 
of the pECFP-Golgi restriction digest 
product. The two bands of the non-digested 
control, indicative for the open circular and 
the supercoiled plasmid, disappear after NotI 
digest, and the band for the linearized 
plasmid is detected ca. 5 kb. 
 
 
 
 
 
DRAQ5TM MergeECFP-Golgi  
Figure 3-43: Living U-87 MG cells, expressing ECFP-Golgi. The ECFP fluorescence 
emission is localized next to the nuclei (DRAQ5TM counterstain). Plan-Apochromat 63x/1.4 
oil, Ar 458, BP475-525; Ar 514, HFT 514/633, NFT 635/VIS, BP530-600; HeNe 633, HFT 
488/543/633, LP650. 
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Figure 3-44: Multifluorescence live cell imaging of U-87 ECFP-Golgi. In the displayed 
optical section, several golgi-cisternae are cut. After incubation with DRAQ5TM and 
doxorubicin, accumulated doxorubicin fluorescence is colocalized with the fluorescence 
emission of the ECFP-Golgi fusion protein. Plan-Apochromat 63x/1.4 oil, Ar 458, HFT 458, 
BP475-525; HeNe 543, HFT 488/543/633, LP560; HeNe 633, HFT 488/543/633, LP650. 
 
3.4.7 Doxorubicin fluorescence in human glioblastoma cells after incubation 
with different doxorubicin formulations 
 
After the CLSM studies on the distribution of doxorubicin in living cells, further CLSM 
experiments were performed, according to results from the flow cytometric experiments. 
Therefore U-87 MG cells were incubated with doxorubicin in solution, doxorubicin 
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nanoparticles, and polysorbate 80-coated nanoparticles amounting to a doxorubicin 
concentration of 10 µM, for 5 minutes at 37 °C (in the incubation chamber of the microscope) 
followed by CLSM image acquisition of the living cells (Fig. 3-45). 
 
Doxorubicin DoxoNPT80DoxoNP
Doxorubicin DoxoNPT80DoxoNP  
Figure 3-45: Distribution of doxorubicin fluorescence in living U-87 MG cells, incubated 
with different doxorubicin formulations (upper row). The rainbow false color mode (lower 
row) displays the fluorescence intensity of each image pixel. The same pattern of fluorescence 
distribution in the cells was observed for all doxorubicin formulations. Plan-Apochromat 
63x/1.4 oil, HeNe 543, HFT 488/543/633, LP650. 
 
After this short period of incubation with dissolved doxorubicin, weak fluorescence was 
detected throughout the cytoplasm with higher intensity in the proximity of the nuclei. The 
same pattern of fluorescence distribution was observed after incubation with DoxoNP and 
coated DoxoNP. Although a cellular uptake of doxorubicin-loaded nanoparticles was not 
seen, the overall intensity of the doxorubicin-related fluorescence emission was much higher, 
compared to dissolved doxorubicin. Since no differences in the distribution pattern of 
doxorubicin fluorescence were found with 10 µM doxorubicin and a short incubaton time (5 
minutes), the incubation with doxorubicin in solution, DoxoNP and polysorbate 80-coated 
DoxoNP was repeated with a decreased doxorubicin concentration (2 µM) and an increased 
incubation period (1 hour). For this experiment KBwt cells were used, which were 
demonstrated to express low levels of pgp (Fig. 3-8), and compared to the U-87 MG cells, 
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they showed similar doxorubicin-related fluorescence in the flow cytometric experiments 
(Fig. 3-18 and 3-19). As shown in Figure 3-46, the incubation with the different doxorubicin 
formulations led to a diffuse distribution of doxorubicin fluorescence in the cytoplasm, and 
again the nuclei were spared out. Compared to the dissolved drug, the doxorubicin related 
fluorescence was higher in cells incubated with doxorubicin nanoparticle formulations. 
However, with the DoxoNP and the polysorbate 80-coated DoxoNP, a distinct doxorubicin 
fluorescence was detected close to the cytoplasmic membrane of the cells. This indicates, that 
the doxorubicin-loaded nanoparticles adsorb to the cell membrane. 
 
Doxo 2 µM 1 h DoxoNP 2 µM 1 h DoxoNP T80 2 µM 1 h  
Figure 3-46: Incubation of KBwt cells with doxorubicin and doxorubicin nanoparticle 
formulations. Dissolved doxorubicin shows distribution all over the cytoplasm (left image), 
whereas after incubation with the doxorubicin-loaded nanoparticles (middle and right image), 
the cells are hemmed by doxorubicin-related fluorescence close to their cytoplasmic 
membrane. Plan-Apochromat 63x/1.4 oil, Ar 514, HFT 514/633, BP530-600. 
 
To investigate whether the nanoparticles permeate into the cells, lyophilized empty PBCA 
nanoparticles were redispersed in PBS, and diluted to a concentration equivalent 10 µM 
doxorubicin in DoxoNP. For the dilution to the final concentration PBS was used, containing 
0.5 mg/ml lucifer yellow carbohydrazide, dilithium salt (LY-CH, Sigma), a water soluble, and 
cell impermeant fluorescent dye (see Fig. 3-47). U-373 MG cells were incubated for 1 hour 
with LY-CH solution (0.5 mg/ml) and with PBCA nanoparticles in PBS 0.5 mg/ml LY-CH. 
After a washing step with PBS, fluorescence images were acquired by CLSM. Figure 3-48 
shows clear differences between the application of LY-CH solution and PBCA nanoparticles 
+ LY-CH. Several brightly fluorescent LY-CH-filled vesicles depicted pinocytosis in U-373 
MG cells, whereas the combination of PBCA nanoparticles with LY-CH led to a clearly 
different pattern of fluorescence distribution. The cell margins appeared as fluorescent hems. 
Intracellular LY-CH fluorescence was not detected. This indicates that the PBCA 
nanoparticles do not enter the cytoplasm of the cells. 
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Figure 3-47: Chemical structure of lucifer yellow 
carbohydrazide (dilithium salt). Due to its cell 
impermeant character, this fluorescent dye has been 
used for visualization of pinocytosis vesicles, and for 
studies of the three dimensional structure of 
invertebrate neurons, after direct injection into the 
studied cells (Stewart 1978). 
 
 
Lucifer Yellow solution PBCA-NP + Lucifer Yellow  
Figure 3-48: Incubation of U-373 MG cells with lucifer yellow solution  (left image) and a 
mixture of PBCA nanoparticles + lucifer yellow (right image). After 1 hour of incubation 
lucifer yellow solution is found in pinocytosis vesicles inside the cells (left image), whereas 
the cells incubated with the nanoparticles + lucifer yellow are lined by lucifer yellow 
fluorescence at their cell membrane, and no fluorescence is found inside the cells. Plan-
Apochromat 63x/1.4 oil, Ar 488, HFT 488, LP505. 
 
3.5 Discussion 
 
In the present study polybutylcyanoacrylate-nanoparticles, loaded with doxorubicin, exceeded 
the antiproliferative effect of dissolved doxorubicin against pgp-overexpressing cells. When 
the nanoparticles were coated with the surfactant polysorbate 80, the inhibition of cell growth 
was further increased. This effect was observed at high concentrations equivalent to 2 and 3 
µM doxorubicin. Although these amounts of drug are far above clinically applicable 
concentrations, the nanoparticle formulations indeed overcome the pgp-mediated drug efflux 
mechanism. 
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In the flow cytometric experiments with KBwt cells (weak pgp expression) differential effects 
on the cell-associated fluorescence were observed after incubation with drug formulations 
equivalent to 500 nM doxorubicin. These results were similar to the effects in pgp-negative 
U-87 MG, U-118 MG, and U-373 MG glioblastoma cell variants, also incubated with 
equivalent 500 nM doxorubicin. These differential amounts of cell-associated doxorubicin 
fluorescence may have occured due to an enhancement of doxorubicin uptake, either by 
adsorption of doxorubicin-loaded nanoparticles to the cell membrane, or by an uptake of 
whole nanoparticles into the cells. 
However, no differences in the increase in cell-associated fluorescence were observed 
between the different doxorubicin formulations in the pgp-overexpressing KBv1 cells 
compared to the wild type cells. This observation can be explained by the assumption that 
doxorubicin is released from the nanoparticles outside the cells, diffuses into the cytoplasm, 
and is immediately transported out of the cells by the activity of the pgp efflux transporter. At 
higher concentrations, equivalent to 2 and 3 µM doxorubicin, the efflux transporter is 
considered to be saturated, leading to differential doxorubicin accumulation by KBv1 cells as 
observed in KBwt and the pgp-negative glioblastoma cells. 
It is conceivable that adsorption of nanoparticles to the cell surface has enhanced 
doxorubicin uptake by creating a high doxorubicin concentration gradient around the cells, 
and consequently has enhanced the diffusion of the drug into the cells. This assumption is 
supported by the results from the CLSM studies with living cells, indicating, that the 
nanoparticles are not penetrating into the cells. A cellular uptake of doxorubicin-loaded 
nanoparticles, e.g. via an endocytotic mechanism, was not observed. It should be pointed out 
that, when the cells were incubated with the drug-loaded nanoparticles, particle-bound as well 
as free drug may have contributed to the observed intracellular fluorescence. However, the 
results from the experiments with LY-CH and empty PBCA nanoparticles indicate retaining 
of the nanoparticles on the cell surface, even though LY-CH was not covalently linked to the 
nanoparticle surface, and weakly stained or unstained nanoparticles could have passed the cell 
membrane due to their differing surface properties. 
Although Rejman et al. reported on a size-dependent internalization of fluorescently 
labeled latex nanoparticles in non-phagocytic B16 cells (Rejman et al. 2004), also a lack of 
nanoparticle uptake in vitro has been demonstrated for several other nanoparticle types, 
indicating a major influence of the surface properties and the susceptibility of the used cell 
type. Bertin et al. synthesized amphiphilic block copolymeric nanoparticles from 
indomethacin-containing norbornene and tosylated hexaethylene glycol-containing 
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norbornene, 140–200 nm in size (Bertin et al. 2006). When applied to Her2-expressing human 
SKBR3 breast cancer cells, an uptake of the nanoparticles was only observed when the 
nanoparticle surface had been functionalized with an anti-Her2 antibody. The nanoparticles 
without antibody conjugation did not enter the cells. Moreover, also smaller nanoparticles 
have been reported not to enter into cells in vitro. Tkachenko et al. studied the influence of 
peptidic surface modifications of gold nanoparticles, ca. 20 nm in size (Tkachenko et al. 
2004). In NIH/3T3 cells, a lack of nanoparticle uptake was observed despite a modification of 
the nanoparticle surface with HIV-1 Tat transduction domain protein, which was assumed to 
enhance nanoparticle uptake. However, when applied to HepG2 hepatocyte cells, the same 
type of nanoparticles entered the cells. Furthermore, KB cells, expressing folic acid receptors, 
were able to internalize fluorescein isothiocyanate-labeled polyamidoamine dendrimers (1-10 
nm in size), conjugated with folic acid (Quintana et al. 2002). The dendrimers without folic 
acid conjugation were excluded by the KB cells, and folic acid receptor-negative NIH/3T3 
cells also showed no uptake of the nanodevices. These results indicate, that the particle 
surface modality rather than the particle size determines the cellular uptake in vitro. Since the 
PBCA nanoparticles used in the presented study were not further functionalized, except for 
the Tween80® coating, the abovementioned enhancement mechanism of doxorubicin delivery 
to the pgp-overexpressing cells is conceivable. 
This hypothesis is further supported by a study from de Verdiere et al., who reported on 
the enhanced antiproliferative activity of doxorubicin, bound to polyisohexylcyanoacrylate 
nanoparticles, against pgp-overexpressing P388 cells (de Verdiere et al. 1997). The 
experiments were also performed in two-compartment wells, where direct interaction of the 
nanoparticles with the cells during the incubation period was prevented by a polycarbonate 
membrane. Under these conditions the drug-loaded nanoparticles did not exceed the effect of 
the dissolved doxorubicin, suggesting that the direct interaction of the particulate form with 
the cell membrane is important for the observed enhanced antiproliferative effects. Moreover, 
concluding from drug accumulation studies, the authors postulated an enhanced uptake of 
doxorubicin by ion pair formation of doxorubicin and polycyanoacrylic acid, both released by 
nanoparticle degradation. 
However, the role of Tween80® in the further enhancement of cytotoxicity of 
doxorubicin-loaded nanoparticles remains unclear, since Twen80® itself had no 
antiproliferative effect. It may be speculated that the surfactant could influence nanoparticle 
adsorption on the cell surface, or might enhance membrane permeability of the drug by 
solubilization of the water-dissolved portion of the drug, while a concentration gradient is 
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created by the nanoparticles. Another effect could be the modulation of the pgp-mediated 
drug efflux by polysorbate 80, which has been described to enhance daunorubicin cytotoxicity 
in P388 cells (Woodcock et al. 1992). This effect also may contribute to the suggested 
mechanism of the purported overcome of the blood-brain barrier by polysorbate 80-coated 
doxorubicin nanoparticles (Gulyaev et al. 1999), which however remains controversial. 
In vivo, the mode of application of the nanoparticle could produce an enhanced uptake of 
doxorubicin through the blood brain barrier via different mechanisms. Kreuter et al. 
investigated the influence of various apolipoproteins (Apo) on the delivery of nanoparticle-
bound dalargin and loperamide (Kreuter et al. 2002). For this purpose both drugs were bound 
to PBCA nanoparticles and coated with various apolipoproteins. The achieved antinociceptive 
effect of both nanoparticle-bound drugs was determined in the tail flick test after intravenous 
injection to mice. The effect was significantly increased when the Apo B- or Apo E-coated 
nanoparticles were precoated with Tween 80®. Moreover, when polysorbate 80-coated 
nanoparticles were administered to Apo E-deficient ApoEtm1Unc mice, the antinociceptive 
effect of the drug formulations was markedly reduced compared to normal mice. ApoB and 
ApoE are known low density lipoprotein (LDL) receptor ligands. Binding to LDL receptors 
initiates endocytosis of the ligand-receptor complex (Goldstein et al. 1985). Therefore, the 
adsorption of the ApoB and/or ApoE from blood after i.v. administration might target the 
Tween 80®-coated nanoparticles to LDL receptor-expressing cells, such as brain capillary 
endothelial cells. Consequently, the enhancement of drug delivery to the brain, using the 
coated PBCA nanoparticle carrier system, could be explained by this LDL receptor-mediated 
endocytotic  mechanism, followed by the intracellular degradation of the nanoparticles and 
drug release. Then the drug may be distributed within the brain by diffusion. 
Olivier et al. reported on a completely different effect of drug delivery enhancement with 
coated nanoparticles (Olivier et al. 1999), contradictory to the results of Kreuter et al. (Kreuter 
et al. 2002). The coating of dalargin-loaded PBCA NP with Tween 80® led to a complete 
desorption of the drug from the nanoparticles. Despite of that, and compared to non-
biodegradable polystyrene nanoparticles, the coated PBCA NP formulation still exhibited a 
potent and prolonged analgetic effect in mice (tail flick test). Moreover, Olivier et al. 
performed in vitro experiments on BBB permeabilization effects using a co-culture of bovine 
brain capillary endothelial cells and rat astrocytes as a BBB model. A concentration of 10 
µg/ml PBCA NP induced a permeabilization of the artificial BBB. Again, Olivier et al. 
proposed a non-specific permeabilization, respectively disruption of the BBB due to the 
toxicity of the carrier as the major account for the enhanced dalargin penetration into the 
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CNS, when associated with PBCA NP and polysorbate 80. However, further studies on the 
interaction of PBCA NP with the BBB in vitro and in vivo did not confirm a generalized toxic 
effect as a primary mechanism for drug delivery to the brain (Alyautdin et al. 2001; Kreuter et 
al. 2003). Nevertheless, an additional, undirected route may contribute to the enhanced drug 
delivery to the brain too. As a result of tumor growth and progression, the BBB can be 
partially disrupted. Thus, the administration of drug-loaded nanoparticle formulations at 
certain, especially late stages of the tumor development may enable drug transport or carriage 
through the leaking endothelium to the site of the tumor. Since Tween 80®-coated PBCA NP 
can deliver doxorubicin across an intact BBB too (Gulyaev et al. 1999), this drug formulation 
is considered to be also effective in earlier stages of brain tumor development. 
Further investigations have to be performed, to determine whether PBCA nanoparticles, 
with or without Tween80®-coating, indeed penetrate into cells or not. A stable fluorescent 
labeling of the PBCA nanoparticles would provide a major advantage for monitoring a 
potential cellular uptake in vitro, and consequently further elucidate the in vivo mechanism of 
nanoparticle drug delivery. Regardless of the drug delivery mechanism, PBCA nanoparticle-
mediated drug delivery to the brain may be considered as an attractive delivery pathway for 
pharmacologically active compounds, which otherwise would be excluded from the brain by 
physiological efflux mechanisms at the BBB, such as the pgp. 
 
3.6 Summary 
 
The chemosensitivity of KBwt and pgp-overexpressing KBv1 cells against doxorubicin was 
determined with the crystal violet based cytotoxicity assay. As expected, the KBv1 cells were 
highly resistant to doxorubicin, and a cytotoxic effect was observed at a drug concentrations 
of 1 µM and above. The KBwt cells were less sensitive to doxorubicin than expected from 
their pgp expression status. This can be well explained by an upregulation of the pgp-
expression in these cells during the time of incubation with the pgp-substrate doxorubicin. 
When the KBv1 cells were incubated with different doxorubicin formulations, the 
doxorubicin nanoparticle formulations exceeded the antiproliferative effect of the dissolved 
drug at doxorubicin concentrations equivalent to 2 and 3 µM dissolved drug. The coating of 
the nanoparticles with the surfactant polysorbate 80 led to a further increase of the 
antiproliferative effect. 
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The flow cytometric experiments showed formulation-dependent effects on the cell-
associated doxorubicin fluorescence in pgp-negative human glioblastoma cells as well as in 
KBwt cells. In pgp-overexpressing KBv1 cells these differential effects were not observed at 
a drug concentration equivalent to 500 nM doxorubicin. However, at a concentration of 2 µM 
doxorubicin similar effects were observed with KBv1 cells as observed for the pgp-negative 
glioblastoma cells and the KBwt cells. 
The confocal laser-scanning microscopic (CLSM) studies with living cells showed that 
the doxorubicin-related fluorescence originates from drug, distributed in the cytoplasm, but 
not localized in the nucleus, where doxorubicin fluorescence is quenched by the nuclear 
DNA. Within the cytoplasm the drug slightly accumulated in the vicinity of the nuclei, 
whereas a distinct colocalization of doxorubicin with the cell membrane and cellular 
organelles, such as the golgi, the endoplasmic reticulum, and the mitochondria was not 
observed. Similar cytoplasmic doxorubicin distribution was observed after incubation of 
KBwt cells with dissolved and nanoparticle-bound doxorubicin, whereas a higher overall 
doxorubicin–related fluorescence was observed in case of  the nanoparticle formulations. 
Moreover, cells were hemmed by doxorubicin fluorescence when incubated with the 
nanoparticles, indicating that the particles do not enter the cytoplasm. With a mixture of 
“empty” PBCA nanoparticles and lucifer yellow, pgp-negative U-373 MG were hemmed by 
lucifer yellow derived fluorescence, supporting the hypothesis that the nanoparticles do not 
enter the cells. 
Based on these results, the enhanced antiproliferative efficacy of the doxorubicin 
nanoparticle formulations against pgp-overexpressing cells can be ascribed to drug release 
from nanoparticles after adsorption to the cell surface. The resulting concentration gradient of 
dissolved drug around the cells and the cytoplasm leads to a fast and high increase in the 
intracellular doxorubicin concentration, exceeding the pgp efflux capacity. 
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Chapter 4 
Investigations on the platelet-derived growth 
factor receptor as a target for the treatment of 
malignant brain tumors 
 
 
 
4.1 Introduction 
 
4.1.1 Platelet-derived growth factor (PDGF) 
 
Since the 1970s PDGF, a major mitogen of fibroblasts, smooth muscle and other cells (Heldin 
and Westermark 1999) has been subject of extensive studies, focusing on the two isoforms 
designated PDGF-A and –B. The other two members of the PDGF family PDGF-C and -D 
were discovered more recently (Reigstad et al. 2005). PDGF was identified as a constituent of 
whole blood serum that was absent in cell-free serum (Kohler and Lipton 1974; Ross et al. 
1974; Westermark and Wasteson 1976). Subsequently it was purified from human platelets 
where the α-granules are the major storage sites of PDGF (Antoniades et al. 1979; Heldin et 
al. 1979; Deuel et al. 1981; Raines and Ross 1982). However, as shown in Table 4-1, PDGF-
A and PDGF-B can be synthesized by a number of different cell types (Heldin and 
Westermark 1999). Moreover, PDGF-C and –D are expressed in various embryonic and adult 
tissues (Reigstad et al. 2005). In embryonic mice, PDGF-C is expressed in the kidney, lung, 
brain, heart, spinal cord, and other tissues. It also is expressed in human adult tissues, such as 
kidney, testis, liver brain, and heart. 
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Table 4-1: PDGF expression in normal cells (from Heldin and Westermark 1999). 
+
+
+
+
+
+
+
+
+
+
+
+
+
+
PDGF-B
+Oocyte
+Uterine endometrial/myometrial cells
+Mammary epithelial cells
+Retinal pigment epithelial cells
+Macrophages
+Vascular smooth muscle cells
+Vascular endothelial cells
+Astrocytes
+Platelets/Megakaryocytes
+Neurons
+Schwann cells
+Skeletal myoblasts
+Glomerular mesangial cells
+Leydig cells
+Placental cytotrophoblasts
+Keratinocytes
+Fibroblasts
PDGF-ACell Type
 
 
4.1.2 Gene location, biosynthesis and structure of PDGF 
 
The genes for PDGF-A and PDGF-B are located on chromosomes 7 and 22 (Dalla-Favera et 
al. 1982; Swan et al. 1982; Betsholtz et al. 1986), whereas those for PDGF-C and PDGF-D 
are located on chromosomes 4 and 11 (Uutela et al. 2001). The A and B chain, consisting of ~ 
100 amino acid residues, show 60 % amino acid sequence identity. PDGF-C and -D share an 
overall sequence identity of 42 %, with a high similarity in the CUB region (complement 
subcomponents C1r/C1s, Uegf, and Bmp1), which is an innate domain of the C- and D-type 
(Bergsten et al. 2001; LaRochelle et al. 2001). 
The mature forms of PDGF-A and PDGF-B originate from their respective precursor 
proteins, after proteolytic processing (Ostman et al. 1991), whereas the subtypes PDGF-C and 
PDGF-D (mature forms) carry an innate CUB domain, consisting of 110 amino acid residues, 
which has to be cleaved extracellularly to make the C-terminal growth factor domains active 
(Li et al. 2000; Bergsten et al. 2001; LaRochelle et al. 2001). Though the biosynthesis of 
PDGF-A and PDGF-B is strictly regulated, the assembly to the different dimeric subtypes is 
suggested to be a random process (Hammacher et al. 1988; Hart et al. 1990). 
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The platelet-derived growth factors are either cationic homodimers consisting of the 
polypeptide subtypes A, B, C, and D, or heterodimers of the A and B subunits, all connected 
by two interchenar disulfide bonds. All PDGF monomer subtypes bear eight highly conserved 
cysteine residues. The X-ray structure of the platelet-derived growth factor-BB isoform with a 
resolution of 3.0 Å, published by Oefner et al. 1992, has revealed that two of those cysteine 
residues (cysteines 43 and 52 in PDGF-B) form disulfide bridges between the two PDGF 
chains within the PDGF dimer. The second cysteine residue from the N-terminal in the first 
PDGF chain forms a disulfide bridge with the fourth cysteine residue of the second chain and 
vice versa. All other cysteine residues form intramolecular disulfide bonds. Both chains are 
folded into twisted antiparallel pairs of β-strands, and the two monomers are arranged in an 
antiparallel manner referring to the two β-strands containing the connecting cysteine residues 
(Oefner et al. 1992; Haniu et al. 1993; Haniu et al. 1994). Fig. 4-1 shows the structure of the 
PDGF-B dimer with its cysteine linkage (Borkham-Kamphorst et al. 2005), also described as 
cystine knot. 
 
 
Figure 4-1: Structure of PDGF-B dimer. The structures of the two subunits are shown in 
brown and metallic blue, respectively. The disulfide bridges are shown as stick models. 
 
Other growth factors showing similarities to the three dimensional structure of PDGF-BB are 
NGF, TGF-β, (Murray-Rust et al. 1993) and VEGF, despite a low sequence homology of 
19 % (Muller et al. 1997). All these growth factors are dimers and show the characteristic 
cystine knot structure (Sun and Davies 1995). Though the quarternary structure seems to be 
crucial for the biological activity of PDGF (Prestrelski et al. 1994) the formation of the 
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biologically active PDGF-B dimer does not require interchain disulfide bonds (Kenney et al. 
1994). 
 
4.1.3 Expression of PDGF receptors 
 
The biological effects of all dimeric PDGF variants are mediated by transmembrane protein 
tyrosine kinase receptors, the PDGF receptors (PDGFR). The two subtypes PDGFRα and 
PDGFRβ (Yarden et al. 1986; Matsui et al. 1989) are differentially expressed in various cell 
types (Tab. 4-2) according to Heldin and Westermark (Heldin and Westermark 1999). 
 
Table 4-2: Expression of PDGF receptor subtypes in normal cell types (from Heldin and 
Westermark 1999, modified). 
 
+Myeloid hematopoietic cells
+
+
+
+
+
+
+
+
+
+
+
+
+
+
β-Receptor
+Schwann cells
Mammary epithelial cells
+Retinal pigment epithelial cells
+Platelets/Megakaryocytes
T cells
+Vascular smooth muscle cells
Capillary endothelial cells
Pericytes
Macrophages
+Astrocytes
+Neurons
Myoblasts
+Liver sinusoidal endothelial cells
Itoh cells of the liver
+Leydig cells
+Kidney mesangial cells
+Fibroblasts
α-ReceptorCell Type
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4.1.4 Gene locations and structure of PDGFRs 
 
The gene encoding for PDGFRα is situated on chromosome 4q12, which is close to two other 
gene loci, the gene for the SCF receptor c-kit and the VEGF receptor-2 (Spritz et al. 1994), 
both protein tyrosine kinase receptors. The PDGFRβ gene is localized on chromosome 5, also 
close to another tyrosine kinase receptor gene, c-fms, encoding for the macrophage colony 
stimulating factor-1 (CSF-1) receptor (Roberts et al. 1988). Moreover, the PDGFR proteins 
show structural similarity with CSF-1 and SCF receptor proteins (Coussens et al. 1986; 
Yarden et al. 1987). The molecular weight of the PDGFR subtypes is ~ 170 kDa (PDGFRα) 
and 180 kDa, respectively (PDGFRβ). The transmembrane part connects five extracellular 
immuno-globulin-like domains to an intracellular tyrosine kinase domain, containing a 
characteristic sequence, which is unique for PDGF receptor kinase (Claesson-Welsh et al. 
1989). 
 
4.1.5 Interaction of PDGF with PDGFR, and PDGF receptor cycle 
 
The PDGF receptors form homo- and heterodimeric receptor complexes, whereas 
dimerization takes place upon binding of the dimeric PDGF ligand only (Bishayee et al. 1989; 
Heldin et al. 1989; Seifert et al. 1989). As illustrated in Figure 4-2, the A- and B-chain of 
PDGF show similar affinity to PDGFRα, but only the B-chain is also able to bind the 
PDGFRβ subtype. Consequently, PDGF-AA leads to the formation of PDGFRαα complexes, 
PDGF-AB to PDGFRαα and -αβ dimers, and PDGF-BB to the dimerization of all three 
possible combinations of α- and β-receptors (Hart et al. 1988; Hammacher et al. 1989; Seifert 
et al. 1989; Kanakaraj et al. 1991). PDGF-CC behaves similarly to PDGF-AB. It specifically 
leads to PDGFRαα and PDGFRαβ, but not to PDGFRββ dimer formation (Li et al. 2000; 
Gilbertson et al. 2001). PDGF-DD is regarded as PDGFRββ selective, due to its high binding 
affinity to the β-homodimer and its much lower affinity to PDGFRαβ (Bergsten et al. 2001; 
LaRochelle et al. 2001). 
After receptor binding the ligand-receptor complex is internalized via an endocytotic 
mechanism into endosomes, where the ligand dissociates from the receptor molecules. Later 
on the receptor proteins are recycled and transported to the plasma membrane again or are 
degraded after fusion of the endosomes with lysosomes (Sorkin et al. 1991; Liu et al. 1996). 
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As an alternative route, PDGF receptor proteins can undergo cytosolic degradation in 
proteasomes (Mori et al. 1995). 
 
PDGF-B
PDGF-B
PDGF-B
α α α β β β
Ig-like domains
Cytosol
Kinase domains
Outside the cell
Dimeric ligands
4
PDGF-A
PDGF-A
PDGF-A PDGF-D
PDGF-D
PDGF-C
PDGF-C
 
 
Figure 4-2: Binding affinities of PDGF isoforms to PDGF receptor subtypes. α- and β-
receptors are bound and dimerized with different specificities of the PDGF isoforms. The 
illustration schematically shows the three possible combinations of PDGFR subtypes. The 
dimeric ligands bind to the three outer Ig-like domains, whereas the Ig-like domain 4 is 
interacting with the corresponding domain of a second receptor monomer (based on Heldin 
and Westermark 1999). 
 
4.1.6 PDGFR-mediated effects 
 
The homo- and heterodimeric receptor complexes PDGFRαα, -ββ, and –αβ mediate 
qualitatively different effects on PDGF responsive cells (Table 4-3). Consequently, due to the 
different binding affinities of the PDGF isoforms to the PDGFR subtypes, the reaction of a 
cell upon stimulation with PDGF is determined by the qualitative and quantitative expression 
of the PDGFR monomers. Compared to the other isoforms, PDGF-AB has a stronger 
mitogenic and chemotactic effect on cells expressing both PDGFRα and -β subtypes 
(Heidaran et al. 1991; Ekman et al. 1999). As an explanation for the cellular effects 
preferentially mediated by the different PDGF dimers, it has been suggested, that binding of 
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different isoforms leads to a particular phosphorylation pattern of the dimerized PDGF 
receptors (Rupp et al. 1994; Ekman et al. 1999). 
 
Table 4-3: PDGFR homodimers-mediated cellular effects (from Heldin and Westermark 
1999,  modified).  
Inhibition
Inhibition
Stimulation
Stimulation
Stimulation of edge ruffling, loss
of stress fibers, circular ruffles
Stimulation
PDGFRβ
Weak stimulationCa2+ mobilization
GAP* junctional
communication
Apoptosis
Stimulation or inhibition 
depending on cell type
Chemotaxis
Stimulation of edge ruffling and
loss of stress fibers
Actin reorganization
StimulationCell growth
PDGFRαEffect
*GAP: GTPase activating protein  
 
4.1.7 PDGFR signal transduction 
 
For the start of any PDGFR signal transduction the dimerization of two PDGFR monomers is 
necessary. This approximates the intracellular kinase domains of both monomers and causes 
autophosphorylation of conserved tyrosine residues within the kinase domains, Tyr-849 in 
PDGFRα (Heldin and Westermark 1999) and Tyr-857 in PDGFRβ (Kazlauskas and Cooper 
1989). Activation of the kinase domains increases their catalytic efficiency and entails 
autophosphorylation of several tyrosine residues outside the kinase domains, creating docking 
sites for various adapter proteins, listed in Table 4-4 (Heldin and Westermark 1999). 
The PDGFR signal transduction is intracellularly regulated by several effects, e.g. in 
human arterial smooth muscle cells PDGF increases cAMP formation and protein kinase A 
activity through a mitogen activated protein (MAP) kinase-mediated activation of cytosolic 
phospholipase A2, arachidonic acid release, and prostaglandin E2 synthesis (Graves et al. 
1996). Furthermore, the PDGF receptor signalling is modulated by tyrosine phosphatases, 
which are balancing the phosphorylation state of several tyrosine residues after PDGF 
receptor activation. A prominent member of these tyrosine phosphatases is SHP-2, which is 
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capable of dephosphorylation of autophosphorylated PDGF receptors and of substrates of the 
PDGF receptor kinase (Klinghoffer and Kazlauskas 1995). 
 
Table 4-4: Signal transduction molecules interacting with intracellularly phosphorylated 
PDGF receptor domains (Heldin and Westermark 1999). 
Activates the nucleotide exchange factor C3G
Activates the serin/threonin kinases PAK and NIK
Binds Grb2/SOS
Binds to promotor regions of specific genes
Deactivates RAS
Dephosphorylates autophosphorylated receptors and binds Grb2/SOS
Increase in intracellular calcium and diacyl-glycerol concentration 
(subsequently certain members of the PKC members)
Activates members of serine/threonine, PKC, and RHO kinase 
families; activates Akt/PKB and JNK/SAPK kinases
Downstream signal transduction
Grb2
Grb7
Nck
Crk
SHP-2
GAP
Stat5
Shc
Src
PLCγ
PI 3-kinase
Adapter protein
 
 
 
Furthermore, PDGFR signal transduction forms a complex regulative system of interactions 
with integrin signalling (Assoian 1997; Frisch and Ruoslahti 1997). The growth of several 
PDGF-responsive cell types is dependent on contacts with extracellular matrix molecules. 
These contacts are mediated and controlled by integrins, transmembrane receptors for matrix 
molecules. Growth factor-mediated effects like cell proliferation and cell migration can be 
enhanced by integrin signalling (Assoian 1997; Frisch et al. 1997). PDGF β-receptors can 
interact with certain integrins by formation of PDGFR/integrin complexes after PDGFR 
autophosphorylation, as shown for NIH 3T3 cells (Sundberg and Rubin 1996; Schneller et al. 
1997). Transient, PDGF-independent tyrosine phosphorylation of PDGF receptors was 
observed after binding of collagen and fibronectin to β1-integrin to PDGF receptors in human 
fibroblasts (Sundberg et al. 1996). Moreover, the binding of PDGF to PDGF receptors 
stimulated the synthesis of collagen binding β1 integrin subunit α2 in human fibroblasts too 
(Ahlen and Rubin 1994). 
 
Chapter 4 Targeting of PDGFR in human glioblastoma 93
 
 
Phosphorylated
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MAPK
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factors
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Figure 4-3: Binding of various adapter proteins to phosphorylated PDGF receptor tyrosine 
kinase domains after dimerization of two receptor monomers. The drawing exemplarily 
illustrates the MAP kinase and the PLCγ signal transduction pathway. PLC: Phospholipase C; 
PIP2: Phosphatidylinositol-4,5-bisphosphate; IP3: Inositol-1,4,5-trisphosphate; Grb2: adapter 
protein with SH2 and SOS domain; SOS: son of sevenless nucleotide exchange factor 
(drosophila related protein); RAS: RAS protein kinase; RAF: RAF protein kinase; MAPK: 
mitogen activated protein kinase. 
 
4.1.8 Oncogenic potential of PDGF 
 
PDGF and PDGF receptors are expressed in many different embryonic and adult tissues, 
where they serve a broad variety of physiological functions. As reviewed in detail by Heldin 
and Westermark (Heldin and Westermark 1999) and Reigstad et al. (Reigstad et al. 2005), 
PDGF/PDGFR are crucial in embryonic development and contribute to wound healing 
processes. Furthermore they are suggested to contribute to tissue homeostasis and to exert 
neurotrophic effects in the CNS. 
However, PDGF has also been suggested to be involved in tumorigenesis, due to the 
finding of genetic aberrations in PDGF/PDGFR genes. The amplification of the PDGFRα 
gene has been shown to lead to an overexpression of an aberrant receptor protein (Fleming et 
al. 1992; Kumabe et al. 1992; Hermanson et al. 1996). Some dermatofibrosarcoma and giant-
cell sarcoma exhibit an abnormal PDGF-B gene resulting from a fusion of the PDGF-B gene 
to the collagen gene COL1A1 (Simon et al. 1997). A constitutively active PDGF β-receptor 
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has been described in chronic myelomonocytic leukemia, where the PDGFRβ gene is fused to 
the TEL gene by a chromosome translocation (Golub et al. 1994; Carroll et al. 1996). 
Besides the described genetic aberrations, it has been suggested that PDGF may exert a 
transforming potential by an autocrine PDGF receptor activation, when PDGF and PDGFR 
are coexpressed. The v-sis oncogene product, respectively its cellular counterpart, the c-sis 
oncogene product, is identical to the PDGF-B precursor protein. Moreover, it is identically 
synthesized, assembled, processed, and secreted (Doolittle et al. 1983; Robbins et al. 1983; 
Ostman et al. 1991). The transduction of cells with the acutely transforming retrovirus simian 
sarcoma virus (SSV, Devare et al. 1983) or the Parodi-Irgens feline sarcoma virus (Besmer et 
al. 1983) carrying the v-sis oncogene, leads to v-sis expression and to transformation of the 
transduced cells, if the target cells express either PDGF α- or β-receptors (Leal et al. 1985; 
Beckmann et al. 1988). According to the binding affinity of PDGF-A, the transfection of cells 
with the PDGF-A gene leads to transformation only in α-receptor positive cells (Matsui et al. 
1989; Matsui et al. 1989). In sis-transformed cells the newly synthesized PDGF-B is not only 
able to bind membranous PDGF receptors, but it also binds to immature PDGF receptors, 
which haven´t been transported to the cellular membrane yet. However, the transforming 
signal is suggested to be a result of the interaction of PDGF-B with the membranous receptors 
(Johnsson et al. 1985). 
Apart from its transforming effect in vitro, the sis-gene furthermore causes development 
of fibrosarcoma (Pech et al. 1989) and glioblastoma in mice (Uhrbom et al. 1998). Heldin and 
Westermark pointed out as unlikely that an autocrine growth stimulation is sufficient to cause 
a fully malignant phenotype in the virally induced tumors (Heldin and Westermark 1999) and 
that additional, yet unknown aberrations might contribute to the transformation of the cells. 
More recent studies have also involved the more recently discovered members of the 
PDGF subtype family, PDGF-C and PDGF-D. An autocrine activation loop, consisting of 
PDGF α-receptors and PDGF-CC has been suggested to be important for the malignancy of 
Ewing family sarcoma (Zwerner and May 2002). When PDGF-C was co-expressed with a 
dominant negative PDGF-C mutant in a fibroblast transformation model, anchorage 
dependent cell growth was reduced. Other authors have provided contradicting results, by 
showing the expression of only PDGFR β-receptors in ewing family sarcoma cell lines and 
tissues (Uren et al. 2003). Since PDGF-C does not bind homodimeric PDGFRβ receptors, an 
increasing effect of PDGF-C on the proliferation of Ewing family sarcoma seems rather 
unlikely. PDGF-C mRNA was detected in several glioblastoma and medulloblastoma cell 
lines and in five glioblastoma multiforme tissues, whereas little expression was found in 
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normal foetal and adult brain tissue (Andrae et al. 2002; Lokker et al. 2002), indicating 
PDGF-C to play a role in the development and/or the maintenance of those tumors mentioned. 
In glioblastoma and medulloblastoma PDGF-D has been suggested to mimic PDGF-B, which 
was not detected in a majority of the cases investigated by Lokker et al. (Lokker et al. 2002). 
Moreover, PDGF-D has been shown to accelerate migration of prostate fibroblast cells and 
accelerate progression and metastasis of prostate cancer in immunodeficient mice (Ustach et 
al. 2004). It is coexpressed with PDGF β-eceptor in human prostate cancer tissue and has 
been linked to prostate cancer progression by colocalization with its activator urokinase 
plasminogen activator in prostate cancer cells (Ustach and Kim 2005). Finally, compared to 
normal tissues, PDGF-D is upregulated in human lung and ovarian cancers, and in sera of 
lung and ovarian cancer patients increased PDGF-D levels were detected (LaRochelle et al. 
2002). 
As becomes obvious from Table 4-5, several tumors coexpress at least one PDGFR 
subtype and one PDGFR ligand subtype, capable of binding the coexpressed receptor (Heldin 
and Westermark 1999).  
 
Table 4-5: Expression of PDGF and PDGF receptors in human malignancies (from Heldin 
and Westermark 1999). 
 
++Gastric carcinoma
++Acute megaloblastic leukemia
+Colorectal carcinoma
+
+
+
+
+
+
+
+
PDGFRα
+
+
+
+
+
+
+
+
PDGF-B
+
+
+*
+
+
+
+
+
PDGFRβ
Ovarian carcinoma
Midget carcinoid
Breast cancer
+Prostate cancer
Pancreatic carcinoma
Kaposi sarcoma
Capillary hemangioblastoma
+Mesothelioma
Choriocarcinoma
Soft tissue sarcoma
+Meningioma
Medullablastoma
PDGF-ACell Type
* cytosolic protein  
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However, the question whether autocrine PDGFR stimulation is responsible either for the 
development or for the maintenance of spontaneous tumors in humans is not sufficiently 
answered yet. Many of the PDGF/PDGFR expression studies referred to the mRNA detection, 
but not to the detection of the ligand or the receptor protein. Moreover, in most of the studied 
tumors the expression of PDGF and PDGF receptors was unknown in the normal tissues from 
which the tumor had developed. It also has to be highlighted, that except for the analysis of 
PDGF/PDGFR expression no further investigations have been done to determine the receptor 
activation in terms of autophosphorylation or binding of substrates to the PDGFR kinase 
domain. Heldin and Westermark mention, that even if an autocrine activation loop between 
PDGF and PDGF receptors of the tumor cells should occur, it is unknown if this plays a 
crucial role in the development of the tumor or even contributes to it (Heldin and Westermark 
1999).  
In summary, PDGF has been linked to oncogenic effects, but a generally accepted 
assertion about its contribution to tumorigenesis, maintenance, and progression of certain 
tumor types remains controversial. 
 
4.1.9 PDGF and PDGFR antagonists and PDGFR inhibitors 
 
As mentioned above, PDGF is implicated in autocrine and paracrine stimulation processes, 
possibly leading to several pathological conditions. This poses the question for the clinical use 
of the PDGF inhibition and the inhibition of PDGF receptors, respectively. PDGF antiserum 
has been shown to inhibit neointimal smooth muscle cell accumulation in a restinosis model 
in the rat (Ferns et al. 1991). Several other approaches have been carried out to bind PDGF in 
order to prevent it from binding to its receptor, including soluble extracellular PDGF receptor 
domains (Duan et al. 1991), PDGF binding DNA aptamers (Green et al. 1996), and low 
molecular weight compounds capable of binding PDGF (Mullins et al. 1994). Moreover 
monoclonal antibodies against PDGF receptors can be used as virtual PDGFR antagonists, 
functioning as a block for ligand binding and consequently for PDGF receptor activation 
(LaRochelle et al. 1993; Ramakrishnan et al. 1993; Lokker et al. 1997). 
The selective inhibition of the PDGF tyrosine receptor kinase by low molecular weight 
compounds is currently evaluated for clinical purposes, e.g. for the treatment of human 
glioblastoma (National cancer institute 2005; U.S. National institutes of health 2005; U.S. 
National institutes of health 2005). Presuming that maintenance and progression of various 
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malignancies in humans essentially depend on the autocrine and paracrine stimulation, this is 
a promising approach. Up to now several classes of selective PDGF receptor inhibitors have 
been described. A series of 3-indoleacrylonitrile tyrphostins, 2-chloro-3-phenylquinolines, 
and 3-arylquinoxalines have been examined for their potency of inhibition of platelet-derived 
growth factor receptor tyrosine kinase, whereas the potency decreased in the order from 
quinoxalines > quinolines > indoles (Gazit et al. 1996). Lipophilic groups (methyl, methoxy) 
in the 6 and 7 positions and phenyl at the 3 position of quinoxalines and quinolines were 
essential for potency. Compared to their affinities to EGF-, HER-2/c-ErB-2 receptors, the 
compounds showed selectivity for the inhibition of autophosphorylation of PDGF receptors in 
experiments with isolated membranes of Swiss 3T3 mouse fibroblasts. However, only a few 
compounds were selective for PDGFR inhibition and showed IC50 values in the low 
micromolar range (1-1.5 µM). A commercially available tyrphostin is the compound AG-
1296, which selectively inhibits autophosphorylation of the PDGFR kinase and the PDGF-
dependent DNA synthesis in Swiss 3T3 cells and in porcine aorta endothelial cells with a 50 
% inhibitory concentration of 1 µM (Kovalenko et al. 1994; Kovalenko et al. 1997). 
Furthermore, certain compounds from the classes of bisindolylmethanones as well as of 3-
arylquinolines showed higher potency of inhibition of PDGFR autophosphorylation with IC50 
values in the high nanomolar range (Dolle et al. 1994; Maguire et al. 1994; Bohmer et al. 
2003). 1-Phenylbenzimidazoles (Palmer et al. 1998) including the recently described 
compound CP-673451 (Roberts et al. 2005) consist the most potent class of PDGF receptor 
kinase inhibitors by now. Moreover, leflunomide, a registered drug against rheumatoid 
arthritis (Arava®), and its active metabolite A771726 also have been shown to inhibit PDGFR 
autophosphorylation, but at concentrations of 65 µM and 75 µM respectively (Shawver et al. 
1997; Eckhardt et al. 1999; Xu et al. 1999). Finally, the phenylaminopyrimidine imatinib 
(Gleevec®), which is registered for the treatment of chronic myelogenous leukemia (CML) 
and for the treatment of gastrointestinal stromal tumors (GIST), selectively inhibits 
autophosphorylation of the PDGFR kinase with an IC50 value of 100 nM (Kilic et al. 2000). 
Fig. 4-4 shows the chemical structures of representative examples of different compound 
classes with their IC50 values for the inhibition of PDGFR autophosphorylation. 
 
98 Targeting of PDGFR in human glioblastoma Chapter 4
 
N
Cl
H3CO
H3CO
Tyrphostin CP17, IC50 = 1.5 µM
Gazit et al. 1996
Tyrphostin AG-1296, IC50 = 300 nM
Kovalenko et al. 1994
N
NH3CO
H3CO
CP39, IC50 = 200 nM
Mahboobi et al. 2002
N
H O
N
H
HO
N
H O
N
H
O
O
N
CP53, IC50 = 100 nM
Mahboobi et al. 2002
Leflunomide (SU101), IC50 = 65 µM
Shawver et al. 1997
N
H
O
N
O
F3C
SU0020 (A771726), IC50 = 75 µM
Xu et al. 1999
N
H
O
F3C OH
N
Imatinib (STI-571), IC50 = 100 nM
Buchdunger et al. 2000
N
N
N
H
N
H
N
O
N
N
CP-673451, IC50 = 1 nM
Roberts et al. 2005
N
N
NH2
N
N
O
O
 
Figure 4-4: Chemical structures of various PDGF receptor tyrosine kinase inhibitors with 
their IC50 value referring to inhibition of PDGFR autophosphorylation. 
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4.2 Objective 
 
Glioblastoma multiforme, the most common form of malignant brain tumors in adults, is 
resistant to all forms of therapy, causing the death of most patients within 9–12 months after 
diagnosis. Glioblastoma are known to exhibit numerous genetic and physiological peculi-
arities such as the coexpression of platelet derived growth factors (PDGF) and their receptors 
(PDGFR) (Nister et al. 1991), an observation, which has been suggested to result in an 
increase in cell proliferation due to an autocrine loop (Hermanson et al. 1992; Guha et al. 
1995; Yu et al. 1998; Lokker et al. 2002). The expression of different PDGFR ligands 
(PDGF-A, PDGF-B, PDGF-C, and PDGF-D) and PDGFR subtypes (PDGFRα and PDGFRβ) 
has been reported in various glioblastoma cell lines (Nister et al. 1991), including U-87 MG, 
U-118 MG, and U-373 MG cells. 
Recently, the inhibition of the growth of U-343 MG and U-87 MG human glioblastoma 
cells by disruption of the PDGF/PDRFR autocrine loops with the selective tyrosine kinase 
inhibitor imatinib was reported as well as the growth inhibition of subcutaneous and 
intracranial tumors in nude mice, established by the injection of human U-343 and U-87 MG 
cells, suggesting that PDGF receptors might be a therapeutic target for glioblastoma (Kilic et 
al. 2000). Furthermore, imatinib was reported to act as a radiosensitizer in human 
glioblastoma cells through the inhibition of PDGFR (Holdhoff et al. 2005). Currently the 
efficacy of imatinib in the treatment of human adult glioma is evaluated in clinical trials 
(Raymond E 2004; National cancer institute 2005; U.S. National institutes of health 2005), as 
well as in combination with hydroxyurea (Dresemann 2003; Dresemann 2004) and with or 
without radiation therapy in childhood glioma (U.S. National institutes of health 2005). 
The aim of this work was to corroborate the expression and the functionality of PDGFR 
and PDGF subtypes in human U-87 MG, U-118 MG, and U-373 MG glioblastoma cells as a 
prerequisite for an autocrine loop, to study the effect of exogenous PDGF-BB on the 
proliferation of human glioblastoma, and to investigate the purported antiproliferative activity 
of selective PDGF receptor tyrosine kinase inhibitors against human glioblastoma cells. 
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4.3 Materials and methods 
 
4.3.1 Drugs and chemicals 
 
Imatinib (STI-571) was a gift from Novartis (Basel, Switzerland); a 10 mM stock solution 
was prepared in DMSO. Paclitaxel was from Bristol-Myers Squibb (Munich, Germany) and 
was used as a 100 µM stock solution in 70 % ethanol. Doxorubicin was purchased from 
Sigma (Munich, Germany), a 1 mM stock solution in DMSO was made. Topotecan 
(GlaxoSmithKline, Munich, Germany) was kept as a 1 mM stock solution in 70 % ethanol. 
Mitoxantrone (Sigma, Munich, Germany) was stored as a 3 mM stock solution in 70 % 
ethanol. Leflunomide was kindly provided by Aventis (Bad Soden, Germany), whereas AG-
1296 was obtained from Calbiochem-Novabiochem (Bad Soden, Germany). The latter 
compounds were dissolved in DMSO yielding concentrations of 100 mM and 10 mM, 
respectively. All stock solutions were stored at -20 °C. 
 
4.3.2 Cell lines and culture conditions 
 
The human U-87 MG (ATCC HTB 14, passage 126), the U-118 MG (ATCC HTB 15, 
passage 448) and the U-373 MG (ATCC HTB-17, passage 182) glioblastoma/ astrocytoma 
cell lines (Beckman et al. 1971) were obtained from the American Type Culture Collection 
(ATCC). Cell banking and quality control were performed according to the "seed stock 
concept" (Hay 1988). U-87 MG and U-373 MG cells were grown in Eagle´s minimum 
essential medium (EMEM, Sigma, Munich, Germany) containing L-glutamine, 2.2 g/l 
NaHCO3, 110 mg/l sodium pyruvate, and 5 % fetal calf serum (FCS, Biochrom, Berlin, 
Germany), whereas the U-118 MG cells were maintained in Dulbecco´s minimum essential 
medium (DMEM, Sigma, Munich, Germany) which was also supplemented with 5 % FCS. 
Human CCD-11Lu fibroblasts (ATCC CCL-202, passage 10) and human A431 epidermoid 
carcinoma cells (ATCC CRL-1555) (Giard et al. 1973) were cultured in DMEM 
supplemented with 10 % FCS. All cells were cultured in a water-saturated atmosphere of 95 
% air and 5 % carbon dioxide at 37 °C in 75-cm² culture flasks (Nunc, Wiesbaden, Germany) 
and were serially passaged following trypsinization using trypsin (0.05 %)/EDTA(0.02 %) 
(Roche Diagnostics, Mannheim, Germany). Human K-562 chronic myelogenous leukemia 
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(CML) cells, German collection of microorganisms and cell cultures (DSMZ, Braunschweig, 
Germany; ACC 10, passage 21) (Koeffler and Golde 1980) were kindly provided by Dr. 
Robert Gastpar, department of hematology and internist oncology, University of Regensburg. 
Cells were cultured in RPMI-1640 (Sigma, Munich, Germany) medium, supplemented with 5 
% FCS. Cells were passaged every 4-5 days. Swiss 3T3 mouse fibroblasts (ATCC CCL-92) 
(Todaro and Green 1963) were kindly provided by Prof. Dr. Frank Böhmer, research unit of 
molecular cell biology, University of Jena. Cells were maintained in DMEM containing 10 % 
FCS and were passaged once a week. HeLa cell derived human KB cells (ATCC CCL-17) 
(Eagle 1955) were cultured in DMEM 10 %, supplemented with 300 ng/ml vninblastine and 
passaged every 4-5 days. MCF7 breast adenocarcinoma cells (ATCC HTB-22) (Sugarman et 
al. 1985; Bacus et al. 1990) were maintained in EMEM 5 % with weekly passaging. 
MCF7/Topo cells were additionally cultured with 500 ng/ml topotecan. 
 
4.3.3 Isolation of total RNA 
 
For the RNA isolation procedure all cells types were cultured in 75 cm2 culture flasks and the 
total RNA was isolated by the guanidinium thiocyanate method (Chomczynski and Sacchi 
1987). To prevent a loss and destruction of RNA by RNAses during isolation and storage, all 
surfaces that may come into contact with the RNA preparation were treated with a 0.1 % 
solution of DEPC (diethyl pyrocarbonate, Fluka, Steinheim, Germany) in millipore water. 
Solution D was prepared by dissolving 250 g of guanidinium thiocyanate (Merck, Darmstadt, 
Germany) in 293 ml of DEPC treated water and addition of 17.6 ml of a 0.1 M sodium citrate 
solution (Merck) pH 7.0 and 26.4 ml of a 0.5 % sarcosyl (N-lauryl sarcosine sodium salt; 
Merck) solution. 360 μl of β-mercaptoethanol (Serva, Heidelberg, Germany) were added to 
solution D before use. Almost confluent (90 %) cultures of U-87 MG, U-118 MG, U-373 MG, 
and CCD-11Lu cells, were used for the isolation prodecure whereas the RNA of K-562 CML 
suspension cells was isolated when the cells had reached a density of 10 million per flask. 
After the culture medium was removed, cells were lysed by the addition of 5 ml of solution D. 
The lysate was mixed with 0.5 ml of sodium acetate (pH 4, 2 M), 5 ml of water-saturated 
phenol, and 1 ml of chloroform, followed by vortexing. After incubation on ice for 15 minutes 
and centrifugation at 10,000 g (Sorvall RC-5B, DuPont, Wilmington, Delaware, USA) for 15 
minutes at 4 °C, the aqueous phase of the mixture was transferred into a new reaction vessel. 
An equal volume of isopropyl alcohol p.a. (Merck, Darmstadt, Germany) was added for RNA 
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precipitation, and after an incubation period of 1 hour at -20 °C the RNA was pelleted by 
centrifugation at 15,000 g for 15 minutes at 4 °C. The supernatant was discarded and the RNA 
pellet was resuspended in 1 ml of solution D. As a further purification step the RNA was 
precipitated again by addition of 1 ml of isopropyl alcohol p.a., incubation for 1 hour at -20 
°C, and centrifugation at 13,000 g for 30 minutes at 4 °C. The supernatant was removed and 
the pellet was washed with 70 % ethanol. After centrifugation at 15,000 g for 15 minutes at 4 
°C the pellet was dried at room temperature under sterile conditions, and afterwards it was 
redissolved in DEPC treated water (DEPC water) and stored at -80 °C. The concentration and 
purity of the isolated RNA samples were measured using a Cary 100 UV-Vis 
spectrophotometer, confirming A260/280 ratio values between 1.4 and 1.9. 
 
4.3.4 RT-PCR 
 
For RT-PCR M-MLV reverse transcriptase (Invitrogen, Karlsruhe, Germany) and Taq-
polymerase (Promega, Mannheim, Germany) were used. The PCR primer sequences (Tab. 4-
6) for PDGFR were taken from the literature (Denk and Knorr 2002). All other primer 
sequences (Tab. 4-6) were computed with the Web-Primer program, (http://genome-
www2.stanford.edu /cgi-bin/SGD/web-primer) whereas the template nucleotide sequences for 
primer design were obtained from the NCBI database.  
 
Table 4-6: Primer sequences for RT-PCR (5´-3´). All primers were synthesized by MWG 
Biotech AG. 
5´-TTGCCATTGACTGAAAGAACA-3´5´-TCCAAGCTCAAAGAAGCAGA-3´MDR1
5´-TTCGCATCTCTGTCTCTCCTG-3´5´-ATGTTGTATCCCCTCTTCCCT-3´MRP
5´-TCAGCAACCACTTGTGTTCA-3´5´-GGGTAGAGCTAAGACCATGGC-3´PDGF-D
5´-AACCCCAGCTCTGTTCTGGAT-3´5´-GCCTTGGGATACTTTGAATCA-3´BCRP
5´-TTTCTTTGCGGGGGTATGTCC-3´5´-ACGTGGCTTTTCTGGTATCTT-3´PDGFRβ
5´-GCTTCAGCTCTCGGTTCTCAG-3´5´-TCAAAGTCCCATCCATCAAAT-3´PDGFRα
5’-GGAATTCTGGCGTGAGGGA-3´5’-CGGGATCCCCAACTGGGAC-3’β-actin
5´-AAGGTTTGGCTCAGCTGTGT-3´5´-TCCGGGGCTCTATGGGTTT-3´Bcr-Abl
5´-GCCAGAAAATGGTATCGGTT-3´5´-GGAGTCGCTGCT TCCAAAGT-3´PDGF-C
5´-GAGGACTTTGGGAAATGGAGG-3´5´-AGGAGGGAGACTGTGGTAGGG-3´PDGF-B
5´-TGACTCCGAGGAATCTCGTAA-3´5´-ATACCTCGCCCATGTTCTG-3´PDGF-A
Antisense-PrimerSense-PrimermRNA
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Primers were synthesized by MWG Biotech AG (Ebersberg, Germany). RT-PCR was carried 
out with a Mastercycler (Eppendorf, Wesseling-Berzdorf, Germany) gradient. PCR was 
performed with an initial step at 95 °C for 30 seconds, then 32 cycles at 60 °C for 1 minute 
and 72 °C for 30 seconds, followed by a final elongation step at 72 °C for 2 minutes. The 
PCR products were detected by agarose gel electrophoresis (1.5 % agarose [peqGOLD, 
Peqlab, Erlangen, Germany] in tris-borate-EDTA buffer, 0.4 µg/ml ethidium bromide [Sigma, 
Munich, Germany]). 
 
4.3.5 Immunostaining 
 
The expression of the PDGF receptor protein by human glioblastoma cells was visualized by 
immunofluorescence. CCD-11Lu fibroblasts were used as positive control. The cells were 
seeded into chamberslides (Nunc, Wiesbaden, Germany). At 90 % confluence of the cells the 
medium was removed and the cells were washed with phosphate buffered saline (PBS, 8.0 g/l 
NaCl, 1.0 g/l Na2HPO4·2H2O, 0.2 g/l KCl, 0.2 g/l KH2PO4 and 0.15 g/l NaH2PO4·H2O) 
containing 0.1 % NaN3 and 2 % FCS. 50 µl (1:100 dilution in PBS) of the primary anti 
PDGFRα and PDGFRβ antibody solution (monoclonal anti-human PDGFRαMAB1264, 
monoclonal anti-human PDGFRβ MAB1263, R&D Systems, Wiesbaden-Nordenstadt, 
Germany) were added, and the cells were incubated at room temperature for 1 hour. The 
supernatant was removed and the cells were washed 3 times with PBS. 50 µl (1:100 dilution 
in PBS) of the secondary antibody solution (polyclonal rabbit anti-mouse IgG fluorescein 
isothiocyanate (FITC) conjugated, F0261, DAKO, Hamburg, Germany) were added and the 
cells were incubated for 1 hour at 4 °C, protected from light. After removal of the supernatant 
and washing (3 times with PBS) the cells were inspected under a fluorescence microscope 
(DMI-RB, Leica, Wetzlar, Germany). For non-specific binding cells were processed without 
primary antibody.  
For the determination of the expression of the p-glycoprotein 170 (pgp) and of the breast 
cancer resistance protein (bcrp) the glioblastoma cell variants were seeded into chamberslides 
(Nunc, Wiesbaden, Germany). KBv1 cells served as positive control for pgp while MCF7 
wild type cells were used as positive control for bcrp. After 48 hours of attachment period the 
cells were fixed with 4 % PFA solution in PBS for 20 minutes at room temperature. After 
discarding the fixative the cells were washed 3 times with 300 µl PBS 0.5 % bovine serum 
albumin (BSA, Serva, Heidelberg, Germany) and permeabilized by incubation with 0.1 % 
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Triton X-100 solution in PBS 0.5 % BSA, 150 µl per well, for 10 minutes at room 
temperature. The cells were washed again 3 times with 300 µl PBS 0.5 % BSA and then were 
incubated with 125 µl of a 1:200 dilution of monoclonal mouse anti-human pgp Ab2 primary 
antibody Clone F4 (Dianova, Hamburg, Germany) and monoclonal mouse anti-human bcrp 
BXP-21 primary antibody (Calbiochem, Bad Soden, Germany), respectively, for 1 hour at 
room temperature. After removing the excess primary antibody and washing 3 times with 
PBS 0.5 % BSA, the cells were incubated with 125 µl of 1:200 diluted Cy5-conjugated rabbit 
anti-mouse IgG secondary antibody (Dianova, Hamburg, Germany) for 1 hour at room 
temperature. The incubation of the cells with the anti-bcrp antibody was followed by a 10 
minutes incubation period with the nucleic acid stain SYTOXGreen® (500 nM in PBS 0.5 % 
BSA, 125 µl per well, Molecular probes, Eugene, Oregon, USA). The cells were washed 3 
times with PBS 0.5 % BSA and with millipore water. After air drying and mounting using 
fluoromount mounting medium (Serva, Heidelberg, Germany), the cells were inspected with a 
Carl Zeiss Axiovert 200M confocal laser-scanning microscope, equipped with a LSM510 
scanning unit. 
 
4.3.6 Flow cytometric determination of PDGFR expression 
 
The human glioblastoma cells were trypsinized and suspended in medium to 1 million 
cells/ml. The cells were washed with PBS and stained in the same way as for fluorescence 
microscopy (immunostaining of PDGFR). For flow cytometric analysis with a FACSCalibur 
(BD Biosciences, Heidelberg, Germany) the cells were centrifuged after the last washing step, 
the supernatant was discarded, and the pellet was suspended in 0.5 ml of PBS. For each 
measurement 100,000 events were acquired, and fluorescence was measured in the FL1 
channel. 
 
4.3.7 Fluorimetric quantification of intracellular Ca2+ mobilization 
 
The PDGF receptor-mediated effect of PDGF-BB on [Ca2+]i mobilization (Berridge et al. 
1984; Moolenaar et al. 1984; Diliberto et al. 1992) in human glioblastoma cells was 
determined by the ratiometric Fura-2 method, which is based on a shift of the excitation 
spectra of the Ca2+ indicator dye Fura-2 (Takahashi et al. 1999) and the Ca2+-dye chelate. In 
brief: after 12 hours under serum-free culture conditions, cells were trypsinized and 
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suspended in loading buffer (120 mM NaCl, 5 mM KCl, 2 mM MgCl2·6 H2O, 1.5 mM 
CaCl2·2 H2O, 25 mM HEPES, 10 mM Glucose, pH 7.4) containing 1 % BSA at a 
concentration of 106 cells/ml, and loaded with 1.0 µM of Fura-2. The cells were immediately 
used for the assay after a postincubation step (30 minutes). After addition of 20 ng/ml of 
rhPDGF-BB fluorescence ratio (R, 340/380 nm excitation) was measured at 510 nm with a 
Perkin-Elmer LS 50 B fluorimeter (Rodgau-Jügesheim, Germany). During the assay the dye-
loaded cells were maintained at 25 °C. The fluorescence values were converted into [Ca2+]i 
concentrations using the Grynkiewicz equation (Grynkiewicz et al. 1985; Takahashi et al. 
1999). 
 
4.3.8 Chemosensitivity assay 
 
The assays were performed as described previously (Bernhardt et al. 1992). In brief: tumor 
cell suspensions (100 µl/well) were seeded into 96-well flat bottomed microtitration plates 
(Greiner, Frickenhausen, Germany) at a density of ca. 15 cells/microscopic field 
(magnification 320x). After 2-3 days the culture medium was removed by suction and 
replaced by fresh culture medium (200 µl/well) containing varying drug concentrations or 
vehicle. Drugs were added as 1000-fold concentrated feed solutions. On every plate 16 wells 
served as controls and 16 wells were used per drug concentration. After various times of 
incubation the cells were fixed with glutardialdehyde (Merck, Darmstadt, Germany) and 
stored in a refrigerator. At the end of the experiment all plates were stained with crystal violet 
(Serva, Heidelberg, Germany) simultaneously. Absorbance was measured at 578 nm using a 
Biotek 309 Autoreader (Tecnomara, Fernwald, Germany). 
 
4.3.9 Incubation of the cells with exogenous PDGF-BB 
 
Incubation of the cells with PDGF was performed by analogy with the chemosensitivity 
assays. Cells were seeded in medium supplemented with FCS. Instead of drug 3 
concentrations (0.1, 1.0, and 10 ng/ml) of recombinant human PDGF-BB (BIOCHROM AG) 
were used in different serum-free media (EMEM, DMEM, HAMs F12, and MCDB 105 
(Sigma, Munich, Germany). Growth curves were quantified by the crystal violet method. 
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4.3.10   MTT assay 
 
(Gupta et al. 2002; Sargent 2003) Human K-562 CML cells were seeded into 96 well plates, 
100 µl of cell suspension per well. After 24 hours the medium was removed after 
centrifugation and 200 µl of medium, containing different concentrations of imatinib (0.1, 1.0, 
2.5, 5.0, and 10 µM), were added. After varying times of incubation the medium was 
removed, 100 µl of a MTT (Sigma, Munich, Germany) solution (5 mg/ml) in PBS were 
added, and the cells were left in the incubator for 2.5 hours. The microplates were centrifuged 
and the supernatant was removed. The formed formazan was dissolved with 100 µl of DMSO 
per well, and the absorbance was measured at 540 nm using a Biotek EL 309 plate reader. 
 
4.3.11   Flow cytometric calcein-AM efflux assay (pgp/ABCB1 assay) 
 
The assay was performed with minor modifications according to the cited literature (Homolya 
et al. 1993; Hollo et al. 1994; Homolya et al. 1996). Calcein-AM was obtained from 
Molecular Probes (Molecular Probes, Eugene, Oregon, USA). Calcein-AM was stored as a 
aliquoted 1 mM stock solution in DMSO (Merck, Darmstadt, Germany) at -20 °C. The 
loading buffer consisted of 120 mM NaCl, 5 mM KCl, 2 mM MgCl2·6H2O, 1.5 mM 
CaCl2·2H2O, 25 mM HEPES and 10 mM glucose, and was adjusted to pH 7.4. The loading 
suspension contained loading buffer supplemented with 20 mg/ml of BSA (Serva, Heidelberg, 
Germany) and 5 µl/ml of Pluronic F127 (20 % in DMSO, Molecular Probes, Eugene, Oregon, 
USA). KBv1 cells were trypsinized 3-4 days after the last passaging and washed with PBS at 
25 °C. To 0.75 ml cell suspension containing 1·106 cells in loading buffer 0.25 ml loading 
suspension was added. The samples were mixed with different concentrations of imatinib and 
vortexed. After 15 minutes calcein-AM solution (1 mM in DMSO) was added to achieve a 
concentration of 1 µM. After an incubation for 10 minutes at 37 °C/5 % CO2 and 
centrifugation for 7 minutes at 4 °C at 1100 rpm the supernatant was discarded. The cell pellet 
was rinsed once with ice cold PBS and resuspended in 0.5 ml of loading buffer per 1·106 cells. 
The calcein fluorescence was measured by a FACSCalibur™ (Becton Dickinson, Heidelberg, 
Germany) flow cytometer using the FL1 detection channel. Each measurement included data 
acquisition of 30,000 events, gated from a FSC/SSC dotplot. The following photomultiplier 
settings were used: E-1 for FSC, 270 for SSC and 300 for FL1. Data were analyzed by the 
WinMDI 2.8 FACS analysis software. 
Chapter 4 Targeting of PDGFR in human glioblastoma 107
 
 
4.3.12   Flow cytometric mitoxantrone efflux assay (bcrp/ABCG2 assay) 
 
The assay was performed according to the cited literature (Spritz et al. 1994; de Bruin et al. 
1999; Maliepaard et al. 1999; Robey et al. 2001) with modified assay conditions. ABCG2-
expressing MCF-7/Topo cells were passaged 3 or 4 days before the assay was carried out, 
trypsinized, washed with PBS at 25 °C, and adjusted to number of 1of  1·106 cells per ml with 
culture medium. Mitoxantrone was added to the cell suspensions to achieve a concentration of 
20 µM (6.67 µl of 3 mM stock solution in 70 % ethanol). Different concentrations of imatinib 
were added after a short vortexing step. Again the cell suspensions were vortexed followed by 
30 minutes of incubation at 37 °C/5 % CO2, which is a sufficient incubation period for 
mitoxantrone uptake into the cells, according to the literature. The cells were washed with ice-
cold PBS and resuspended in culture medium. After an incubation period of 1 hour at 37 °C/5 
% CO2 an equilibrium of mitoxantrone had developed between the cytoplasm of the cells and 
the surrounding medium. After the medium was removed by centrifugation, the cell pellet was 
rinsed once with ice-cold PBS, and resuspended in 0.5 ml of PBS (2·106 cells/ml). Data 
acquisition for all samples was performed using a FACSCalibur™ (Becton Dickinson, 
Heidelberg, Germany), collecting data of 20,000 events, gated from a FSC/SSC dotplot. The 
following photomultiplier settings were used: E-1 for FSC, 200 for SSC, 450 for FL1 and 700 
for FL4. FL4 histograms were analyzed by the WinMDI FACS 2.8 data analysis software. 
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4.4 Results 
 
4.4.1 Detection of PDGFR and PDGF mRNAs by RT-PCR 
 
To investigate, if the requirements for an autocrine PDGF/PDGFR loop are fulfilled in human 
glioblastoma cells, the total RNAs of U-87 MG, U-118 MG, and U-373 MG cells were 
isolated, and the PDGF/PDGFR mRNAs were detected by RT-PCR. All of the three human 
glioblastoma cell lines showed positive results for different PDGFR subtypes (Fig. 4-5 and 4-
6). The PCR products of all PDGF variants were detected in U-87 MG and U-373 MG cells, 
whereas PDGF-D mRNA was not detected in U-118 MG glioblastoma cells (Fig. 4-7). All 
PDGF and PDGFR subtypes were additionally detected in non-malignant human CCD-11Lu 
fibroblasts. The RT-PCR results are summarized in Table 4-7. 
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Figure 4-5:  Detection of the PCR products of PDGFR mRNAs by agarose gel electro-
phoresis. Except U-373 MG, which shows only one band (756 bp) for the PDGFRα mRNA, 
the other glioblastoma cell variants U-87 MG and U-118 MG as well as the CCD-11Lu 
fibroblasts show bands for both PDGFR mRNA subtypes (PDGFRα 756 bp, PDGFRβ 233 
bp). PCR products of β-actin (304 bp) were used as control. CCD-11Lu fibroblast cDNA was 
used as a positive control for the detection of PDGFR cDNA subtypes. 
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Figure 4-6:  Detection of the competitively amplified PCR templates of PDGFR mRNAs by 
agarose gel electrophoresis. The U-373 MG cells show only one band indicative of PDGFRα 
mRNA (756 bp), whereas in U-118 MG cells two bands show the presence of mRNA of both 
PDGFR subtypes. On the contrary, only the one PCR product, indicating the PDGFRβ mRNA 
(233 bp), was detected in U-87 MG cells. PCR products of β-actin (304 bp) were used as 
control. 
 
CCD11-Lu
U-118 MG
U-373 MG
U-87 MG
300 bp
900 bp
100 bp
200 bp
300 bp
900 bp
100 bp
200 bp
β-a
ct
in
30
4 
bp
PD
G
F-
A
 2
88
 b
p
PD
G
F-
B
   
95
 b
p
PD
G
F-
C
 8
70
 b
p
PD
G
F-
D
 2
23
 b
p
D
N
A
 st
an
da
rd
β-a
ct
in
30
4 
bp
PD
G
F-
A
 2
88
 b
p
PD
G
F-
B
   
95
 b
p
PD
G
F-
C
 8
70
 b
p
PD
G
F-
D
 2
23
 b
p
D
N
A
 st
an
da
rd
 
 
Figure 4-7:  Agarose gel electrophoresis of PCR products of PDGF mRNA subtypes. U-87 
MG, U-373 MG, and CCD-11Lu show bands for all of the four subtypes PDGF-A, -B, -C and 
–D whereas U-118 MG lacks the band for PDGF-D. Primers for β-actin (product band at 304 
bp) were used as control. 
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Table 4-7: Relative amounts of PDGF and PDGFR mRNA detected by RT-PCR. The RT-
PCR results indicate a differential expression of PDGFR subtypes in human glioblastoma 
cells. Each of the three cell lines shows high levels of at least one PDGFR subtype (++) and 
all cells are positive for every PDGF subtype, only U-118 lacks mRNA for PDGF-D (-). 
 
+
++
+
+
- ‡
++
U-373 MG
+
++
+
+
+
+
CCD11-Lu
-+PDGF-D
++++PDGF-C
++PDGF-B
+++PDGF-A
+++PDGFRβ
++ †+ *PDGFRα
U-118 MGU-87 MGPCR product
* positive for mRNA,† positive, broad band, ‡ negative, i.e. no PCR product.  
 
4.4.2 Expression of PDGFR protein 
 
The detection of mRNA for PDGFR subtypes in human glioblastoma cells suggests a 
differential expression of PDGFR protein. This hypothesis was investigated by fluorescence 
microscopy after immunostaining of the different PDGFR proteins. The results of the 
immunostaining (Fig. 4-8) confirmed the RT-PCR data by demonstrating the PDGFR 
phenotype in the human glioblastoma cells as well as in the fibroblast cells. The flow 
cytometric data (Fig. 4-9 and 4-10) is in agreement with the microscopic results. U-87 MG 
cells mainly express PDGFRβ, the expression of the PDGFRα subtype is weak. U-118 MG 
cells bear both PDGFR subtypes at similar levels, whereas mainly the PDGFRα subtype was 
detected in the U-373 MG cells. 
In summary, all of the human glioblastoma cell lines express at least one subtype of the 
PDGFR protein. In view of the positive RT-PCR results for PDGF-A and PDGF-B, which 
were detected in all three glioblastoma cell lines, a PDGFR/PDGF autocrine loop is 
conceivable. 
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Figure 4-8: Immunochemical determination of PDGFR expression. Micrographs of human 
CCD-11Lu fibroblasts, human U-87 MG, U-118 MG, and U-373 MG glioblastoma cells, 
immunostained with anti-human PDGFR antibodies; phase contrast image (left) and 
fluorescence image (right). Control: non-specific binding of the FITC-labeled secondary 
antibody. 
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Figure 4-9:  Flow cytometric determination of PDGFR phenotype: density dotplot and 
corresponding overlay histograms of the PDGFR staining data of human glioblastoma cell 
variants. The density plots show all events occurred during the measurement, including cell 
debris (upper row). Intact cells were gated and used for histogram analysis (lower row). The 
non-specific binding of the FITC-labeled secondary antibody is shown in red, binding of anti 
PDGFRα in green and binding of anti PDGFRβ in black. 
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Figure 4-10:  Relative fluorescence of human glioblastoma cells after immunostaining of 
PDGFRs compared to non-specific binding of the FITC-conjugated secondary antibody (100 
AU). The comparison of the geometric means shows various degrees of PDGFR subtype 
expression by the different glioblastoma cell variants. 
 
Chapter 4 Targeting of PDGFR in human glioblastoma 113
 
 
4.4.3 Ratiometric determination of intracellular Ca2+ concentration after 
activation of receptor tyrosine kinases EGFR and PDGFR 
4.4.3.1 Fura-2 assay 
The ratiometric Ca2+ indicator dye Fura-2 is a commonly used compound for the fluorimetric 
determination of changes in the intracellular Ca2+ concentration. The cells of interest are 
incubated and thereby loaded with the lipophilic Fura-2 acetoxymethylester (Fura2/AM, Fig. 
4-11), which is capable of permeating through the plasma membrane into the cytosol. After 
cleavage by cytoplasmic esterases the now highly hydrophilic and membrane impermeable 
compound accumulates inside the cells. 
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Figure 4-11:  Chemical structure of the calcium indicator dye Fura-2/AM. 
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Figure 4-12:  Fluorescence excitation and emission spectra of the Fura-2/Ca2+ complex (A) 
and the free Fura-2 (B). 
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After enzymatic ester hydrolysis in the cytosol an equilibrium is formed between free and 
Ca2+-bound Fura-2, whereby both Fura-2 forms show different excitation, but similar 
fluorescence emission spectra (Fig. 4-12). The fluorimetric readout of a given Ca2+ 
concentration is the ratio R of the fluorescence emission F at 510 nm of the Ca2+-bound form 
(λex = 340 nm, F340 nm) and the free form of Fura-2 (λex = 380 nm, F380 nm): 
 
nm
nm
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Changes in the intracellular Ca2+ concentration shift the equilibrium either towards the free or 
the Ca2+-bound form of Fura-2, and thus the measured fluorescence ratio is accordingly 
decreased or increased. The actual intracellular Ca2+ concentration [Ca2+]i can be calculated 
from the fluorescence ratio R using the equation after Grynkiewicz (equation 2) (Grynkiewicz 
et al. 1985): 
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The Grynkiewicz equation also considers the dissociation constant Kd of the Fura-2/Ca2+ 
complex and the relative fluorescence contribution Sfb of Ca2+-free and Ca2+-bound Fura-2 at 
an excitation wavelength of 380 nm. Rmax constitutes the fluorescence ratio of all the Fura-2 
from the loaded cells, quatitatively bound to Ca2+. Therefore the cells are permeabilized with 
the steroidal saponin digitonin, so the dye leaks into the surrounding sample buffer and is 
completely bound to Ca2+. After measurement of Rmax the potent Ca2+ complexing agent 
EGTA is added to the sample, all Fura-2 is set free from its Ca2+ complex, and Rmin, 
representing the fluorescence ratio of quantitatively free Fura-2, can be determined. 
 
4.4.3.2 Mobilization of intracellular Ca2+ upon stimulation of epidermal growth 
factor (EGF) receptors in A431 cells 
An increase in intracellular Ca2+ concentration upon activation of receptor tyrosine kinases 
has been reported in literature (Diliberto et al. 1992). A prerequisite for the intracellular Ca2+ 
mobilization is the coupling of a PLCγ pathway to the initial activation of the receptor 
tyrosine kinase of interest (Berridge et al. 1984; Carpenter and Ji 1999). In this study human 
Chapter 4 Targeting of PDGFR in human glioblastoma 115
 
 
A431 epidermoid carcinoma cells (Giard et al. 1973) and Swiss 3T3 mouse fibroblast cells 
were used as models for transferring the Fura-2 method to tyrosine kinase receptors and to 
confirm its functionality for the determination of RTK activity. After loading of the cells with 
the Ca2+ indicator dye, according to the materials and methods section, various concentrations 
of recombinant human epidermal growth factor (rhEGF) were added to the samples. The Ca2+ 
response was monitored over a time period of 300 seconds The acquired calcium signals are 
shown in Fig. 4-13. 
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Figure 4-13:  Mobilization of intracellular Ca2+ in human A431 cells after stimulation with 
various concentrations of rhEGF. A concentration-dependent increase in the maximal [Ca2+]i 
can be observed as well as a delay of the Ca2+ response towards lower rhEGF concentrations. 
Compared to the commonly observed immediate response of G-protein coupled receptors a 
few seconds after addition of an agonist, the beginning of the Ca2+ mobilization in A431 cells 
is delayed by at least 30 seconds at the highest used rhEGF concentration. 
 
4.4.3.3 Mobilization of intracellular Ca2+ upon stimulation of PDGF receptors in 
Swiss 3T3 cells 
Since the PLCγ pathway is known to be connected to the PDGF receptor autophosphorylation 
(Ronnstrand et al. 1992; Larose et al. 1993; Valius et al. 1993), Swiss 3T3 mouse embryo 
fibroblast cells were used as a model for monitoring the PDGF receptor-mediated Ca2+ 
release. In Swiss 3T3 mouse embryo fibroblasts a strong [Ca2+]i mobilization was observed 
upon PDGF-BB stimulation (Fig. 4-14), which was suppressed by imatinib in a concentration-
dependent manner (Fig. 4-15, 4-16). Imatinib was added 5 seconds prior to the PDGF-BB 
EGF
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stimulus. The experiment was performed in triplicate, and an IC50 value of 4.2 µM was 
calculated for imatinib. 
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Figure 4-14: Mobilization of intracellular Ca2+ in Swiss 3T3 embryo cells after stimulation 
with various concentrations of rhPDGF-BB. As shown before for the stimulation of the EGF 
receptors in A431 cells, PDGF triggered a concentration-dependent increase in the maximum 
[Ca2+]i in the mouse fibroblast cells. Also a delay of the Ca2+ response towards lower 
rhPDGF-BB concentrations was observed. 
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Figure 4-15:  Effect of imatinib on the mobilization of intracellular Ca2+ upon stimulation of 
Swiss 3T3 mouse fibroblasts with 20 ng/ml of rhPDGF-BB. Calcium transients in the absence 
and presence of different imatinib concentrations.  
PDGF
PDGF
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Figure 4-16: Concentration-dependent inhibition of PDGFR-mediated Ca2+ mobilization in 
Swiss 3T3 mouse fibroblasts by imatinib. 
 
4.4.3.4 Effect of PDGF-BB on the mobilization of intracellular Ca2+ in human 
glioblastoma cells 
Due to the constitutive expression of histamine H1 receptors by U-87 MG and U-373 MG 
cells, histamine was used at a concentration of 100 µM to trigger a [Ca2+]i signal as a control. 
FCS was used as a positive control in U-118 MG cells, which lack H1 receptors. 
Upon stimulation with 20 ng/ml of rhPDGF-BB, U-87 MG cells showed slow and 
moderate [Ca2+]i mobilization, compared to the control (Fig. 4-17), whereas in U-118 MG 
cells only a marginal [Ca2+]i increase was observed. In U-373 MG cells no mobilization of 
[Ca2+]i was detected. Considering the flow cytometric data shown above, the U-87 MG 
glioblastoma variant with a relatively high expression of the PDGFRβ protein showed the 
highest sensitivity with respect to [Ca2+]i mobilization upon PDGF-BB stimulation. In U-118 
MG cells, expressing almost equal amounts of the PDGFRα and PDGFRβ subtypes, only a 
slight sensitivity was detected, whereas U-373 MG cells, which mainly express the PDGFRα 
subtype, did not respond to the PDGF-BB stimulus. These results confirm the previously 
reported PDGFRβ-associated [Ca2+]i mobilization upon PDGF stimulation (Diliberto et al. 
1992) and the functionality of the PDGF receptors in the U-87 MG and U-118 MG 
glioblastoma variants. 
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Figure 4-17: Effect of PDGF-BB on the 
intracellular Ca2+ mobilization in human 
glioblastoma cells after a 12 hours culture 
period in serum-free medium; rhPDGF-BB 
20 ng/ml (red), histamine 100 µM (blue), 
and FCS 10 % (green). The U-87 MG 
variant showed a moderate response to 
PDGF-BB. In U-118 MG cells marginal 
Ca2+ mobilization was observed. In U-373 
MG cells no increase in [Ca2+]i was 
detected. 
 
 
4.4.4 Effect of selective PDGFR tyrosine kinase inhibitors on the proliferation 
of human glioblastoma cells 
 
To investigate, whether the proliferation of human glioblastoma cells can be mainly ascribed 
to PDGFR-mediated processes, the cells were incubated with the selective PDGFR tyrosine 
kinase inhibitor imatinib. Doxorubicin was used as positive control for the inhibition of cell 
growth. Imatinib showed no inhibition of cell growth up to a concentration of 10 µM (Fig. 4-
18). The assays were also performed with an extended incubation period of 264 hours with 
similar results (Fig. 4-19), which are opposite to a report in the literature (Kilic et al. 2000). 
To investigate if the inhibition of PDGFR-mediated pathways does affect the proliferation 
of glioblastoma cells, U-87 MG and U-373 MG cells were additionally incubated with the 
selective PDGFR inhibitors tyrphostin AG-1296 (Kovalenko et al. 1994), leflunomide 
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(Eckhardt et al. 1999), and two indolylmethanone compounds, CP39 and CP53 (Bohmer et al. 
2003). U-118 MG cells were incubated with all tyrosine inhibitors but leflunomide. For 
chemical structures of all used tyrosine kinase inhibitors see Fig. 4-4. The incubation of the 
human glioblastoma cells with AG-1296 (Fig. 4-20) and leflunomide (Fig. 4-21) up to a 
concentration of 10 µM also did not inhibit cell growth. Leflunomide showed a cytotoxic and 
cytostatic effect on U-373 MG and U-87 MG cells, respectively, at a concentration of 100 
µM. Both of the bisindolylmethanone compounds CP39 and CP53 exhibited a cytotoxic effect 
on U-87 MG and on U-373 MG cells at a concentration of 10 µM and a cytostatic effect at 
100 µM (Fig. 4-22, 4-24). U-118 MG showed chemosensitivity to both compounds at 1 µM 
(cytotoxic effect). At higher concentrations of 10 µM and 100 µM a cytostatic effect was 
observed (Fig. 4-23). 
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Figure 4-18: Effect of the tyrosine kinase inhibitor imatinib on the proliferation of human 
glioblastoma cells. Imatinib lacks inhibitory activity against the human U-87 MG, U-118 MG, 
and U-373 MG glioblastoma cells. After 160 hours no difference between incubation with 
imatinib and the vehicle control is observed. ? vehicle, imatinib concentration: ? 0.1 µM, ? 
1 µM, ? 2.5 µM, and ? 10 µM; ? doxorubicin (50 nM). 
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Figure 4-19: Incubation of human glioblastoma cells with imatinib over 264 hours. At a 
concentration of 10 µM, imatinib slightly affected cell proliferation of U-87 MG and U-373 
MG in the exponential growth phase. Both cell variants recovered and reached absorbance 
values of the vehicle control. In U-87 MG cells the drug exhibited cytotoxic respectively 
cytocidal effects at the end of the incubation period (days 10 and 11). No inhibition of cell 
proliferation was observed in U-118 MG. ? vehicle, imatinib concentration: ? 1 µM, ? 5 
µM, and ? 10 µM; ? paclitaxel 8 nM. 
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Figure 4-20: Incubation of human glioblastoma cells with tyrphostin (AG-1296). No 
inhibition of cell proliferation was observed in any of the three cell variants up to a 
concentration of 10 µM AG-1296. ? vehicle, AG-1296 concentration: ? 0.1 µM, ? 1 µM, 
? 2.5 µM, ? 5 µM and ? 10 µM; ? paclitaxel 8 nM. 
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Figure 4-21:  Effect of leflunomide on the proliferation of U-87 MG and U-373 MG 
glioblastoma cells. Incubation with leflunomide did not affect cell proliferation of U-373 MG 
cells, whereas in U-87 MG a very weak inhibition of cell growth was observed at a 
concentration of 10 µM. At a concentration of 100 µM leflunomide exhibited a cytostatic 
effect on U-87 MG and a cytotoxic effect on U-373 MG cells. ? vehicle, Leflunomide 
concentration: ? 0.1 µM, ? 1 µM, ? 10 µM, and   100 µM; ? paclitaxel 8 nM.  
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Figure 4-22: Effect of the bisindolylcompounds CP39 and CP53 (see also Fig. 4-4) on the 
proliferation of U-87 glioblastoma cells. Incubation did affect cell proliferation at 
concentrations of 10 µM and 100 µM respectively, showing a cytostatic effect on cell growth. 
? vehicle, CP39/CP53 concentration: ? 0.1 µM, ? 1 µM, ? 10 µM, and   100 µM; ? 
paclitaxel 8 nM.  
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Figure 4-23: Incubation of U-118 MG glioblastoma cells with CP39 and CP53 (see also Fig. 
4-4). At concentrations of 0.1 µM and 1.0 µM the cell proliferation was slightly inhibited by 
both compounds, but the cells started to recover after 120 hours of incubation time. A 
cytostatic effect was observed at 10 µM and 100 µM of CP39 and CP53 respectively. ? 
vehicle, CP39/CP53 concentration: ? 0.1 µM, ? 1 µM, ? 10 µM, and   100 µM; ? 
paclitaxel 8 nM.  
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Figure 4-24: Effect of CP39 and CP53 (see also Fig. 4-4) on the proliferation of U-373 MG 
glioblastoma cells.. The cells showed a chemosensitivity similar to that of U-87 MG (Fig. 4-
22). Both compounds were cytotoxic at a concentration of 10 µM, but the cells started to 
recover after about 100 hours. At 100 µM CP39 and CP53 exhibited a cytostatic effect on the 
cells. ? vehicle, CP39/CP53 concentration: ? 1 µM, ? 10 µM, and   100 µM; ? paclitaxel 
8 nM. 
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4.4.5 Influence of pgp and bcrp on imatinib 
4.4.5.1 Expression of pgp and bcrp in human glioblastoma cell variants 
Since imatinib has been discussed to be a substrate of the pgp and the bcrp resistance 
transporter, respectively (Burger et al. 2004; Houghton et al. 2004; Illmer et al. 2004), the 
lack of the antiproliferative activity of imatinib against the human glioblastoma cell variants 
could be ascribed to the expression of these resistance proteins. Therefore the expression of 
pgp and bcrp was investigated on all of the three glioblastoma cell variants used in the 
chemosensitivity assays, using RT-PCR and immunostaining. Fig. 4-25 shows the results of 
the RT-PCR experiments. 
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Figure 4-25: Agarose gel electrophoresis of RT-PCR products. All three glioblastoma cell 
variants show a band for the bcrp PCR-product, indicating the respective mRNA, but not for 
the mdr1 PCR-product (positive control β-actin). 
 
Indicating the expression of bcrp but lack of expression of the pgp in all three cell variants, 
the results of the RT-PCR experiments were confirmed by immunostaining for the pgp 
expression (Fig. 4-26), but not for the bcrp expression (Fig. 4-27). The KBv1 cells showed 
high expression of pgp along the plasma membrane and a slight accumulation of FITC 
fluorescence emission in an organelle close to the nucleus, presumably the golgi apparatus, 
where the immature pgp is processed. The glioblastoma cells lacked pgp expression and only 
very weak fluorescence was detected in the cytoplasm, most likely derived from non-specific 
binding of the secondary antibody, since the nuclei remained completely non-fluorescent. 
Membranous bcrp was clearly detected in a high portion of MCF7 wild type breast cancer 
cells, whereas the identically labeled glioblastoma cells showed no appearance of bcrp. 
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Figure 4-26: Human glioblastoma cells after immunostaining with anti-pgp primary 
antibody and FITC-conjugated secondary antibody. The positive control KBv1 shows 
expression of pgp at the cellular membrane, whereas the three glioblastoma variants lack pgp 
expression. Only weak, non-specific binding throughout the cells can be observed. Plan 
Apochromat 63x 1.4 Oil Ar laser 488 nm, LP505 nm. 
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Figure 4-27: Human glioblastoma cells after immunostaining with anti-bcrp primary 
antibody and Cy5-conjugated secondary antibody. Most of the MCF7 wild type cells show 
membranous expression of bcrp, the three glioblastoma variants lack bcrp expression. Left: 
bcrp, HeNe laser 633 nm, LP650 nm, green false color; middle: nuclei, Ar laser 488 nm, 
LP505 nm, blue false color; right: merged detection channels. Plan Neofluar 40x 1.3 Oil. 
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4.4.5.2 Modulation of pgp and bcrp by imatinib 
In addition to the determination of pgp and bcrp in the human glioblastoma cell variants 
imatinib was tested for its ability to modulate those two resistance proteins using the calcein-
AM efflux assay for pgp (Homolya et al. 1996) and the mitoxantrone efflux assay for bcrp 
(Table 4-8). 
As a lipophilic ester, the non-fluorescent calcein-AM rapidly permeates the plasma 
membrane of cells. Inside the cells highly fluorescent calcein is formed after calcein-AM 
cleavage by non-specific esterases. Calcein accumulates inside the cells due to its high 
hydrophilicity, leading to cytosolic trapping of the compound. Since calcein-AM is a substrate 
for the pgp and extruded by pgp-expressing cells, the increased intracellular calcein 
fluorescence correlates with a lowered expression of pgp and with an increased inhibition of 
pgp by tested compounds, respectively. 
By analogy to the calcein-AM efflux assay, the ABCG2 assay works by loading of bcrp-
expressing MCF7/Topo cells with the fluorescent bcrp substrate mitoxantrone. After a certain 
period of incubation with a potential bcrp modulator, the cell-associated mitoxantrone 
fluorescence is determined by a flow cytometer. High cell-associated fluorescence correlates 
with high mitoxantrone retention within the cells and consequently with a high inhibitory 
activity (bcrp inhibition) of the test compound. 
 
Table 4-8: Pgp/ABCB1 and bcrp/ABCG2 modulation by imatinib. While imatinib starts 
modulation of the pgp at concentrations beyond therapeutically relevant levels (>10 µM), the 
bcrp function is not affected until an imatinib concentration of 10 µM, which is equivalent to 
the maximally suitable plasma concentration of imatinib. 
 
982.7413.4730.0
1391.73234.20100.0
513.777.4210.0
354.826.433.0
313.376.401.0
290.806.300.3
286.516.290.1
300.245.690.0
Geometric mean
(BCRP)
Geometric mean
(PGP170)
Imatinib
[µM]
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4.4.6 Effect of a combination of imatinib with paclitaxel on the proliferation of 
human glioblastoma cells 
 
To investigate, if imatinib can enhances the cytotoxicity of the cytostatic agent paclitaxel, 
both compounds were administered in combination. As becomes obvious from the growth 
curves (Fig. 4-28), a combination of imatinib with paclitaxel did not increase the effect of 
paclitaxel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-28: Combined incubation of 
human U-87 MG, U-118 MG, and U-
373 MG glioblastoma cells with imatinib 
and paclitaxel. Combination of the two 
drugs did not increase the inhibition of 
cell proliferation. A slight inhibition is 
observed for U-373 MG at a 
concentration of 10 µM imatinib. ? 
Vehicle, ? imatinib (10 µM), ? 
paclitaxel (8 nM), ? imatinib (10 µM) + 
paclitaxel (8 nM). 
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4.4.7 Effect of imatinib on the proliferation of human glioblastoma cells in 
PDGF-free medium 
 
To study the effect of imatinib in the absence of PDGF, experiments were carried out in 
serum-free HAMs F12 medium (Fig. 4-29). There was no increase in inhibition compared to 
that observed in serum-supplemented media. Only U-373 MG cells showed sensitivity at an 
imatinib concentration of 10 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-29:  Effect of imatinib on the 
proliferation of human glioblastoma 
cells in serum-free HAMs F12 medium. 
Proliferation of U-118 MG was not 
inhibited under these conditions, 
whereas U-373 MG cells were sensitive 
against 10 µM imatinib. ? Vehicle, 
imatinib concentration: ? 0.1 µM, ? 1 
µM, ? 2.5 µM and ? 10 µM; ? 
vehicle + 10 % FCS. 
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4.4.8 Effect of imatinib on the proliferation of human K-562 CML cells 
 
As imatinib is a registered drug for the treatment of chronic myelogenous leukemia, its 
activity against bcr-abl positive leukemia cells was investigated as a control. Total RNA of 
human K-562 cells was isolated and the bcr-abl oncogene mRNA was detected by RT-PCR 
(Fig. 4-31). Since the K-562 cells are non-adherent cells, but growing in suspension, the 
crystal violet method cannot be used for the determination of chemosensitivity. The 
suspension cells are lost during the initial removing step of culture medium prior to the 
fixation step. Thus the antiproliferative effect of imatinib against the bcr-abl positive K-562 
CML cells was investigated by the MTT assay. 
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Figure 4-30:  Chemical structures of MTT and its reduced form, the purple formazan. MTT 
is positively charged and water soluble, but sufficiently lipophilic to pass the plasma 
membrane of cells. After accumulation and reduction at the mitochondrial membrane, the 
purple MTT formazan precipitates and forms crystal needles inside the cell. 
 
MTT is sensitive to chemical and enzymatic reduction. The yellow, water soluble tetrazolium 
bromide, is reduced to the purple formazan (λmax (absorbance) = 540 nm), which is not soluble in 
water, but in organic solvents such as DMSO. Incubation of cells with an aqueous MTT 
solution leads to an accumulation of the positively charged MTT at the inner membrane of 
mitochondria due to their high membrane potential. Thus the major part of the MTT present 
in the cytosol is reduced by mitochondrial dehydrogenases. After removal of the aqueous 
phase, the crystallized MTT formazan is redissolved in DMSO, and the absorbance of the 
solution is measured at 540 nm (A540). A540 corresponds to the relative amount orthe the 
relative activity of mitochondrial dehydrogenases in treated cells compared to the cells of the 
control. It has to be pointed out that reducing or oxidizing agents may lead to an increase or 
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decrease in the measured A540 values. Furthermore, A540 not necessarily correlates with the 
number viable cells. For example, after cell lysis cellular dehydrogenases still can be active, 
pretending cell viability. 
The results of the MTT assay with K-562 cells incubated with imatinib confirmed the 
antiproliferative effect of imatinib against CML cells at therapeutically relevant 
concentrations (Fig. 4-31). 
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Figure 4-31: Left: agarose gel electrophoresis of RT-PCR products of K-562 mRNA. The 
band at 157 bp shows the presence of bcr-abl mRNA in human K-562 CML cells. Primers for 
β-actin (product band at 304 bp) were used as control. Right: MTT assay with human K-562 
CML cells. The bcr-abl positive cells were incubated for 6 days with various concentrations 
of imatinib. Cell growth was clearly inhibited at a concentration of 0.1 µM. ? Vehicle, 
imatinib concentration: ? 0.1 µM, ? 1 µM, ? 2.5 µM, and ? 10 µM.. 
 
4.4.9 Effect of exogenous PDGF on the proliferation of human glioblastoma 
cells 
 
In FCS-supplemented HAMs F12 medium the glioblastoma cells showed normal proliferation 
behaviour (Fig. 4-32). Addition of 10 ng/ml rhPDGF-BB did not increase cell proliferation in 
serum-free HAMs F12 medium, where the proliferation was generally very slow (Fig. 4-32). 
The experiment was also performed in serum-free MCDB105 medium (Pollack et al. 1990) 
and in serum-free standard culture media (EMEM and DMEM, respectively) with similar 
results (Fig. 4-33, 4-34). In serum-free MCDB105 medium even the maintenance of the 
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human glioblastoma cells failed, a result, which is contradictory to a report from the literature 
(Pollack et al. 1990). Up to 80 % of the cells detached and lost their characteristic 
morphology after the first 30 minutes in serum-free MCDB105 medium. 
To investigate the relevancy of PDGF in cell proliferation, the human glioblastoma cells 
were incubated with exogenous PDGF-BB in serum-free HAMs F12 medium. The resulting 
growth curves are shown for U-87 MG, U-118 MG, and U-373 MG cells (Fig. 4-32). 
Exogenous PDGF-BB did not stimulate cell growth at the selected concentrations i. e. there 
was no difference in cell proliferation compared to the vehicle control. 
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Figure 4-32: Incubation of human glioblastoma cell variants in the presence of recombinant 
human PDGF-BB in serum-free HAMs F12 medium. PDGF-BB had no effect on cell 
proliferation up to a concentration of 10 ng/ml. ? Vehicle, rhPDGF-BB concentration: ? 0.1 
ng/ml, ? 1 ng/ml, and ? 10 ng/ml, ? vehicle +10 % FCS 
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Figure 4-33: Incubation of human glioblastoma cell variants in the presence of recombinant 
human PDGF-BB in serum-free MCDB105 medium. Again, PDGF-BB had no effect on cell 
proliferation up to a concentration of 10 ng/ml. ? Vehicle, rhPDGF-BB concentration: ? 0.1 
ng/ml, ? 1 ng/ml, and ? 10 ng/ml, ? vehicle + 10 % FCS. 
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Figure 4-34: Incubation of human glioblastoma cell variants in the presence of recombinant 
human PDGF-BB in serum-free standard culture medium EMEM (U-87 MG, U-373 MG) 
respectively DMEM (U-118 MG). As observed in the experiments with serum-free HAMs 
F12 and MCDB105 medium, PDGF-BB had no effect on cell proliferation up to a 
concentration of 10 ng/ml. ? Vehicle, rhPDGF-BB concentration: ? 0.1 ng/ml, ? 1 ng/ml, 
and ? 10 ng/ml, ? vehicle + 10 % FCS. 
Chapter 4 Targeting of PDGFR in human glioblastoma 139
 
 
4.5 Discussion 
 
Expression and functionality of PDGFR in human glioblastoma cells. 
The three human glioblastoma cell lines U-87 MG, U-118 MG, and U-373 MG show 
differential expression of the PDGF receptor subtypes (Fig. 4-5, 4-6, 4-8 – 4-10). These 
results are in agreement with the data of a report in the literature (Nister et al. 1991). The 
mRNA of the two major ligand subtypes (PDGF-A and –B) were also detected in all of the 
three cell variants (Fig. 4-7, Tab. 4-7). 
After the demonstration of Ca2+ mobilization in A431 cells upon stimulation with various 
concentrations of EGF (Fig. 4-13) by the Fura-2 method (Takahashi et al. 1999), the 
functionality of PDGFRs was investigated in Swiss 3T3 mouse fibroblasts and in the human 
glioblastoma cells. In Swiss 3T3 cells the PDGF-BB triggered Ca2+ transients (Fig. 4-14) 
were inhibited by imatinib in a concentration-dependent manner (Fig. 4-15, 4-16), confirming 
its antagonistic activity on the PDGFR tyrosine kinase. In the three glioblastoma cell variants 
the mobilization of intracellular Ca2+ upon stimulation with PDGF-BB (Fig. 4-17) correlated 
with the expression of the PDGFRβ  subtype, demonstrated by the flow cytometric 
experiments (Fig. 4-9, 4-10). The results of the fluorimetric Ca2+ measurements demonstrate 
the sensitivity of the glioblastoma variants to PDGF-BB as well as the functionality of the 
identified PDGF receptors. Considering the demonstrated expression of PDGFRs, together 
with the detection of PDGF-A and PDGF-B mRNA by RT-PCR, the proposed autocrine 
activation of the PDGF receptors (Hermanson et al. 1992; Guha et al. 1995; Yu et al. 1998; 
Lokker et al. 2002) seems possible. 
 
Effect of selective tyrosine kinase inhibitors on human glioblastoma cells in vitro. 
Kilic et al. reported on the inhibition of the proliferation of the human glioblastoma cell lines 
U-87 MG and U-343 MG at an imatinib concentration of 3 µM (Kilic et al. 2000). At 
concentrations of 6 and 10 µM the drug even reduced the number of seeded cells (Kilic et al. 
2000). By contrast, the results of this work show that the incubation of the human 
glioblastoma cell variants U-87 MG, U-118 MG, and U-373 MG with the selective PDGFR 
tyrosine kinase inhibitor imatinib had no inhibitory effect on cell proliferation in serum-
supplemented medium over standard and extended incubation period incubation (Fig. 4-18, 4-
19). The compound also lacked antiproliferative activity when the cells were incubated in 
serum-free medium (Fig. 4-29). Although showing high activity against bcr-abl positive K-
562 CML cells (Fig. 4-31) (Gambacorti-Passerini et al. 1997), imatinib was inactive against 
140 Targeting of PDGFR in human glioblastoma Chapter 4
 
the glioblastoma cells at therapeutically relevant concentrations (Lyseng-Williamson and 
Jarvis 2001). Moreover, a combination of imatinib with the cytostatic agent paclitaxel did not 
result in a noticeable effect (Fig. 4-28). Furthermore, tyrphostin AG-1296 (Kovalenko et al. 
1994) had no inhibitory effect (Fig. 4-20). Leflunomide (Eckhardt et al. 1999) exhibited a 
cytotoxic and cytostatic effect on U-87 MG and U-373 MG cells respectively at a 
concentration of 100 µM (Fig. 4-21). Though leflunomide has been shown to inhibit PDGF 
receptor autophosphorylation with an IC50 value of 65 µM (Shawver et al. 1997), it has to be 
doubted whether the observed antiproliferative effect is caused by the disruption of the 
PDGF/PDGFR auto- or paracrine loop. More likely it may be ascribed to other toxic, but 
rather non-specific effects at such a high concentration of leflunomide. The 
bisindolylmethanone compounds CP39 and CP53 (Bohmer et al. 2003) showed similar effects 
on U-87 MG and U-373 MG. For both compounds concentrations above their IC50 value 
(PDGFR kinase inhibition) were needed to result into an antiproliferative effect (Fig. 4-22, 4-
24). Though U-118 MG showed a higher chemosensitivity (Fig. 4-23) compared to U-87 MG 
and U-373 MG, the applied drug concentrations in the range of the IC50 value (PDGFR kinase 
inhibition) were not sufficient to yield an according inhibition of cell growth. 
Referring to the results for imatinib, the contrast to the findings of Kilic et al. may be 
explained by the different conditions prevailing during the cytotoxicity assays. In this study 
the imatinib-containing culture media were not changed throughout the whole incubation 
period, whereas Kilic et al. replaced the culture medium every 48 hours. Bernhardt et al. 
showed that changes of the culture medium within a cytotoxicity assay affects cell 
proliferation leading to an overestimation of the activity of the tested drugs (Bernhardt et al. 
1992). This might in part explain the reported antiproliferative activity of imatinib. 
Additionally, Kilic et al. used platelet-poor plasma, whereas serum-free media were used in 
this study to provide PDGF-free assay conditions. 
Another explanation for the lack of the antiproliferative activity of imatinib would be 
prephosphorylation of the PDGF receptor protein at the activation loop within the receptor 
tyrosine kinase domain, which has been pointed out by Böhmer et al. (Bohmer et al. 2003) to 
be a critical determinant of imatinib inhibitory activity. At isolated receptors the 
phosphorylation of PDGFRβ at this site required one order of magnitude higher 
concentrations of STI-571 for inhibition of receptor kinase activity than non-activated 
PDGFRβ. But in intact cells imatinib inhibited preactivated and non-preactivated receptor 
kinases due to the regeneration of the inactive tyrosine kinase conformation by the action of 
protein tyrosine phosphatases (Bergsten et al. 2001). As a consequence the inhibitory activity 
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of imatinib should not depend on PDGF receptor stimulation, neither by endogenous PDGF 
(autocrine and paracrine stimulation) nor by exogenous PDGF present in FCS. 
 
Influence of pgp/ABCB1 and bcrp/ABCG2 on the antiproliferative activity of imatinib 
against human glioblastoma cells. 
Furthermore, a possible reason for the lack of the antiproliferative activity of imatinib against 
the glioblastoma cells, the influence of the drug resistance proteins pgp and bcrp, was also 
investigated. This included the detection of the pgp and bcrp mRNAs by RT-PCR, and the 
detection of the respective proteins by immunostaining, as well as the determination of pgp 
and bcrp modulation by imatinib using the flow cytometric Calcein-AM- (Homolya et al. 
1996) and the mitoxantrone assay, respectively. Neither the pgp mRNA (Fig. 4-25) nor the 
pgp protein (Fig. 4-26) was detected in the three glioblastoma variants. Interestingly, although 
the bcrp mRNA was detected in all three glioma cell types (Fig. 4-25) the protein was not 
detected by the immunostaining method (Fig. 4-27). Consequently, the lack of 
antiproliferative efficacy of imatinib cannot be ascribed to those two resistance mechanisms. 
Moreover, the results from the calcein-AM- and mitoxantrone efflux-assays showed a very 
weak modulation of both resistance tranporters by imatinib at therapeutically relevant 
concentrations (Tab. 4-8). Considering these results, an expression of pgp and bcrp at the 
blood-brain barrier and in glioblastoma in vivo, should have a negligible effect on imatinib 
pharmacokinetics at the blood-brain barrier and on site of the intracranial tumor, respectively. 
 
Effect of exogenous PDGF on the proliferation of human glioblastoma cells. 
The proliferation of the glioblastoma cells was not increased by incubation with exogenous 
rhPDGF-BB under serum-free conditions (Fig. 4-32 - 4-34). The lacking response to 
exogenous PDGF is in contrast to the results in the literature (Pollack et al. 1990), where the 
effect of exogenous PDGF on human glioblastoma cells was investigated by [³H]thymidine 
incorporation method. However, although commonly used, [³H]thymidine incorporation 
seems to be inappropriate to investigate effects on cell proliferation, because changes in 
[³H]thymidine incorporation may relate to changes in the size of the intracellular nucleotide 
pool rather than changes in DNA synthesis, and DNA synthesis continues in the absence of 
[³H]thymidine incorporation (Wilson 2000). 
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Inhibition of human glioblastoma by imatinib. 
Kilic et al. also reported on an inhibition of the growth of subcutaneously and intracranially 
implanted glioblastoma tumors in nude mice (Kilic et al. 2000). The observed efficacy in vivo 
may result from a high dose administration of 50 mg/kg of imatinib (i.p. and p.o.), leading to 
a plasma concentration beyond therapeutical levels (1.2-3 µM) in cumulative steady state 
after oral administration (Lyseng-Williamson et al. 2001). 
Since PDGFRβ is expressed on vascular endothelial cells and PDGF has been shown to 
have angiogenic activity in various models (Bergsten et al. 2001) the reported in vivo effect 
may also be ascribed to an antiangiogenic activity of imatinib (Pollack et al. 1990; 
Cherrington et al. 2000; Morin 2000), which can take place at achievable intracranial drug 
concentrations. Buchdunger et al. showed that STI-571 potently inhibits serum-stimulated 
capillary sprouting from rat aorta in vitro at an IC50 value of 0.66 µM. Furthermore, imatinib 
was reported to inhibit PDGF-, VEGF- and bFGF-stimulated vascularization of a 
subcutaneous implant in mice (Buchdunger et al. 2002). 
 
4.6 Summary 
 
The results of this study suggest that the PDGF/PDGFR autocrine loop is not as relevant for 
malignancy and cell proliferation of human glioblastoma cells as has been proposed in the 
literature (Hermanson et al. 1992; Guha et al. 1995; Yu et al. 1998; Lokker et al. 2002). The 
reported induction of brain tumors in mice using a PDGF-B chain retrovirus (Uhrbom et al. 
1998) is not indicative for a dominant role of PDGF in the proliferation and the survival of 
wild type tumors. The role of growth factors like nerve growth factor (Sultana et al. 1998; 
Singer et al. 1999), epidermal growth factor, transforming growth factor alpha, and others 
(Steck et al. 1986; Sultana et al. 1998; Yamada et al. 1998; Singer et al. 1999), that have also 
been identified in human astrocytoma, should be considered as well. The coexpression of a 
receptor and its ligand alone without proof of functional implications on tumor biology, as in 
case of PDGF receptors, is insufficient to provide a basis for a new therapeutic concept. This 
has, for instance, been shown for small cell lung cancer and Ewing sarcoma cells, both 
expressing c-KIT (Soria et al. 2003), and for melanoma in mice, expressing PDGFR (McGary 
et al. 2004). 
A close look to the literature reveals that the current clinical trials (Dresemann 2003; 
Dresemann 2004; Raymond E 2004; National cancer institute 2005; U.S. National institutes 
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of health 2005; U.S. National institutes of health 2005) with glioblastoma and imatinib are 
mainly based on the report from Kilic et al. (Kilic et al. 2000). Beyond it there is only indirect 
indication of a major relevance of PDGF and PDGFR in the proliferation of human 
glioblastoma. Considering the poor outcome and prognosis of malignant glioma patients, the 
clinical evaluation of the efficacy of imatinib is of course warranted. However, the results of 
this study suggest that clinical antitumor effects of imatinib against glioblastoma are not 
mediated by PDGFR. 
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Chapter 5 
Investigations on the mechanism of action of 
new monastrol analogs on human glioblastoma 
cells by confocal laser-scanning microscopy 
 
 
 
5.1 Introduction 
 
5.1.1 The mitotic spindle as a pharmacological target in cancer chemotherapy 
 
Due to its crucial role in cell division the mitotic spindle has been targeted in the treatment of 
cancer for several decades. The mitotic spindle consists of dynamic structures, the 
microtubules, and of associated proteins, contributing to the assembly and functionality of the 
whole spindle complex. 
 
5.1.1.1 The role of microtubules in the mitotic spindle 
The microtubules are hollow cylindrical structures made up of 13 protofilaments, which are 
composed of alternating α- and β-tubulin along the microtubule longitudinal axis. The 
process of polymerization, which necessitates GTP, shows different dynamics at the both ends 
of the microtubules, giving them a polar character. Both ends grow and shorten alternately by 
polymerization and depolymerization, respectively. However, the plus- (+) end shows a net 
growth by rapid polymerization, and at the minus- (-) end net shortening occurs, due to a 
dominating depolymerization (Walker et al. 1988). 
In the mitosis phase, all microtubules are associated at their (-)-ends with the microtubule-
organizing centers, the centrosomes, from which they are nucleated (Bailly and Bornens 
1992). Various classes of microtubules are distinguished in the mitotic spindle, serving 
different functions during mitosis (Fig. 5-3). At the early anaphase the daughter chromosomes 
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start to get separated polewards by a shortening of the kinetochore microtubules and by a 
contributing effect of motor proteins. In the later anaphase the spindle poles move apart from 
each other by the action of motor proteins, that connect and couple overlapping microtubules 
at the equator of the mitotic spindle. Furthermore, astral microtubules radiate away from the 
centrosomes in all directions, and stabilize the position of the spindle in the mitotic cell by 
contributing to the separation of the poles. 
 
5.1.1.2 Microtubule-interfering agents 
Microtubule-interfering agents, also named “spindle-poisons”, represent an important class of 
anticancer drugs, and some of them have been used in the treatment of cancer for almost 40 
years. The earliest class of compounds, which was identified of arresting cells in the mitosis 
phase with aberrant mitotic spindles, were the vinca alkaloids (Palmer et al. 1960). The two 
representatives vincristine and vinblastine were introduced into clinical practice in the 1960s. 
Still they are in use as important chemotherapeutic agents in combinative treatment regimen, 
e.g. for the curative therapy of testicular cancer, Hodgkin disease, and acute lymphocytic 
leukemia, or for the palliative therapy of solid tumors. Since the vinca alkaloids had derived 
from the periwinkle plant (Vinca rosea L.), many other compounds were identified to act as 
so-called “spindle poisons” after the intensive screening of natural compounds. 
In 1986, paclitaxel entered into clinical trials. Due to its therapeutic success, the interest in 
microtubules as a pharmacological target structure increased dramatically, and led to 
extensive efforts put in the development of further, more potent, and better tolerated inhibitors 
of the microtubule function. Many other natural products were identified for their interfering 
activity with the microtubular dynamics. Amongst them, currently evaluated in preclinical 
investigations, are naturally derived compounds, such as epothilones, which are secondary 
metabolites from myxobacteria (Altmann et al. 2000), and coral-derived eleutherobin 
derivatives (Hamel et al. 1999; McDaid et al. 1999). By now, also many new taxanes, 
paclitaxel prodrugs, and new formulations of classical microtubule-interfering agents are in 
clinical development (Wood et al. 2001). 
All of those drugs have a common principle in their mechanism of action. The 
microtubule function is maintained in a dynamic state of polymerization and 
depolymerization (Mitchison and Kirschner 1984; Desai and Mitchison 1997). 
Antimicrotubule drugs disrupt this dynamic process, leading to a breakdown of the integrative 
function of polymeric tubulin. In this way it also can be explained, how e.g. the taxanes and 
the vinca alkaloids cause mitotic arrest, although acting in reciprocal ways. While the vinca 
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alkaloids promote destabilization of microtubules, leading to depolymerization, paclitaxel and 
other taxanes block the microtubule depolymerization (Schiff et al. 1979; Schiff and Horwitz 
1980). Both attacks to the mitotic spindle function lead to a blockade in the cell cycle 
progression from the prometaphase/metaphase to the anaphase (Jordan and Wilson 1998). Fig. 
5-1 and Fig. 5-2 show the chemical structures of microtubule-interfering agents, inhibiting 
microtubule polymerization and depolymerization, respectively. 
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Figure 5-1: Chemical structures of compounds leading to microtubule depolymerization. 
Although producing depolymerization via a common mechanism, these compounds can be 
subdivided by their differing binding sites, whereas the vinca alkaloids and cryptophycin, as 
well as colchicine, podophyllotoxin, nocodazole, and combretastatin A-4 share common 
tubulin binding sites (Mollinedo and Gajate 2003). 
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Figure 5-2: Inhibitors of microtubule depolymerization. The cellular target of paclitaxel, 
docetaxel, RPR 109881A, IDN 5109, and discodermolide is the β-tubulin in the microtubule 
polymer. The exact binding site for eleutherobin is not known yet (Wood et al. 2001; 
Mollinedo et al. 2003). 
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Figure 5-3 further illustrates the role of microtubules in mitosis. Destabilization of 
microtubules, e.g. by microtubule-interfering agents, leads to free kinetochore sites, which 
activate the mitotic spindle assembly checkpoint. This protein complex blocks the transition 
to the anaphase by inhibition of the anaphase-promoting complex. On the other hand, 
microtubule-stabilizing agents block the formation of spindle fibers even before mitosis is 
started. When cells are in mitosis already, these agents stabilize the spindle, finally preventing 
cytokinesis and cell cycle progression. 
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Figure 5-3: Schematic drawing of the mitotic spindle. Two so-called asters are formed by 
microtubules, radiating away from the microtubule-organizing centers (centrosomes), which 
contain a pair of centrioles each. The microtubules serve different functions during mitosis. 
The chromosomes are attached to the spindle via kinetochore microtubules, which contribute 
to the chromosome movement towards to spindle poles. The symmetrical respectively bipolar 
shape of the spindle complex is maintained by overlap microtubules, also responsible for 
spindle pole separation in the anaphase. The astral microtubules contribute to the positioning 
of the spindle and to the separation of the poles. Destabilization of microtubules, e.g. by 
microtubule-interfering agents, leads to free kinetochore sites, which activate the mitotic 
spindle assembly checkpoint. This protein complex blocks the transition to the anaphase by 
inhibition of the anaphase promoting complex (from Sorger et al. 1997, modified). Bub: 
budding uninhibited by benzimidazole; Mad: mitosis arrest deficient. 
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However, several interactions of drugs with tubulin provoke side effects, which are unrelated 
to the effect on the mitotic spindle. Tubulin polymers (microtubules) also play a crucial role 
in non-mitotic cytoskeletal functions, such as motility and cell-cell contacts. Thus, the 
disruption of the microtubule dynamics with drugs not only affects dividing cells, but also 
non-dividing cells. 
New compounds are developed with a major emphasis to overcome common limitations 
in the clinical applicability. A major problem in the clinical use of current agents is the 
development of resistance due to p-glycoprotein (pgp) 170 expression in the tumor tissue or 
due to alterations in the tubulin binding sites, reducing the affinity and thereby the efficacy of 
current tubulin-binding drugs. The vinca alkaloids and the taxanes are both pgp substrates 
(Kohno et al. 1988; Hunter et al. 1991; Zacherl et al. 1994), and it has been shown that pgp 
expression causes resistance and reduced sensitivity, respectively, to those compounds in vitro 
(Izquierdo et al. 1996; Loe et al. 1996). The new compounds IDN 5109 (Bayer, Leverkusen, 
Germany) and RPR 109881A (Aventis, Strasbourg, France) are expected to circumvent the 
pgp-mediated multi-drug resistance in vivo, and already have shown promising preclinical 
effects when applied to pgp-overexpressing tumor cell lines (Polizzi et al. 1999; Gelmon et al. 
2000). However, not only pgp is involved in the resistance to multiple antineoplastic agents, 
but also, for instance, the multi-drug resistance-associated protein (MRP) and the p110 major 
vault glycoprotein (Bosch and Croop 1996; Izquierdo et al. 1996; Loe et al. 1996). 
In summary, despite the ongoing development of novel microtubule-interfering 
compounds it is likely, that they will suffer from the same severe side effects as the older 
classical drugs. 
 
5.1.2 Control of the mitotic spindle assembly 
 
The assembly and disassembly of microtubules is physiologically regulated by a balance of 
microtubule-stabilizing and destabilizing proteins, binding along the microtubules (Andersen 
2000). Stabilizing proteins include the large group of the so-called microtubule-associated 
proteins (MAPs) (Mandelkow and Mandelkow 1995). These MAPs are substrates of the 
cyclin-dependent kinase 1 (CDK1), and, depending on their phosphorylation state, they 
control the microtubule dynamic properties in the transition from the G2 to the M phase of the 
cell cycle. During mitosis an increased phosphorylation reduces the affinity of the MAPs to 
microtubules, and thereby their promoting effect on tubulin-polymerization (Drechsel et al. 
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1992; Masson and Kreis 1995; Ookata et al. 1995). Destabilizing factors, promoting 
microtubule depolymerization, are oncoprotein 18/stathmin, and katanin (McNally and Vale 
1993; Larsson et al. 1997; Ahmad et al. 1999; Andersen 2000). The Xenopus kinesin central 
motor 1 (XKCM1), a kinesin-related protein, particularly contributes to the microtubule 
depolymerization during  mitotic spindle assembly (Walczak et al. 1996). 
Furthermore, microtubule-binding motor proteins are essential for the microtubule 
function. These motor proteins can be subdivided into two major classes, the kinesins and 
dyneins. They move continuously along the microtubules, and thereby can carry various 
membrane-enclosed organelles, such as mitochondria, golgi stacks, and secretory vesicles, to 
their destination within the cell. Moreover, they serve important functions in the mitosis 
phase, e.g. movement of cytoskeletal filaments against each other, which is an indispensable 
process too. The N-terminal kinesins play a crucial role in mitotic spindle formation and in 
chromosome separation and transport. They move towards the (+)-end of the microtubules 
(Mandelkow and Hoenger 1999). However, another kinesin subfamily, the C-terminal motor 
domain type kinesins move towards the (-)-end (Noda et al. 2001; Xu et al. 2002). The 
dyneins are also (-)-end-directed motor proteins, contributing to vesicular trafficking, and to 
the positioning of cell organelles. 
During mitosis, the chronology of interplay between microtubule-dynamics and motor 
proteins is controlled by several regulatory molecules, such as Bub, and Mad kinases. Those 
are essential components of the mitotic spindle assembly check point (Sorger et al. 1997; 
Skoufias et al. 2001), which monitors that all chromosomes are bivalently attached to 
microtubules via kinetochores, before the mitosis is moving from the metaphase to the 
anaphase (Li and Benezra 1996; Rudner and Murray 1996; Sorger et al. 1997). 
Other proteins, such as the Aurora B family kinases, play an essential role in chromosome 
segregation and subsequent cytokinesis, the cytoplasmic division of the cell in the end of 
mitosis. They are also required for the orientation, condensation, and cohesion of 
chromosomes, and they are involved in microtubular dynamics (Shannon and Salmon 2002). 
Representing crucial elements in the progression of mitosis, the Aurora B family kinases and 
other regulatory proteins may provide new targets in cancer chemotherapy (Wood et al. 
2001). Presently, the disruption of microtubule dynamics is of major clinical relevancy. 
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5.1.3 Motor protein-dependent mitotic spindle assembly and maintenance 
 
Although tubulin is the most abundant protein within the mitotic spindle, numerous additional 
proteins contribute to its proper functionality. The most prominent proteins are the kinesins, 
microtubule-associated motor proteins. 
Due to the cell cycle-dependent degradation of several kinesins, it has been suggested that 
the expression of certain subtypes is restricted to proliferating tissues, and crucial for mitosis 
progression (Brown et al. 1994; Funabiki and Murray 2000; Hill et al. 2000). Furthermore, 
these mitotic kinesins have been demonstrated to serve different functions during cell division 
(Tab. 5-1). Dysfunction of certain members of this protein family has been shown to result in 
mitotic arrest. For example, the kinesin CENP-E has been shown to be an essential 
component of the mitotic spindle assembly checkpoint in vitro (Abrieu et al. 2000). It 
connects the checkpoint complex to free kinetochores of microtubule-attached chromosomes 
(Schaar et al. 1997; Yao et al. 2000) and interacts with different kinetochore proteins (Chan et 
al. 1998). Playing a vital role in mitosis, this and other kinesins have been considered as 
potential new pharmacological targets for the treatment of malignancies. 
 
Table 5-1: Role of various mitotic kinesins in mitosis (from Wood et al. 2001). 
 
+Human cellsMicrotubule organization in metaphase
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MKLP1
-
-
n.d.
+
n.d.
-
-
+
Mitotic
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Human cells
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Drosophila, 
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Late mitotic spindle microtubule 
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Spindle pole separationEg5 (2)
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(1) Dysfunction of kinesin causes mitotic arrest (+), dysfunction does not cause mitotic arrest (-). 
effect not determined (n.d.)
(2) Eg5 is the Xenopus laevis homolog of the human KSP kinesin.  
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The general structural features of the kinesin motors are similar throughout the whole protein 
superfamily (Vale and Fletterick 1997). The motor domain, which is the force-producing 
element of the protein, is divided into two major parts. The first part is a highly conserved 
globular catalytic core, whereas the second part, the neck region, has a length of ca. 40 amino 
acids, either adjacent at the N- or C-terminus of the catalytic core. Beyond the motor domain 
many kinesin proteins contain a long α-helical coiled-coil domain, which is termed the 
“stalk”. Finally, an additional globular domain is often found at the end of the stalk. This tail 
domain is thought to target the motor to a particular cargo within the cell. 
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Figure 5-4: Schematic drawing of the prometaphase-metaphase transition. The spindle 
poles move apart from each other, due to the overweight of outward-directed forces. Dynein 
mediates the interaction between astral microtubules and the actin cortex (dynactin). The 
major contribution to the outward-directed forces is given by the bipolar kinesins, which 
enforce antiparallel sliding of the interdigitating microtubules of the spindle midzone. 
Together, these two forces overcome the inward-directed force, produced by C-terminal 
kinesins, also located at the spindle midzone. The short arrows indicate the moving direction 
of the motor proteins along the microtubules, which is opposite to the direction of the 
produced force. 
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Driven by ATP hydrolysis, the kinesins produce a directed force along microtubules.The N-
terminal kinesins are (+)-directed, the C-terminal kinesins are (-)-directed. In mitosis, the N-
terminal kinesins produce an outward-directed force, whereas the C-terminal kinesins act vice 
versa. A further (-)-directed force is exerted by the dynein motor proteins. The specific 
movement of the mitotic spindle is suggested, not to be driven by the sole action of one type 
of motor protein, but to be produced by multiple, complementary and antagonistic motors, 
which work simultaneously (Sharp et al. 2000). 
In the interphase-prophase the centrosome doubles, and between the two future poles of 
the spindle slightly interdigitating microtubules are formed. This initial spindle assembly is 
balanced by dynein, mediating the interaction with the actin cortex at the cell membrane, and 
C-terminal kinesins in the midzone of the spindle. The dyneins pull the poles apart (outward-
directed force) and the C-terminal kinesins push them towards each other (inward-directed 
force). The C-terminal kinesin force is limited due to the low extent of microtubule overlap in 
the midzone. With the continuous growth of the interdigitating microtubules, the kinesin force 
gradually increases until a steady state between the dynein and the kinesin forces is reached. 
After the degradation of the nuclear envelope in the prometaphase, the length of the astral 
microtubules is decreased and the position of the bipolar spindle is determined and 
maintained by the action of the C-terminal kinesins and the bipolar kinesins (e.g. Eg5 
kinesin). The bipolar kinesins generate an outward-directed force and are located in the 
spindle midzone too. The poles move further apart due to the overcome of the inward-directed 
C-terminal kinesin force by the action of bipolar kinesins and cortical dynein (Fig. 5-4). This 
further elongation of the spindle results in the “metaphase spindle steady state structure”, 
holding a tension between the spindle poles, generated by the competing inward and outward 
forces. After passing the metaphase-anaphase checkpoint (mitotic spindle assembly 
checkpoint) the tension is released by inactivation of the C-terminal kinesins. Right before the 
spindle disassembles again the final steady state is achieved in the telophase. 
 
5.1.4 Mitotic arrest through Eg5 kinesin inhibition 
 
The inhibition of Eg5 kinesin results in a characteristic spindle morphology, the monaster 
spindle (Fig. 5-5). This might be explained by an imbalance between the outward- and 
inward-directed forces, generated by dyneins and C- and N-terminal kinesins, after inhibition 
of Eg5. The C-terminal kinesins slide the antiparallel overlap microtubules vice versa to the 
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Eg5 kinesin-directed force, resulting in a net inward movement of the spindle poles (Fig. 5-
5A). Thereby, the kinetochore microtubules, in part attached to chromosomes, are pushed 
apart from the spindle pole axis (Fig. 5-5B, 5-5C). Finally, free as well as chromosome-
attached kinetochore microtubules radiate away from the maximally approached spindle poles 
(Fig. 5-5D). Since both centrosomes still consist of two intact and separate entities after this 
process, the term “monoastral spindle” seems incorrect, although this is the current 
denomination. 
 
A B
C D
Monoaster spindle
Spindle poles start moving
towards each other
Kinetochore microtubules start to move apart 
from the spindle axis
Kinetochore microtubules
are forced outwards  
Figure 5-5: Schematic drawing of monaster spindle formation. The inhibition of bipolar 
Eg5 kinesin leads to an overweight of the inward-directed force of the C-terminal kinesins. 
The spindle poles are pulled towards each other (A). Due to the decreasing distance between 
the poles (B) the kinetochore microtubules are forced apart from the spindle axis (C). Finally, 
the spindle poles are situated right next to each other, and the microtubules originating from 
both poles form the characteristic so-called monaster spindle (D). 
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However, using fluorescence microscopic techniques, the centrosomes can hardly be 
distinguished from each other, unless they are specifically stained, distinctly different from 
tubulin. After the monaster spindle has completely formed, mitotic arrest may occur due to 
several free kinetochores of chromosomes, which are only partially connected to 
microtubules. As a consequence, the mitotic spindle assembly checkpoint cannot be satisfied 
and the transition from the metaphase to the anaphase is blocked. Since Eg5 is exclusively 
expressed during mitosis, this mechanism of inhibition is likely to leave other essential 
cellular functions unaffected, especially in non-mitotic cells. Due to this major difference to 
the commonly used microtubule-interfering agents, specific Eg5 kinesin inhibitors are 
considerd a very promising approach to the development of a new class of anticancer agents 
with minimal side effects on resting cells. 
 
5.1.5 Eg5 kinesin inhibitors 
 
In 1998, Sakowicz et al. screened a number of natural compounds for selective inhibition of 
kinesin (Sakowicz et al. 1998), and identified adociasulfate-2, which competitively inhibited 
the kinesin motor domain interaction with microtubules in vitro. However, this first kinesin 
inhibitor was not specific for a certain kinesin subtype. 
Since only the Eg5 kinesin was known to be crucial for the formation of a bipolar mitotic 
spindle (Blangy et al. 1995), the formation of monopolar spindles was used as a determinant 
in the search for specific Eg5 inhibitors. Mayer et al. identified the first specific Eg5 kinesin 
inhibitor, monastrol, using a mitotic spindle phenotype-based screening method (Mayer et al. 
1999). This compound, a 4-aryl-3,4-dihydro-pyrimidine-2(1H)-thione, led to the formation of 
a monopolar spindle, and also a direct inhibition of the Eg5 motor domain activity was 
confirmed in vitro. Moreover, Eg5 inhibition by monastrol did not affect the transition from 
the G2 cell cycle phase to mitosis, led to a reversible mitotic arrest, and had no effect on 
cellular processes involving other kinesins (Mayer et al. 1999; Kapoor et al. 2000). These 
results brought about the concept of the specific Eg5 kinesin inhibition as a new approach in 
cancer chemotherapy. However, racemic monastrol and its eutomer, (S)-monastrol, were 
determined to be only moderately potent allosteric inhibitors of Eg5 (Gartner et al. 2005), 
with IC50 values of 34 µM and 14 µM, respectively, determined in the microtubule-stimulated 
ATPase activity assay (Maliga et al. 2002). Therefore, new monastrol analogs were 
synthesized (Gartner et al. 2005; Sarli et al. 2005), in order to obtain more potent Eg5 kinesin 
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inhibitors. In 2003, Hotha et al. reported on the tetrahydro-β-carboline compound HR22C16, 
which selectively inhibited Eg5 kinesin with an IC50 value of 800 nM (Hotha et al. 2003). A 
derivative of HR22C16 showed an about one order of magnitude higher potency, with an IC50 
value of 90 nM. However, it was not reported whether this compound was cell permeable or 
not. A series of β-carboline derivatives was synthesized by Sunder-Plassmann et al. (Sunder-
Plassmann et al. 2005). After the screening of a small library of 60 compounds for Eg5 
inhibitory activity, the most potent compound showed an IC50 value of 650 nM. 
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Figure 5-6: Chemical structures of various kinesin inhibitors. Adociasulfate-2, was isolated 
from a marine sponge, the genus Haliclona (also known as Adocia). Sakowicz et al. suggested 
kinesins as a useful pharmacological target for the first time (Sakowicz et al. 1998). The 
identification of the first specific Eg5 kinesin inhibitor monastrol (Mayer et al. 1999) initiated 
the development and the preclinical evaluation of further, more potent Eg5 inhibitors as 
potential new anticancer agents. Among the other lead compounds structural resemblance to 
monastrol is only observed for the β-carbolin derivative HR22C16 (Hotha et al. 2003). 
Terpendole E inhibits Eg5 kinesin specifically (Nakazawa et al. 2003), but with an even lower 
potency than monastrol. Based on CK0106023 (Sakowicz et al. 2004), a series of new 2-
(aminomethyl)quinazolinone derivatives has been synthesized, of which one is in clinical 
phase II evaluation. The KSP-IA represents the most potent specific Eg5 kinesin inhibitor by 
now (Tao et al. 2005). 
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Further lead structures are currently considered for the development of more potent specific 
Eg5 kinesin inhibitors. Among them are terpendole E (IC50 = 23 µM) (Nakazawa et al. 2003), 
CK0106023 with a Ki value of 12 nM (Sakowicz et al. 2004), and KSP-IA, a compound 
derived from a dihydropyrazole lead structure (IC50 = 10 nM Tao et al. 2005). 
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5.2 Objective 
 
The inhibition of kinesin Eg5 by small molecules, such as monastrol, is currently evaluated as 
an approach to develop a novel class of antiproliferative drugs for the treatment of malignant 
tumors. Due to the moderate potency of the lead compound monastrol, new monastrol analogs 
were synthesized by Giannis and coworkers at the University of Leipzig (Gartner et al. 2005; 
Sarli et al. 2005), in order to obtain more potent Eg5 kinesin inhibitors. With respect to the 
treatment of primary and secondary CNS tumors, several of those compounds were evaluated 
in our laboratory for their antiproliferative activity against human glioblastoma cell variants 
(Müller et al. 2006), using the crystal violet chemosensitivity assay (Bernhardt et al. 1992). 
Compared to monastrol, the antiproliferative potency of the investigated compounds was at 
least one order of magnitude higher. The compounds were neither inactivated by hydrolysis 
nor by binding to serum proteins. Furthermore, at effective antiproliferative concentrations, 
the compounds were neither substrates nor modulators of pgp in the flow cytometric calcein-
AM assay (Homolya et al. 1993; Hollo et al. 1994; Homolya et al. 1996). The results have 
been published in part by Müller et al. (Müller et al. 2006). 
The objective of this work was to investigate the effect of new monastrol analogs on 
human glioblastoma cells by means of confocal laser-scanning microscopy. The experiments 
were performed to investigate, whether the observed antiproliferative activity of the test 
compounds was accompanied by formation of monaster spindles and subsequent mitotic 
arrest of the treated cells. Since the common clinical side effects of classical microtubule-
interfering agents are ascribed to the damage of the microtubule cytoskeleton (Quasthoff and 
Hartung 2002), the effect of the new monastrol analogs on the cytoskeleton of quiescent cells 
was also evaluated. The effects of the new compounds were compared to the classical tubulin-
depolymerizing agent vinblastine. Furthermore, the effect on the β-actin cytoskeleton was 
investigated, which is also an essential component of the cytoskeleton of mitotic and 
quiescent cells. 
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5.3 Materials and methods  
 
5.3.1 Tested compounds 
 
The new monastrol analogs MG-Pr99-S, MG-Pr98-S, VS-17, VS-38, VS-48, and VS-54, 
were synthesized and characterized as described (Gartner et al. 2005; Sarli et al. 2005). These 
compounds as well as another substance from this series, VS-83, were provided by the 
workgroup of Prof. Giannis (University of Leipzig, Germany). S-Trityl-L-cysteine (Brier et 
al. 2004) was purchased from MP BIOMEDICALS (Eschwege, Germany), whereas 
monastrol, prepared as described (Gartner et al. 2005), also was provided by Prof. Giannis. 10 
mM stock solutions were prepared in DMSO; a 1 mM stock solution of vinblastine (SIGMA, 
Munich, Germany) was made in 70 % ethanol. All compound stocks were stored at –20 °C. 
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Figure 5-7: Chemical structures of the selective Eg5 inhibitor monastrol, the non-specific 
kinesin inhibitor S-trityl-L-cysteine, and the new monastrol analogs. 
 
5.3.2 Culture of the human glioblastoma cells 
 
The human U-87 MG (ATCC HTB 14, passage 126) glioblastoma/astrocytoma cell line 
(Beckman et al. 1971) was obtained from the American Type Culture Collection (ATCC). 
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Cell banking and quality control were performed according to the "seed stock concept" (Hay 
1988). The cells were grown in Eagle´s minimum essential medium (EMEM, Sigma, 
Deisenhofen, Germany), containing L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium pyruvate, 
and 5 % fetal calf serum (FCS, Biochrom, Berlin, Germany). The cells were cultured in a 
water-saturated atmosphere of 95 % air and 5 % carbon dioxide at 37 °C in 25-cm² culture 
flasks (Nunc, Wiesbaden, Germany), and were serially passaged following trypsinization 
using trypsin (0.05 %)/EDTA(0.02 %) (Roche Diagnostics, Mannheim, Germany). 
Mycoplasma contamination was routinely monitored, and only mycoplasma-free cultures 
were used. 
 
5.3.3 Confocal laser-scanning microscopy 
5.3.3.1 Treatment of the cells 
Cells were seeded into 8-well Lab-Tek Chamber Slides (NUNC, Wiesbaden, Germany). At 75 
% confluence the culture medium was replaced with medium containing 50 µM monastrol, 1 
µM S-trityl-L-cysteine, or 10 nM vinblastine. The concentrations of the new monastrol 
analogs were selected on the basis of the chemosensitivity data, obtained by the kinetic crystal 
violet assay: VS-17: 10 µM; VS-38: 5 µM; VS-48: 10 µM; VS-54: 5 µM; VS-83: 5 µM; MG-
Pr99-S: 1 µM; MG-Pr98-S: 5 µM. Cells were incubated at 37 °C for 2 hours. 
5.3.3.2 Fixation and permeabilization of the glioblastoma cells 
After the incubation with drugs, the medium was carefully removed, and the cells were fixed 
with 4 % paraformaldehyde solution in phosphate buffered saline (PBS) for 20 minutes at 
room temperature. Thereafter, each well was washed 3 times with PBS containing 0.5 % 
bovine serum albumin (BSA, SERVA, Heidelberg, Germany). Cells were permeabilized by 
incubation with PBS, containing 0.5 % BSA and 1 % Triton-X 100 (SERVA, Heidelberg, 
Germany) for 10 minutes at room temperature, followed by three washing steps with PBS 0.5 
% BSA. 
5.3.3.3 Staining  
Chromosomes were stained with SYTOXGreen® nucleic acid staining dye (MOLECULAR 
PROBES, Eugene, OR, USA). For double staining, microtubules were labeled using the 
mouse anti-human α-tubulin primary antibody (DIANOVA, Hamburg, Germany) and Cy5TM-
conjugated anti-mouse secondary antibody (DIANOVA). Triple staining of DNA, 
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microtubules, and Eg5 kinesin was performed using SYTOXGreen®, α-tubulin primary 
antibody, secondary labeled with the Alexa Fluor® 546-conjugated goat anti-mouse secondary 
antibody (MOLECULAR PROBES), and anti-human Eg5 antibody (BD Biosciences 
Pharmingen, Heidelberg, Germany). All antibodies were used as a 1:200 dilution in PBS, 
containing 0.5 % BSA. β-actin was stained with Alexa Fluor® 647 phalloidin (MOLECULAR 
PROBES). Microscopic images were acquired with a Carl Zeiss Axiovert 200M LSM510 
confocal laser-scanning microscope. Multifluorescence image acquisition was performed in 
the multitrack acquisition mode. The acquisition parameters are given in the respective figure 
legends. 
5.3.3.4 Image processing 
False colours were used for β-actin and Eg5 kinesin (red), tubulin (green) and DNA (blue). 
Images (Fig. 5-8, 5-9, 5-11, 5-13, 5-15) were processed with the AutoDeBlur deconvolution 
software. 
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5.4 Results 
5.4.1 Differential spindle formation in human glioblastoma cells  
5.4.1.1 Effect of monastrol on the spindle formation of human glioblastoma cells 
Fig. 5-8 shows the characteristic effects of monastrol and vinblastine on the spindle formation 
in human U-87 MG glioblastoma cells. Compared to the untreated cells, clear differences in 
the spindle formation were observed. The untreated control showed normal bipolar spindles. 
Monastrol induced a distinctly differing spindle, where the chromosomes surrounded the 
microtubules, radiating away from the spindle poles. The displayed image in Fig. 5-8 shows 
an earlier stage in monaster formation, according to Fig. 5-5C. The two spindle poles are still 
approaching towards each other and can be distinguished as separate entities. As expected, 
neither the integrity of the microtubular spindle fibers was affected, nor the condensed state of 
the chromatin. This indicates that the cell was not able to progress in mitosis, which finally 
would have led to the decondensation of the chromosomal DNA, suggesting that the cell was 
arrested at the mitotic spindle assembly checkpoint. 
After treatment with the microtubule-destabilizing agent vinblastine, the DNA was still 
condensed to chromosomes. However, no microtubules were built up. The chromosomes were 
surrounded by depolymerized tubulin. Few brightly fluorescent spots within the labeled 
tubulin indicate the centrosomes, containing the centrioles, the microtubule-generating 
centers, with a high tubulin content. As becomes obvious, no mitotic checkpoint can be 
passed after treatment with vinblastine. 
5.4.1.2 Effect of new monastrol derivatives on the spindle formation of human 
glioblastoma cells 
The characteristic monaster formation was observed after incubation with monastrol as well 
as with the new monastrol derivatives VS-38, VS-54, VS-83, MG-Pr99-S (enastron), and 
MG-Pr98-S (dimethylenastron). No monasters, but normal spindle formation was observed 
with the compounds VS-17 and VS-48. The incubation of the cells with the non-specific 
kinesin inhibitor S-trityl-L-cysteine and the monastrol analog VS-83 induced spindles similar, 
but distinctly different from the type of monaster, which is induced by the selective Eg5 
inhibitors (Fig. 5-9). 
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Figure 5-8: Mitotic U-87 MG cells, stained with SYTOXGreen® nucleic acid staining dye 
and immunofluorescently labeled α-tubulin. Upper row: control; the untreated cells show a 
normal mitosis metaphase, with arrangement of chromosomes in the middle plane 
perpendicular to the spindle axis. Middle row: vinblastine; the formation of the mitotic 
spindle is impeded by the microtubule-interfering agent vinblastine, leading to tubulin-
embedded chromosomes. Lower row: treatment with monastrol. The displayed spindle 
formation after monastrol treatment shows the movement of the two spindle poles towards 
each other, due to the specific inhibition of the Eg5 kinesin. This results into an overweighted 
dynein action, leading to an approach of the spindle poles. In these pictures (lower row), the 
spindle formation is caught on its way to a characteristic monaster. Plan-Apochromat 63x/1.4 
oil, Ar 488, HFT 488, LP505; HeNe 633, HFT UV/488/543/633, LP560. Upper and middle 
row images were processed with 2-D deconvolution; lower row images were obtained by 3-D 
deconvolution from a z-stack sum-projection. 
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MG-Pr99-SMG-Pr98-SVS-83  
Figure 5-9: Mitotic U-87 MG cells after treatment with the specific Eg5 inhibitor 
monastrol, the non-specific inhibitor S-trityl-L-cysteine, and various new monastrol analogs. 
Except for VS-17 and VS-48 all other compounds produce the characteristic monaster 
spindles. Interestingly, with the non-specific kinesin inhibitor S-trityl-L-cystein, a different 
morphology is observed in the monaster. Compared to the characteristic spindle morphology 
after treatment with specific Eg5 inhibitors, a higher number of microtubules is observed, 
which are not attached to chromosomes yet. This suggests that S-trityl-L-cystein interacts in 
an earlier phase of mitosis, when only a few chromosomes are partially connected to 
kinetochore microtubules. Plan-Apochromat 63x/1.4 oil, Ar 488, HFT 488, LP505; HeNe 
633, HFT UV/488/543/633, LP560. All images were processed with 2-D deconvolution. 
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5.4.2 Expression and distribution of Eg5 in human glioblastoma cells 
 
For the determination of the expression and distribution of Eg5 kinesin in quiescent cells, U-
87 MG were triple stained for Eg5, microtubules, and nuclei. Even though not in mitosis, the 
quiescent cells showed Eg5 kinesin expression (Fig. 5-10). The motor protein was observed to 
be widely distributed within the cytoplasm, forming dot-like clusters. Furthermore, it lacked 
significant colocalization with microtubules, their primary site of interaction in mitosis. 
During mitosis Eg5 was colocalized with tubulin at and between the spindle poles (Fig. 5-11). 
As expected, no colocalization with astral microtubules was observed. 
 
Eg5 kinesin α-tubulin
Nuclei (SYTOXGreen®) Merge
 
Figure 5-10: Multifluorescence image of fixed U-87 MG cells. In these quiescent cells Eg5 
is distributed all over the cytoplasm with a perinuclear accumulation. Quantitative 
colocalization with microtubules is not observed. Plan-Apochromat 63x/1.4 oil; Ar 488, HFT 
488, LP505; .HeNe 543, HFT 488/543, LP560; HeNe 633, UV/488/543/633, LP650. 
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Figure 5-11: Multifluorescence image of a mitotic U-87 MG cell. Eg5 kinesin is colocalized 
with spindle microtubules, parallel to the spindle axis, representing interdigitating overlap 
microtubules. No colocalization was observed with astral microtubules. The images also 
indicate that Eg5 is not colocalized with the more outward-directed kinetochore microtubules, 
which are connected to the chromosomes. Plan-Apochromat 63x/1.4 oil; Ar 488, HFT 488, 
LP505; .HeNe 543, HFT 488/543, LP560; HeNe 633, UV/488/543/633, LP650. Images were 
processed with 2-D deconvolution. 
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5.4.3 Effect of vinblastine on Eg5 distribution in human glioblastoma cells 
 
Vinblastine-treated non-dividing cells showed the same Eg5 distribution pattern, even though 
the microtubule cytoskeleton was collapsed due to the depolymerizing effect of the vinca 
alkaloid (Fig. 5-12). Again, a quantitative colocalization of the two proteins was not observed. 
After treatment with vinblastine, Eg5 showed a diffuse distribution in the mitotic cell, and 
partial colocalization with tubulin (Fig. 5-13). 
 
Eg5 kinesin α-tubulin
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Figure 5-12: Effect of vinblastine on the Eg5 kinesin distribution in U-87 MG. The cell is 
rounded up due to the disrupted microtubule-cytoskeleton. However, the Eg5 distribution is 
not changed. The same dot-like clusters are observed as in the untreated control cells. Plan-
Apochromat 63x/1.4 oil; Ar 488, HFT 488, LP505; .HeNe 543, HFT 488/543, LP560; HeNe 
633, UV/488/543/633, LP650. 
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Figure 5-13: Mitotic U-87 MG cells after treatment with vinblastine. The Eg5 kinesin is 
distributed all over the cell. It does not form big clusters any more, but shows partial 
colocalization with the depolymerized tubulin. As becomes obvious from the adjacent cells, 
Eg5 expression is much lower in non-mitotic cells. Plan-Apochromat 63x/1.4 oil; Ar 488, 
HFT 488, LP505; .HeNe 543, HFT 488/543, LP560; HeNe 633, UV/488/543/633, LP650. 
Images were processed with 2-D deconvolution. 
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5.4.4 Effect of new monastrol analogs on Eg5 distribution in human glio-
blastoma cells 
 
As exemplarily shown for MG-Pr99-S (Fig. 5-14), the incubation of the glioblastoma cells 
with the new monastrol analogs, did not change the cellular distribution of Eg5 in quiescent 
cells, compared to the untreated control (Fig. 5-10). In mitosis Eg5 mainly remained 
colocalized with the spindle microtubules (Fig. 5-15). 
 
Eg5 kinesin α-tubulin
Nuclei (SYTOXGreen®) Merge  
Figure 5-14: Quiescent U-87 MG cells after incubation with MG-Pr99-S. Compared to the 
untreated control (Fig. 5-10), the cellular Eg5 distribution is not altered. Plan-Apochromat 
63x/1.4 oil; Ar 488, HFT 488, LP505; HeNe 543, HFT 488/543, LP560; HeNe 633, 
UV/488/543/633, LP650. 
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Figure 5-15: Mitotic U-87 MG cell after incubation with the monastrol analog MG-Pr99-S. 
A major portion of Eg5 is colocalized with tubulin, suggesting that the process of monaster 
formation does not significantly affect the connection between both proteins. Plan-
Apochromat 63x/1.4 oil; Ar 488, HFT 488, LP505; .HeNe 543, HFT 488/543, LP560; HeNe 
633, UV/488/543/633, LP650. Images were processed with 2-D deconvolution. 
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5.4.5 Effect of new monastrol derivatives on the cytoskeleton of quiescent 
glioblastoma cells 
 
To investigate the effect of Eg5 inhibition on resting cells, again, human U-87 MG 
glioblastoma cells were incubated with selective Eg5 kinesin inhibitors. After fixation, the 
cells were triple stained for β-actin, microtubules, and nuclei. Untreated cells and vinblastine-
treated cells were used as controls. Moreover, the cells were incubated with the non-specific 
kinesin inhibitor S-trityl-L-cystein. 
The untreated glioblastoma cells showed a normal microtubule cytoskeleton phenotype. 
The microtubules formed a network throughout the cells with accumulation near the nucleus, 
where the centrosome, the microtubule generating and organizing center, is situated (Fig. 5-
16). The β-actin cytoskeleton appeared as straight rigid fibers, arranged in a parallel manner, 
forming a cellular cortex (Fig. 5-16). As becomes obvious from the images, the β-actin 
cytoskeleton contributes to the cellular shape and expansion. The treatment with vinblastine 
disrupted the microtubule-system, and led to a characteristic appearance in the fluorescence 
image (Fig. 5-17). The cells lost their typical polygonal shape, and no intact microtubules, but 
small microtubule fragments were observed. However, the β-actin remained unchanged, 
showing the fiber clusters. The non-specific inhibition of kinesin motors by S-trityl-L-
cysteine had no detectable effect, neither on the microtubules nor on the β-actin fibers (Fig. 5-
18). The characteristic cell shape was maintained, and compared to the untreated cells (Fig. 5-
16) no differences were observed. This kinesin inhibition may harm the treated cells in the 
long run, e.g. by blocking cellular transport processes. However, according to the intact 
cytoskeleton, an acute toxicity against non-mitotic cells was not observed. After incubation 
with the selective Eg5 kinesin inhibitors, exemplarily shown for dimethylenastron (MG-Pr98-
S), no cytoskeletal damage was observed (Fig. 5-19). 
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Figure 5-16: Multifluorescence image of fixed U-87 MG cells. The polygonal appearance of 
the cells, grown as a monolayer culture, is primarily coined by β-actin fiber clusters. The 
cytoplasm is spanned by the microtubule network, originating from the centrosome close to 
the nucleus. The image represents the bottom z-plane, in which the cell foots onto the 
microscopic slide. This explains the localization of a few microtubules within the nucleus. 
Plan-Apochromat 63x/1.4 oil; Ar 488, HFT 488, LP505; .HeNe 543, HFT 488/543, LP560; 
HeNe 633, UV/488/543/633, LP650. 
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Figure 5-17: U-87 MG cells after incubation with the microtubule-destabilizing agent 
vinblastine. Although the microtubules are almost quantitatively disrupted, the cellular 
expansion is maintained, since the β-actin fibers are not affected by vinblastine. Plan-
Apochromat 63x/1.4 oil; Ar 488, HFT 488, LP505; .HeNe 543, HFT 488/543, LP560; HeNe 
633, UV/488/543/633, LP650. 
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Figure 5-18: Human U-87 MG glioblastoma cells, incubated with the non-specific kinesin 
inhibitor S-trityl-L-cystein. The microtubule dynamics appear to be unaffected, as well as the 
β-actin cytoskeleton. Again, the image represents a plane near the cell footing on the 
microscopic slide. Plan-Apochromat 63x/1.4 oil; Ar 488, HFT 488, LP505; .HeNe 543, HFT 
488/543, LP560; HeNe 633, UV/488/543/633, LP650. 
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Figure 5-19: Incubation of human glioblastoma cells with the selective Eg5 kinesin inhibitor 
dimethylenastron (MG-Pr98-S). As observed in untreated cells and in cells treated with S-
trityl-L-cystein, both, microtubules and β-actin remained unchanged. Plan-Apochromat 
63x/1.4 oil; Ar 488, HFT 488, LP505; .HeNe 543, HFT 488/543, LP560; HeNe 633, 
UV/488/543/633, LP650. 
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5.5 Discussion 
 
Effect of new monastrol analogs on the spindle formation in human U-87 MG 
glioblastoma cells. 
The formation of the characteristic monaster spindle was demonstrated in human U-87 MG 
glioblastoma cells after incubation with the first identified specific Eg5 kinesin inhibitor 
monastrol (Fig. 5-8). Compared to tubulin-destabilizing agents, such as vinblastine (Fig. 5-8), 
the microtubule spindle fibers were shown to remain unaffected from treatment with 
monastrol (Fig. 5-8). According to the results of the chemosensitivity tests (Müller et al. 
2006), human U-87 MG cells were incubated with the respective inhibitory concentrations of 
the new monastrol analogs. Except for VS-17 and VS-48, all compounds produced the same 
characteristic effect on the formation of the mitotic spindle, as the selective Eg5 kinesin 
inhibitor monastrol (Fig. 5-9). However, compared to the lead compound, the new monastrol 
analogs were more potent, and induced monasters at lower concentrations, confirming the 
observations in other cell types (Gartner et al. 2005). A monaster phenotype, distinctly 
different from the monastrol-induced monaster spindle, was observed after incubation with 
VS-83. This phenotype was similar to monaster formation induced by the non-selective 
kinesin inhibitor S-trityl-L-cysteine (Fig. 5-9). This observation is in contrast to the work of 
Sarli et al., reporting on similar effects of monastrol and VS-83 (Sarli et al. 2005). However, 
Sarli et al. applied 100 µM monastrol and 25 µM VS-83 to synchronized simian BSC-1 cells. 
In addition, the BSC-1 cells were treated for 10 hours, whereas the human U-87 MG 
glioblastoma cells were treated with monastrol (50 µM) and VS-83 (5 µM) for 2 hours. 
 
Expression and distribution of Eg5-related kinesin in human glioblastoma cells. 
Although being described as a mitotic kinesin (Sharp et al. 2000; Wood et al. 2001), the 
expression of Eg5 was observed in mitotic as well as in non-mitotic human U-87 MG 
glioblastoma cells. The motor protein was distributed all over the cytoplasm, forming dot-like 
clusters, without being quantitatively colocalized with the microtubule cytoskeleton (Fig. 5-
10). The Eg5 expression level was observed to be much higher in mitotic than in resting cells 
(Fig. 5-13). 
Compared to untreated cells, the incubation with vinblastine and selective Eg5 inhibitors 
(new monastrol analogs) did not alter the Eg5 distribution in quiescent cells (Fig. 5-10, 5-12, 
5-14). In mitotic cells Eg5 was colocalized with overlap microtubules in untreated cells, and 
remained colocalized with tubulin after treatment with Eg5 inhibiting compounds (Fig 5-11, 
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5-15). Only partial colocalization in mitotic cells was observed after treatment with 
vinblastine, and Eg5 clusters were not observed any more (Fig. 5-13). 
 
Effect of new monastrol analogs on the cytoskeleton of human glioblastoma cells. 
The specific Eg5 inhibitors and the non-specific kinesin inhibitor S-trityl-L-cystein, neither 
did affect the β-actin cytoskeleton, nor did they disrupt the microtubule system in quiescent 
cells (Fig. 5-18, 5-19). These effects were compared to untreated cells (Fig. 5-16), and to the 
treatment of cells with vinblastine, which resulted in a major disruption of the microtubule 
structure, with an uprounding effect on the cell shape (Fig. 5-17). As expected, vinblastine 
treatment had no effect on the β-actin fibers (Fig. 5-17). 
 
5.6 Summary  
 
In summary, these results show, that in human U-87 MG glioblastoma cells, the newly 
synthesized monastrol analogs VS-38, VS-54, VS-83, enastron, and dimethylenastron induce 
the characteristic monaster spindle formation with higher potency, compared to the first 
selective small molecule Eg5 kinesin inhibitor monastrol. This supports the results from the 
chemosensitivity experiments (Müller et al. 2006), where the new monastrol analogs 
exhibited antiproliferative activity against human glioblastoma cells. The compounds gave 
rise to mitotic arrest in human glioblastoma cells by inducing the formation of monaster 
spindles, the characteristic effect of the specific Eg5 kinesin inhibition. 
The microscopic investigations on the effect of the new monastrol analogs on the 
microtubules and on β-actin (cytoskeleton) of resting cells further support the results from the 
cytotoxicity assays. Compared to the antimicrotubular agent paclitaxel, the monastrol analogs 
lacked a cytocidal effect on the cells. As the monastrol analogs have been demonstrated to be 
neither substrates nor modulators of the multi-drug resistance p-glycoprotein 170 (Müller et 
al. 2006), these new Eg5 kinesin inhibitors not only are supposed to be less neurotoxic 
anticancer drugs in comparison to classical tubulin inhibitors, but also may be promising new 
agents for further preclinical studies, aiming at the treatment of primary and secondary CNS 
tumors. 
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The treatment of malignant brain tumors poses a basic challenge in todays cancer therapy. 
Since the quantitative resection is hardly possible due to the invasive growth of the tumor, 
prevention of relapse after resection by concomitant irradiation treatment and chemotherapy 
is of major importance for patient outcome. While the efficiency of surgery and irradiation 
therapy seem to be exploited, new approaches in the chemotherapy may provide hope for the 
future. Amongst them are the exploration of new transport pathways across the blood-brain 
barrier and the overcome of the p-glycoprotein (pgp)-mediated multi-drug resistance, 
respectively, and the evaluation of new pharmacological targets, allowing selective inhibition 
of tumor growth, while minimizing cytotoxic side effects. 
The objective of this work was to investigate, whether doxorubicin-loaded 
polybutylcyanoacrylate (PBCA) nanoparticles are able to provide overcome of the pgp-
mediated multi-drug resistance in vitro, and to investigate the mechanism of the enhanced 
antiproliferative activity of doxorubicin nanoparticles, compared to the efficiency of the drug 
in solution. The doxorubicin nanoparticle formulations exceeded the antiproliferative effect of 
the dissolved drug against pgp-overexpressing KBv1 cells. The flow cytometric determination 
of the cell-associated doxorubicin fluorescence after incubation with the different drug 
formulations indicated an enhanced drug uptake with the nanoparticle formulations in pgp-
negative human glioblastoma cells as well as in KBwt cells with weak pgp expression. No 
differential fluorescence increase was observed in pgp-overexpressing KBv1 cells at a drug 
concentration equivalent 500 nM doxorubicin, but at a concentration of 2 µM doxorubicin 
KBv1 cells showed increased fluorescence after incubation with nanoparticle-bound 
doxorubicin. Confocal laser-scanning microscopic studies with living KBwt cells showed 
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similar cytoplasmic doxorubicin distribution after incubation with different doxorubicin 
formulations. A higher overall doxorubicin–related fluorescence was observed after 
incubation with the nanoparticle-bound drug, and the cells were hemmed by doxorubicin 
fluorescence. With a mixture of empty PBCA nanoparticles and lucifer yellow, pgp-negative 
U-373 MG were hemmed by lucifer yellow derived fluorescence. The results from CLSM 
studies indicate that the nanoparticles do not enter the cells. In conclusion, the enhanced 
antiproliferative effect of the nanoparticle-bound doxorubicin against pgp-overexpressing 
cells can be explained by a concentration gradient of drug, released from nanoparticles after 
adsorption to the cell surface, leading to saturation and overcome of the pgp-mediated drug 
efflux transport. 
As a non-cytotoxic approach in the chemotherapy of malignant glioblastoma, the concept 
of platelet-derived growth factor (PDGF) receptor kinase inhibition was evaluated as the 
second part of this work. Therefore the PDGF receptor expression and activity were 
demonstrated in human glioblastoma cell lines. However, the inhibition of PDGF receptors in 
human glioblastoma cells, using various selective PDGF receptor kinase inhibitors, amongst 
them the registered drug imatinib, did not affect cell growth in therapeutically relevant 
concentrations. Moreover, no enhanced cytotoxicity was observed when imatinib was 
combined with the microtubule-interfering agent paclitaxel. Furthermore, the cells lacked 
expression of the resistance proteins pgp and breast cancer resistance protein (bcrp), 
demonstrating that lack of antiproliferative activity of the PDGF receptor inhibitors cannot be 
ascribed to these drug resistance mechanisms. Moreover glioblastoma cell proliferation was 
independent of PDGF. These results suggest that the single PDGF receptor inhibition by 
selective tyrosine kinase inhibitors, including imatinib, does not represent a suitable approach 
in the treatment of glioblastoma. 
The selective inhibition of the Eg5 kinesin by small molecule inhibitors such as monastrol 
is currently preclinically evaluated as a new approach to the treatment of malignant tumors. 
However, the potency of the first identified selective Eg5 inhibitor monastrol is rather low. 
Several new monastrol analogs exhibited higher antiproliferative activity against human 
glioblastoma cells. In the last part of this work the effects of these new monastrol analogs on 
the spindle formation and the cytoskeleton of mitotic and quiescent glioblastoma cells were 
evaluated by confocal laser-scanning microscopy. Except for the two compounds VS-17 and 
VS-48 all other tested compounds led to the characteristic monoaster spindle formation with a 
potency of at least one order of magnitude higher than that of monastrol. Although the 
expression of the Eg5 kinesin in the human glioblastoma cells was not limited to the mitosis 
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phase, the microtubule and actin cytoskeleton remained unaffected by the new compounds, 
also in non-dividing cells.. These results support the hypothesis that selective Eg5 inhibitors 
may represent an interesting class of potential anticancer drugs, predicted to exhibit less 
cytotoxic side effects in comparison to classical tubulin inhibitors. 
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ABCB1  ATP binding cassette B1 
ABCG2  ATP binding cassette G2 
ACE   automatic component extraction 
AM   acetoxymethylester 
Amp   ampicillin 
APC   anaphase promoting complex 
ATCC   American Type Culture Collection 
ATP   adenosine triphosphate 
AUC   area under the curve 
BBB   blood-brain barrier 
BCNU   carmustine 
bcrp   breast cancer resistance protein 
BCSFB  blood-cerebrospinal fluid barrier 
bFGF   basic fibroblast growth factor 
bp   base pairs 
BP   bandpass filter 
BSA   bovine serum albumin 
Bub   budding uninhibited by benzimidazole 
CCNU   lomustine 
cDNA   complementary DNA 
CDK   cycline-dependent kinase 
c-KIT   cytosolic Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
CLSM   confocal laser-scanning microscopy 
cm   cytoplasmic membrane 
Cmax   maximal plasma concentration 
CML   chronic myelogenous leukemia 
CS   citrate buffered saline 
CSF-1   colony stimulating factor 1 
CNS   central nervous system 
Cy5   cyanine 5 
Da   dalton 
DEPC   diethyl pyrocarbonate 
DMEM  Dulbecco´s modified Eagle medium 
DMSO  dimethylsulfoxide 
DNA   desoxyribonucleic acid 
DoxoNP  doxorubicin-loaded nanoparticles 
DoxoNPT80  polysorbate 80-coated DoxoNP 
ECFP   enhanced cyan fluorescent protein 
EGFP   enhanced green fluorescent protein 
EDTA   ethylenediaminetetraacetic acid 
EEG   electroencephalogram 
EGFR   epidermal growth factor receptor 
EMEM  Eagles minimum essential medium 
ER   endoplasmic reticulum 
FCS   fetal calf serum 
FITC   fluorescein-5-isothiocyanate 
G418   geneticin 
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GAP   GTPase activating protein 
GDP   guanosine diphosphate 
GIST   gastrointestinal stroma tumors 
Grb2   growth factor receptor-bound protein 2 
GTP   guanosine triphosphate 
Gy   Gray 
HAMs F12  Ham's nutrient mixture F-12 
HEPES  N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid) 
HER-2/c-ErB-2 erythroblastic leukemia cytosolic oncogene homolog 2 
HFT   Hauptfarbteiler (main dichroic beam splitter) 
HPLC   high performance liquid chromatography 
IC50   concentration of inhibitor required to give a 50 % inhibition of activity 
IP3   inositol-1,4,5-trisphosphate 
Kan   kanamycin 
L15   Leibovitz L15 medium 
LB   Luria Bertani broth 
LDL   low density lipoprotein 
LOH   loss of heterozygosity 
LP   longpass filter 
LY-CH  lucifer yellow carbohydrazide 
MAB   monoclonal antibody 
MAD   mitosis arrest deficient 
MAP   mitogen activated protein kinase 
MCS   multiple cloning site 
MDM2  murine double minute 2 
MGMT  O6-methylguanine-DNA methyltransferase 
M-MLV  moloney murine leukemia virus 
mRNA  messenger RNA 
MRP   multi-drug resistance-associated protein 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,2-diphenyl-tetrazolium bromide 
NADH  1,4-dihydronicotinamide adenine dinucleotide 
NCBI   National Center for Biotechnology Information 
Neo   neomycin 
NFT   Nebenfarbteiler (secondary dichroic beam splitter) 
NGF   nerve growth factor 
NMDA  N-methyl-D-aspartic acid 
NP   nanoparticles 
nuc   nucleus 
O6BG   O6-benzylguanine 
PBCA   polybutylcyanoacrylate 
PBS   phosphate buffered saline 
PDGF   platelet-derived growth factor 
PDGFR  PDGF receptor 
PFA   paraformaldehyde 
PFS   progression-free survival 
PKC   protein kinase C 
PLC   phospholipase C 
pgp   p-glycoprotein 170 
pH   negative logarithm of the hydrogen ion concentration 
Ph. Eur. 1997  European Pharmacopoeia 1997 
PIP2   phosphatidylinositol-4,5-bisphosphate 
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PLGA   poly(lactid-co-glycolid) 
Po/w   octanol-water partition coefficient 
PSC 833  valspodar 
PTEN   phosphate and tensin homolog 
Pur   puromycin 
Raf   Raf protein kinase 
Ras   Ras protein kinase 
RES   reticuloendothelial system 
rhPDGF  recombinant human PDGF 
RNA   ribonucleic acid 
RPMI-1640  Rosswell Park Memorial Institute-1640 medium 
RT-PCR  reverse transcription-polymerase chain reaction 
SCF   stem cell factor 
SEM   scanning electron microscopy 
SH2   Src homology 2 domain 
Src   Src kinase (from v-src “viral sarcoma”) 
SOC   salt optimized + carbon medium 
SOS   son of sevenless 
SRS   stereotactic radiosurgery 
SSV   simian sarcoma virus 
Taq-polymerase Thermus aquaticus polymerase 
TBE   tris-borat-EDTA-buffer 
TGF-β   transforming growth factor beta 
Topo   topotecan 
TP53   tumor protein p53 
UDP   uridin-5´-diphosphate 
UV-vis  ultraviolet-visible 
VEGF   vascular endothelial growth factor 
WHO   World Health Organization 
XKCM1  Xenopus kinesin central motor 1 
 
